

ANTI-CTLA-4 ANTIBODIES AND USES THEREOF

REFERENCE TO A SEQUENCE LISTING

[0001] This application incorporates by reference the Sequence Listing submitted in Computer Readable Form as file 10360WO01-Sequence.txt, created on June 29, 2018 and containing 178,018 bytes.

FIELD OF THE INVENTION

[0002] The present invention is related to antibodies and antigen-binding fragments of antibodies that specifically bind to the immunomodulatory receptor cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and therapeutic and diagnostic methods of using those antibodies.

BACKGROUND OF THE INVENTION

[0003] Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4; also known as CD152) is a type I transmembrane T cell inhibitory checkpoint receptor expressed on conventional and regulatory T cells. CTLA-4 negatively regulates T cell activation by outcompeting the stimulatory receptor CD28 from binding to its natural ligands, B7-1 (CD80) and B7-2 (CD86). Initial T-cell activation is achieved by stimulating T-cell receptors (TCR) that recognize specific peptides presented by major histocompatibility complex class I or II (MHC I or MHC II) proteins on antigen-presenting cells (APC) (Goldrath *et al.* 1999, *Nature* 402: 255-262). An activated TCR in turn initiates a cascade of signaling events, which can be monitored by expression of transfected reporter genes, driven by promoters regulating the expression of various transcription factors such as activator-protein 1 (AP-1), Nuclear Factor of Activated T-cells (NFAT) or Nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB). The T-cell response is then further refined via engagement of co-stimulatory or co-inhibitory receptors expressed either constitutively or inducibly on T-cells such as CD28, CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4), PD-1 (Programmed Cell Death Protein 1), LAG-3 (Lymphocyte-Activation Gene 3) or other molecules (Sharpe *et al.* 2002, *Nat. Rev. Immunol.* 2: 116-126).

[0004] The co-receptors, CD28 and CTLA-4 compete for the same ligands, CD80 and CD86, expressed on antigen-presenting cells (APC). CTLA-4 binds CD80 and CD86 with a higher affinity than CD28, functions as a decoy and inhibits the activation of CD28 by sequestering away the ligands leading to reduced T-cell activation (Alegre *et al.* 2001, *Nat. Rev. Immunol.* 1: 220-228, Walker *et al.* 2011, *Nat. Rev. Immunol.* 11: 852-863, and Buchbinder *et al.*, 2016, *American Journal of Clinical Oncology*, 39:98-106).

BRIEF SUMMARY OF THE INVENTION

[0005] The present invention provides antibodies and antigen-binding fragments thereof that bind CTLA-4. The antibodies of the present invention are useful, *inter alia*, for targeting immune cells expressing CTLA-4, and for modulating CTLA-4 activity. In certain embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity and/or for stimulating T cell activation, e.g., under circumstances where T cell-mediated killing is beneficial or desirable. In certain embodiments, the antibodies are useful for inhibiting regulatory T cell function and/or for reactivating exhausted T cells. The anti-CTLA-4 antibodies of the invention, or antigen-binding portions thereof, may be included as part of a multi-specific antigen-binding molecule, for example, to modulate the immune response and/or to target the antibodies to a specific cell type, such as a tumor cell, or an infected cell. The antibodies are useful in treating a disease or disorder such as cancer and viral infection.

[0006] The antibodies of the invention can be full-length (for example, an IgG1 or IgG4 antibody) or may comprise only an antigen-binding portion (for example, a Fab, F(ab')₂ or scFv fragment), and may be modified to affect functionality, e.g., to eliminate residual effector functions (Reddy et al., 2000, J. Immunol. 164:1925-1933). In certain embodiments, the antibodies may be bispecific.

[0007] In a first aspect, the present invention provides isolated recombinant monoclonal antibodies or antigen-binding fragments thereof that bind specifically to CTLA-4. In certain embodiments, the antibodies are fully human.

[0008] Exemplary anti-CTLA-4 antibodies of the present invention are listed in Tables 1 and 2 herein. Table 1 sets forth the amino acid sequence identifiers of the heavy chain variable regions (HCVRs), light chain variable regions (LCVRs), heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3), and light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) of the exemplary anti-CTLA-4 antibodies. Table 2 sets forth the nucleic acid sequence identifiers of the HCVRs, LCVRs, HCDR1, HCDR2 HCDR3, LCDR1, LCDR2 and LCDR3 of the exemplary anti-CTLA-4 antibodies.

[0009] The present invention provides antibodies, or antigen-binding fragments thereof, comprising an HCVR comprising an amino acid sequence selected from any of the HCVR amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

[0010] The present invention also provides antibodies, or antigen-binding fragments thereof, comprising an LCVR comprising an amino acid sequence selected from any of the LCVR amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

[0011] The present invention also provides antibodies, or antigen-binding fragments thereof, comprising an HCVR and an LCVR amino acid sequence pair (HCVR/LCVR) comprising any of the HCVR amino acid sequences listed in Table 1 paired with any of the LCVR amino acid sequences listed in Table 1. According to certain embodiments, the present invention provides antibodies, or antigen-binding fragments thereof, comprising an HCVR/LCVR amino acid sequence pair contained within any of the exemplary anti-CTLA-4 antibodies listed in Table 1. In certain embodiments, the HCVR/LCVR amino acid sequence pair is selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/298, 314/322, 330/338, 346/354, 362/370, 378/386, 394/402, 410/418, 426/434, 442/450, 458/466, 474/482, and 490/498. In certain embodiments, the HCVR/LCVR amino acid sequence pair is selected from one of SEQ ID NOs: 194/202 (e.g., H1H19303P), or 290/298 (e.g., H1H19319P2). In certain embodiments, the present invention provides anti-CTLA-4 antibodies or antigen-binding fragments thereof comprising a HCVR and a LCVR, said HCVR comprising an amino acid sequence listed in Table 1 having up to ten amino acid substitutions, and said LCVR comprising an amino acid sequence listed in Table 1 having up to ten amino acid substitutions. For example, the present invention provides anti-CTLA-4 antibodies or antigen-binding fragments thereof comprising a HCVR and a LCVR, said HCVR comprising an amino acid sequence of SEQ ID NO: 194 having up to ten amino acid substitutions, and said LCVR comprising an amino acid sequence of SEQ ID NO: 202 having up to ten amino acid substitutions. In another exemplary embodiment, the present invention provides anti-CTLA-4 antibodies or antigen-binding fragments thereof comprising a HCVR and a LCVR, said HCVR comprising an amino acid sequence of SEQ ID NO: 194 having at least one amino acid substitution, and said LCVR comprising an amino acid sequence of SEQ ID NO: 202 having at least one amino acid substitution.

[0012] The present invention also provides antibodies, or antigen-binding fragments thereof, comprising a heavy chain CDR1 (HCDR1) comprising an amino acid sequence selected from any of the HCDR1 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

[0013] The present invention also provides antibodies, or antigen-binding fragments thereof, comprising a heavy chain CDR2 (HCDR2) comprising an amino acid sequence selected from any of the HCDR2 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

[0014] The present invention also provides antibodies, or antigen-binding fragments

thereof, comprising a heavy chain CDR3 (HCDR3) comprising an amino acid sequence selected from any of the HCDR3 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

[0015] The present invention also provides antibodies, or antigen-binding fragments thereof, comprising a light chain CDR1 (LCDR1) comprising an amino acid sequence selected from any of the LCDR1 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

[0016] The present invention also provides antibodies, or antigen-binding fragments thereof, comprising a light chain CDR2 (LCDR2) comprising an amino acid sequence selected from any of the LCDR2 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

[0017] The present invention also provides antibodies, or antigen-binding fragments thereof, comprising a light chain CDR3 (LCDR3) comprising an amino acid sequence selected from any of the LCDR3 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

[0018] The present invention also provides antibodies, or antigen-binding fragments thereof, comprising an HCDR3 and an LCDR3 amino acid sequence pair (HCDR3/LCDR3) comprising any of the HCDR3 amino acid sequences listed in Table 1 paired with any of the LCDR3 amino acid sequences listed in Table 1. According to certain embodiments, the present invention provides antibodies, or antigen-binding fragments thereof, comprising an HCDR3/LCDR3 amino acid sequence pair contained within any of the exemplary anti-CTLA-4 antibodies listed in Table 1. In certain embodiments, the HCDR3/LCDR3 amino acid sequence pair is selected from the group consisting of SEQ ID NOs: 200/208 (e.g., H1H19303P), and 296/304 (e.g., H1H19319P2).

[0019] The present invention also provides antibodies, or antigen-binding fragments thereof, comprising a HCVR and a LCVR, said HCVR comprising HCDR1 comprising an amino acid sequence differing from an amino acid sequence listed in Table 1 by 1 amino acid, HCDR2 comprising an amino acid sequence differing from an amino acid sequence listed in Table 1 by 1 amino acid, and HCDR3 comprising an amino acid sequence differing from an amino acid sequence listed in Table 1 by 1 amino acid. In certain embodiments, the present invention provides antibodies, or antigen-binding fragments thereof, comprising a HCVR and a LCVR, said LCVR comprising LCDR1 comprising an amino acid sequence differing from an amino acid sequence listed in Table 1 by 1 amino acid, LCDR2 comprising

an amino acid sequence differing from an amino acid sequence listed in Table 1 by 1 amino acid, and LCDR3 comprising an amino acid sequence differing from an amino acid sequence listed in Table 1 by 1 amino acid. For example, the present invention provides anti-CTLA-4 antibodies, or antigen-binding fragments thereof, comprising a HCVR and a LCVR, said HCVR comprising HCDR1 comprising an amino acid sequence of SEQ ID NO: 196 or an amino acid sequence differing from SEQ ID NO: 196 by 1 amino acid, HCDR2 comprising an amino acid sequence of SEQ ID NO: 198 or an amino acid sequence differing from SEQ ID NO: 198 by 1 amino acid, and HCDR3 comprising an amino acid sequence of SEQ ID NO: 200 or an amino acid sequence differing from SEQ ID NO: 200 by 1 amino acid. In another exemplary embodiment, the present invention provides antibodies, or antigen-binding fragments thereof, comprising a HCVR and a LCVR, said LCVR comprising LCDR1 comprising an amino acid sequence of SEQ ID NO: 204 or an amino acid sequence differing from SEQ ID NO: 204 by 1 amino acid, LCDR2 comprising an amino acid sequence of SEQ ID NO: 206 or an amino acid sequence differing from SEQ ID NO: 206 by 1 amino acid, and LCDR3 comprising an amino acid sequence of SEQ ID NO: 208 or an amino acid sequence differing from SEQ ID NO: 208 by 1 amino acid.

[0020] The present invention also provides antibodies, or antigen-binding fragments thereof, comprising a set of six CDRs (*i.e.*, HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained within any of the exemplary anti-CTLA-4 antibodies listed in Table 1. In certain embodiments, the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence set is selected from the group consisting of SEQ ID NOs: 196-198-200-204-206-208 (*e.g.*, H1H19303P), and 292-294-296-300-302-304 (*e.g.*, H1H19319P2).

[0021] In a related embodiment, the present invention provides antibodies, or antigen-binding fragments thereof, comprising a set of six CDRs (*i.e.*, HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained within an HCVR/LCVR amino acid sequence pair as defined by any of the exemplary anti-CTLA-4 antibodies listed in Table 1. For example, the present invention includes antibodies, or antigen-binding fragments thereof, comprising the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences set contained within an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 194/202 (*e.g.*, H1H19303P), and 290/298 (*e.g.*, H1H19319P2). Methods and techniques for identifying CDRs within HCVR and LCVR amino acid sequences are well known in the art and can be used to identify CDRs within the specified HCVR and/or LCVR amino acid sequences disclosed herein. Exemplary conventions that can be used to identify the boundaries of CDRs include, *e.g.*, the Kabat definition, the Chothia definition, and the AbM definition. In general terms, the Kabat definition is based on sequence variability, the Chothia definition is based on the location of the structural loop regions, and the AbM definition is a compromise between the Kabat and Chothia approaches. See, *e.g.*, Kabat,

"Sequences of Proteins of Immunological Interest," National Institutes of Health, Bethesda, Md. (1991); Al-Lazikani *et al.*, *J. Mol. Biol.* 273:927-948 (1997); and Martin *et al.*, *Proc. Natl. Acad. Sci. USA* 86:9268-9272 (1989). Public databases are also available for identifying CDR sequences within an antibody.

[0022] The present invention includes anti-CTLA-4 antibodies having a modified glycosylation pattern. In some embodiments, modification to remove undesirable glycosylation sites may be useful, or an antibody lacking a fucose moiety present on the oligosaccharide chain, for example, to increase antibody dependent cellular cytotoxicity (ADCC) function (see Shield *et al.* (2002) *JBC* 277:26733). In other applications, modification of galactosylation can be made in order to modify complement dependent cytotoxicity (CDC).

[0023] The present invention includes anti-CTLA-4 antibodies comprising a Fc domain, wherein the Fc domain comprises IgG1 or IgG4 isotype as described elsewhere herein.

[0024] The present invention also provides for antibodies and antigen-binding fragments thereof that compete for specific binding to CTLA-4 with an antibody or antigen-binding fragment thereof comprising the CDRs of a HCVR and the CDRs of a LCVR, wherein the HCVR and LCVR each has an amino acid sequence selected from the HCVR and LCVR sequences listed in Table 1.

[0025] The present invention also provides isolated antibodies and antigen-binding fragments thereof that block CTLA-4 binding to its natural ligands (B7-1/CD80 and B7-2/CD86) In some embodiments, the antibody or antigen-binding fragment thereof that blocks CTLA-4 binding may bind to the same epitope on CTLA-4 as B7-1/CD80 and/or B7-2/CD86 or may bind to a different epitope on CTLA-4 from B7-1/CD80 and/or B7-2/CD86.

[0026] The present invention also provides antibodies and antigen-binding fragments thereof that bind specifically to CTLA-4 from human or other species. In certain embodiments, the antibodies may bind to human CTLA-4 and/or to monkey CTLA-4.

[0027] The present invention also provides antibodies and antigen-binding fragments thereof that cross-compete for binding to CTLA-4 with a reference antibody or antigen-binding fragment thereof comprising the CDRs of a HCVR and the CDRs of a LCVR, wherein the HCVR and LCVR each has an amino acid sequence selected from the HCVR and LCVR sequences listed in Table 1.

[0028] The present invention also provides antibodies and antigen-binding fragments thereof that bind to the same epitope as a reference antibody or antigen-binding fragment thereof comprising the CDRs of a HCVR and the CDRs of a LCVR, wherein the HCVR and LCVR each has an amino acid sequence selected from the HCVR and LCVR sequences listed in Table 1. In certain embodiments, the present invention provides antibodies and antigen-binding fragments thereof that bind to the same epitope as a reference antibody or

antigen-binding fragment thereof comprising the CDRs of a HCVR and the CDRs of a LCVR, wherein the HCVR/LCVR amino acid sequence pair has SEQ ID NOs: 194/202.

[0029] The present invention also includes anti-CTLA-4 antibodies that interact with one or more amino acids contained within the extracellular domain of human CTLA-4.

[0030] In one embodiment, the invention provides a recombinant human monoclonal antibody or antigen-binding fragment that has one or more of the following characteristics: (a) binds specifically to human CTLA-4 and/or cynomolgus CTLA-4; (b) blocks the binding of CTLA-4 to CD80 and/or CD86; (c) blocks CTLA-4-induced T cell down regulation and rescues T cell signaling; and (d) suppresses tumor growth and increases survival in a subject with cancer.

[0031] In some embodiments, the antibody or antigen binding fragment thereof may bind specifically to CTLA-4 in an agonist manner, i.e., it may enhance or stimulate CTLA-4 binding and/or activity; in other embodiments, the antibody may bind specifically to CTLA-4 in an antagonist manner, i.e., it may block CTLA-4 from binding to its ligand(s).

[0032] In certain embodiments, the antibodies or antigen-binding fragments of the present invention are bispecific comprising a first binding specificity to CTLA-4 and a second binding specificity for a second target epitope. The second target epitope may be another epitope on CTLA-4 or on a different protein. In certain embodiments, the second target epitope may be on a different cell including a different T cell, a B-cell, a tumor cell or a virally infected cell.

[0033] In a second aspect, the present invention provides nucleic acid molecules encoding anti-CTLA-4 antibodies or portions thereof. For example, the present invention provides nucleic acid molecules encoding any of the HCVR amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

[0034] The present invention also provides nucleic acid molecules encoding any of the LCVR amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

[0035] The present invention also provides nucleic acid molecules encoding any of the HCVR1 amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR1 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

[0036] The present invention also provides nucleic acid molecules encoding any of the

HCDR2 amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR2 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

[0037] The present invention also provides nucleic acid molecules encoding any of the HCDR3 amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR3 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

[0038] The present invention also provides nucleic acid molecules encoding any of the LCDR1 amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR1 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

[0039] The present invention also provides nucleic acid molecules encoding any of the LCDR2 amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR2 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

[0040] The present invention also provides nucleic acid molecules encoding any of the LCDR3 amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR3 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

[0041] The present invention also provides nucleic acid molecules encoding an HCVR, wherein the HCVR comprises a set of three CDRs (*i.e.*, HCDR1-HCDR2-HCDR3), wherein the HCDR1-HCDR2-HCDR3 amino acid sequence set is as defined by any of the exemplary anti-CTLA-4 antibodies listed in Table 1.

[0042] The present invention also provides nucleic acid molecules encoding an LCVR, wherein the LCVR comprises a set of three CDRs (*i.e.*, LCDR1-LCDR2-LCDR3), wherein the LCDR1-LCDR2-LCDR3 amino acid sequence set is as defined by any of the exemplary anti-CTLA-4 antibodies listed in Table 1.

[0043] The present invention also provides nucleic acid molecules encoding both an HCVR and an LCVR, wherein the HCVR comprises an amino acid sequence of any of the HCVR amino acid sequences listed in Table 1, and wherein the LCVR comprises an amino acid sequence of any of the LCVR amino acid sequences listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from

any of the HCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto, and a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto. In certain embodiments according to this aspect of the invention, the nucleic acid molecule encodes an HCVR and LCVR, wherein the HCVR and LCVR are both derived from the same anti-CTLA-4 antibody listed in Table 1.

[0044] In a related aspect, the present invention provides recombinant expression vectors capable of expressing a polypeptide comprising a heavy or light chain variable region of an anti-CTLA-4 antibody. For example, the present invention includes recombinant expression vectors comprising any of the nucleic acid molecules mentioned above, *i.e.*, nucleic acid molecules encoding any of the HCVR, LCVR, and/or CDR sequences as set forth in Table 1. The present invention also provides recombinant expression vectors capable of expressing a polypeptide comprising a heavy or light chain of an anti-CTLA-4 antibody. For example, the present invention includes recombinant expression vectors comprising any of the nucleic acid molecules mentioned above, *i.e.*, nucleic acid molecules encoding any of the heavy chain or light chain sequences as set forth in Table 1. Also included within the scope of the present invention are host cells into which such vectors have been introduced, as well as methods of producing the antibodies or portions thereof by culturing the host cells under conditions permitting production of the antibodies or antibody fragments, and recovering the antibodies and antibody fragments so produced.

[0045] In a third aspect, the present invention provides a pharmaceutical composition comprising a recombinant human antibody or fragment thereof which specifically binds CTLA-4 and a pharmaceutically acceptable carrier. In a related aspect, the invention features a composition which is a combination of an anti-CTLA-4 antibody and a second therapeutic agent. In one embodiment, the second therapeutic agent is any agent that is advantageously combined with an anti-CTLA-4 antibody. Exemplary agents that may be advantageously combined with an anti-CTLA-4 antibody include, without limitation, other agents that bind and/or modulate CTLA-4 signaling (including other antibodies or antigen-binding fragments thereof, etc.) and/or agents which do not directly bind CTLA-4 but nonetheless modulate immune cell activation. Additional combination therapies and co-formulations involving the anti-CTLA-4 antibodies of the present invention are disclosed elsewhere herein.

[0046] In a fourth aspect, the invention provides methods to modulate the immune response in a subject, the method comprising administering a therapeutically effective amount of an anti-CTLA-4 antibody or antigen-binding fragment thereof of the invention to

the subject in need thereof. In certain embodiments, the invention provides methods to enhance the immune response in a subject, the methods comprising administering to the subject an effective amount of an antibody or fragment thereof of the invention that binds CTLA-4. In one embodiment, the invention provides a method to stimulate or enhance T cell activation in a subject. In certain embodiments, the invention provides methods to rescue T cell activity comprising contacting the T cell with an effective amount of an antibody of the invention such that T cell activity is rescued. In one embodiment, the invention provides methods to inhibit a T regulatory (Treg) cell in a subject, the methods comprising administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof of the invention to the subject in need thereof. In certain embodiments, the subject in need thereof may suffer from a disease or disorder such as cancer or viral infection. In certain embodiments, the present invention provides methods to rescue CTLA-4-mediated inhibition of T cell activity comprising contacting the T cell with an effective amount of an antibody of the present invention.

[0047] In a fifth aspect, the invention provides therapeutic methods for treating a disease or disorder such as cancer or viral infection in a subject using an anti-CTLA-4 antibody or antigen-binding portion of an antibody of the invention, wherein the therapeutic methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising an antibody or fragment of an antibody of the invention to the subject in need thereof. The disorder treated is any disease or condition which is improved, ameliorated, inhibited or prevented by stimulation or inhibition of CTLA-4 activity or signaling. In certain embodiments, the antibody or antigen-binding fragment thereof of the invention is administered in combination with a second therapeutic agent to the subject in need thereof. The second therapeutic agent may be selected from the group consisting of an antibody to another T cell co-inhibitor, an antibody to a tumor cell antigen, an antibody to a T cell receptor, an antibody to an epitope on a virally infected cell, a cytotoxic agent, an anti-cancer drug, an anti-viral drug, an anti-inflammatory drug (e.g., corticosteroids), chemotherapeutic agent, radiation therapy, surgery, an immunosuppressant and any other drug or therapy known in the art. In certain embodiments, the second therapeutic agent may be an agent that helps to counteract or reduce any possible side effect(s) associated with an antibody or antigen-binding fragment thereof of the invention, if such side effect(s) should occur.

[0048] In certain embodiments, the present invention provides methods for suppressing tumor growth. For example, the present invention provides to suppress tumor growth due to a primary tumor or a metastatic tumor in a subject. In certain embodiments, the present invention provides methods to enhance survival (e.g., progression-free survival or overall survival) of a subject with cancer. Examples of cancer include, but are not limited to, primary and/or recurrent cancer, including blood cancer (e.g., a hematologic malignancy such as

lymphoma, myeloma or leukemia), brain cancer (e.g., glioblastoma multiforme), lung cancer (e.g., non-small cell lung cancer, including advanced or metastatic NSCLC), squamous cell carcinoma of head and neck, hepatic cell carcinoma, renal cell carcinoma, melanoma, mesothelioma, ovarian cancer, bladder cancer, breast cancer, bone cancer, colorectal cancer, kidney cancer, esophageal cancer, liver cancer, stomach cancer, pancreatic cancer, skin cancer, cervical cancer, intestinal cancer, prostate cancer, and colon cancer. In certain embodiments, the present invention provides methods for inhibiting or suppressing growth of established tumors. The methods comprise administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of an anti-CTLA-4 antibody of the present invention. In certain embodiments, the antibody is administered in combination with a second therapeutic agent selected from the group consisting of a programmed death-1 (PD-1) inhibitor (e.g., an anti-PD-1 antibody such as nivolumab, pembrolizumab or REGN2810), a programmed death-ligand 1 (PD-L1) inhibitor (e.g., an anti-PD-L1 antibody such as atezolizumab, avelumab or durvalumab), a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept, bevacizumab), an angiopoietin-2 (Ang2) inhibitor (e.g., an anti-Ang2 antibody such as nesvacumab), a lymphocyte-activation gene 3 (LAG3) inhibitor, a CD20xCD3 bispecific antibody (e.g., REGN1979), a cytotoxin, a chemotherapeutic agent, a cancer vaccine, surgery, and radiation therapy. Additional examples of additional therapies/therapeutic agents that can be used in combination with an anti-CTLA-4 antibody of the invention for use in treating cancer are described elsewhere herein.

[0049] The antibody or fragment thereof may be administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly, or intracranially. In certain embodiments, the antibody or fragment thereof is administered locally into the tumor (peritumorally or intra-tumorally). The antibody or fragment thereof may be administered at a dose of about 0.1 mg/kg of body weight to about 100 mg/kg of body weight of the subject. In certain embodiments, the antibody is administered in an amount of from about 50 mg to about 1000 mg to the subject in need thereof. In some embodiments, the antibody is administered at a dose of from about 25 mg to about 600 mg. In some embodiments, the antibody is administered at a dose of from about 50 mg to about 1200 mg.

[0050] The present invention also includes use of an anti-CTLA-4 antibody or antigen-binding fragment thereof of the invention in the manufacture of a medicament for the treatment of a disease or disorder that would benefit from the blockade of CTLA-4 binding and/or signaling such as cancer.

[0051] The present invention further includes uses of the antibodies and antigen-binding fragments, or pharmaceutical composition comprising same, (i) in the manufacture of a medicament for treating a disease or disorder that is treatable by antagonizing CTLA-4 (e.g.,

cancer), and/or (ii) in the treatment of a disease or disorder that is treatable by antagonizing CTLA-4 (e.g., cancer).

[0052] In another aspect, the present invention provides a method of treating non-small cell lung cancer (including advanced or metastatic NSCLC) in a subject in need thereof, comprising administering to the subject an anti-CTLA-4 antibody and an anti-PD-1 antibody. In some cases, the anti-CTLA-4 antibody comprises the CDRs of a HCVR comprising the amino acid sequence of SEQ ID NO: 194 and the CDRs of a LCVR comprising the amino acid sequence of SEQ ID NO: 202. In some cases, the anti-CTLA-4 antibody comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, respectively, selected from the group consisting of SEQ ID NOs: 196-198-200-204-206-208. In some cases, the anti-CTLA-4 antibody comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 194, and a LCVR comprising the amino acid sequence of SEQ ID NO: 202. In some cases, the anti-CTLA-4 antibody comprises a human IgG1 heavy chain constant region. In some embodiments, the anti-PD-1 antibody is cemiplimab. The present invention also includes use of such antibodies in the manufacture of a medicament or medicaments for the treatment of cancers (e.g., non-small cell lung cancer, including advanced or metastatic NSCLC).

[0053] Other embodiments will become apparent from a review of the ensuing detailed description.

BRIEF DESCRIPTION OF THE FIGURES

[0054] **Figure 1** shows average tumor volumes ($\text{mm}^3 \pm \text{SEM}$) in each treatment group at multiple post-tumor implantation time points for the experiment described in Study (A) in Example 7. *CTLA-4^{hum/hum}* knock-in mice were implanted SC with MC38.Ova cells (10^6 cells/mouse) on day 0 and separated into four treatment groups (9 mice/group). Mice were administered 10 mg/kg of either one of the three lead anti-human CTLA-4 antibodies (H1H19273P, or H1H19303P, or H1H19319) or 10 mg/kg of hIgG1 isotype control intraperitoneally (IP) on days 3, 7, 10, 14 and 17. Tumor volumes were monitored by caliper measurements twice per week for 37 days. Treatment days indicated by arrows.

[0055] **Figure 2** shows individual tumor volumes at day 24 for the experiment described in Study (A) in Example 7. Day 24 was the last time point in the study when all animals in all groups were alive. Statistical significance was determined by one-way ANOVA with Dunnett's multiple comparisons post-test (**** $p < 0.0001$).

[0056] **Figure 3** shows Kaplan-Meier survival curves for the experiment described in Study (A) in Example 7.

[0057] **Figure 4** shows average tumor volumes ($\text{mm}^3 \pm \text{SEM}$) in each treatment group at multiple post-tumor implantation time points for the experiment described in Study (B) in

Example 7. CTLA-4^{hum/hum} knock-in mice were administered anti-CTLA-4 antibody H1H19303P or an hlgG1 isotype control IP on days 3, 6, 9, 13 and 16. Tumor volumes were monitored by caliper measurements twice per week for 37 days. Treatment days are indicated by arrows.

[0058] Figure 5 shows individual tumor volumes at day 20 for the experiment described in Study (B) in Example 7. Statistical significance was determined by one-way ANOVA with Dunnett's multiple comparisons post-test (**** p< 0.0001).

[0059] Figure 6 shows Kaplan-Meier survival curves for the experiment described in Study (B) in Example 7.

[0060] Figure 7 shows the concentration of total H1H19303P and hlgG1 isotype control antibody in serum, as described in Study (B) in Example 7.

[0061] Figure 8 shows the concentration of mouse anti-human antibodies (MAHA) against H1H19303P (■) or isotype control (●), as described in Study (B) in Example 7.

[0062] Figure 9 shows average tumor volumes (mm³ +/- SEM) in each treatment group at multiple post-tumor implantation time points for the experiment described in Example 8. Treatment days are indicated by arrows.

[0063] Figure 10 shows individual tumor volumes at day 10 after treatment initiation, as described in Example 8.

[0064] Figure 11 shows Kaplan-Meier survival curves for the experiment described in Example 8.

[0065] Figures 12 and 13 show that H1H19303P (also known as REGN4659) delays growth of established tumors in CTLA-4^{hum/hum} mice. Mice were engrafted sc into the flank with Mc38 .Ova cells (5x10⁵ cells/mouse), randomized into treatment groups on day 10 when tumor volumes reached 100 mm³, and REGN4659 (25 mg/kg, 10 mg/kg, n=10) or the isotype control Ab (25 mg/kg, n=10) were administered on days 10,13,17 and tumor volumes were monitored until day 27. Figure 12 shows the average tumor growth curves in each treatment group. Figure 13 shows individual tumor volumes in each treatment group as measured on day 21, the last time point when all animals in the study were alive.

[0066] Figure 14 shows mean fluorescent intensity (MFI) of total (surface and intracellular) human CTLA-4 expression on intratumoral and splenic Tregs and T effector cells in tumor bearing CTLA-4^{hum/hum} mice treated with hlgG1 control antibody. Expression of CTLA-4 on splenic CD8⁺ and CD4⁺ effector cells was indistinguishable from the isotype control staining (MFI=0) and is not shown.

DETAILED DESCRIPTION

[0067] Before the present methods are described, it is to be understood that this invention is not limited to particular methods, and experimental conditions described, as such methods

and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0068] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference in their entirety.

[0069] The term "CTLA-4" refers to the cytotoxic T-lymphocyte-associated protein 4, an immune checkpoint receptor or T cell co-inhibitor, also known as CD152. The amino acid sequence of full-length human CTLA-4 is provided as SEQ ID NO: 505 (accession number NP_005205.2). The term "CTLA-4" includes recombinant CTLA-4 or a fragment thereof. The term also encompasses CTLA-4 or a fragment thereof coupled to, for example, histidine tag, mouse or human Fc, a signal sequence, or a transmembrane and cytoplasmic domain of CD300a (aa 181-299; accession number NP_009192.2). For example, the term includes sequences discussed in the examples, e.g., comprising a myc-myc-polyhistidine tag at the C-terminus of a full-length CTLA-4, or comprising a mouse Fc (mIgG2a) at the C-terminus of a full-length CTLA-4. Unless specified as being from a non-human species, the term "CTLA-4" means human CTLA-4.

[0070] CTLA-4 is a member of the immunoglobulin (Ig) superfamily, and a homolog of CD28, but with greater binding affinity for ligands CD80 and CD86. CTLA-4 is a 223-amino acid type I transmembrane protein containing a V domain, a transmembrane domain, and a cytoplasmic tail that is expressed on activated T cells and regulatory T cells. The CTLA-4 receptor binds to B7-1/CD80 and B7-2/CD86 ligands present on antigen presenting cells (APCs).

[0071] As used herein, the term "T cell co-inhibitor" refers to a ligand and/or receptor which modulates the immune response via T cell activation or suppression. The term "T cell co-inhibitor", also known as T cell co-signaling molecule, includes, but is not limited to, programmed death-1 (PD-1), lymphocyte-activation gene 3 (LAG3), B and T lymphocyte attenuator (BTLA), CD-28, 2B4, LY108, T cell immunoglobulin and mucin 3 (TIM3), T cell immunoreceptor with immunoglobulin and ITIM (TIGIT; also known as VSIG9), leucocyte associated immunoglobulin-like receptor 1 (LAIR1; also known as CD305), inducible T cell costimulator (ICOS; also known as CD278), V-domain Ig suppressor of T cell activation (VISTA) and CD160.

[0072] The term "antibody", as used herein, is intended to refer to immunoglobulin molecules comprised of four polypeptide chains, two heavy (H) chains and two light (L)

chains inter-connected by disulfide bonds (*i.e.*, "full antibody molecules"), as well as multimers thereof (*e.g.* IgM) or antigen-binding fragments thereof. Each heavy chain is comprised of a heavy chain variable region ("HCVR" or " V_H ") and a heavy chain constant region (comprised of domains C_{H1} , C_{H2} and C_{H3}). Each light chain is comprised of a light chain variable region ("LCVR" or " V_L ") and a light chain constant region (C_L). The V_H and V_L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each V_H and V_L is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In certain embodiments of the invention, the FRs of the antibody (or antigen binding fragment thereof) may be identical to the human germline sequences, or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.

[0073] Substitution of one or more CDR residues or omission of one or more CDRs is also possible. Antibodies have been described in the scientific literature in which one or two CDRs can be dispensed with for binding. Padlan *et al.* (1995 FASEB J. 9:133-139) analyzed the contact regions between antibodies and their antigens, based on published crystal structures, and concluded that only about one fifth to one third of CDR residues actually contact the antigen. Padlan also found many antibodies in which one or two CDRs had no amino acids in contact with an antigen (see also, Vajdos *et al.* 2002 J Mol Biol 320:415-428).

[0074] CDR residues not contacting antigen can be identified based on previous studies (for example residues H60-H65 in CDRH2 are often not required), from regions of Kabat CDRs lying outside Chothia CDRs, by molecular modeling and/or empirically. If a CDR or residue(s) thereof is omitted, it is usually substituted with an amino acid occupying the corresponding position in another human antibody sequence or a consensus of such sequences. Positions for substitution within CDRs and amino acids to substitute can also be selected empirically. Empirical substitutions can be conservative or non-conservative substitutions.

[0075] The fully human anti-CTLA-4 monoclonal antibodies disclosed herein may comprise one or more amino acid substitutions, insertions and/or deletions in the framework and/or CDR regions of the heavy and light chain variable domains as compared to the corresponding germline sequences. Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available from, for example, public antibody sequence databases. The present invention includes antibodies, and antigen-binding fragments thereof, which are derived from any of the amino acid sequences disclosed herein, wherein one or more amino acids within one or more

framework and/or CDR regions are mutated to the corresponding residue(s) of the germline sequence from which the antibody was derived, or to the corresponding residue(s) of another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are referred to herein collectively as "germline mutations"). A person of ordinary skill in the art, starting with the heavy and light chain variable region sequences disclosed herein, can easily produce numerous antibodies and antigen-binding fragments which comprise one or more individual germline mutations or combinations thereof. In certain embodiments, all of the framework and/or CDR residues within the V_H and/or V_L domains are mutated back to the residues found in the original germline sequence from which the antibody was derived. In other embodiments, only certain residues are mutated back to the original germline sequence, *e.g.*, only the mutated residues found within the first 8 amino acids of FR1 or within the last 8 amino acids of FR4, or only the mutated residues found within CDR1, CDR2 or CDR3. In other embodiments, one or more of the framework and/or CDR residue(s) are mutated to the corresponding residue(s) of a different germline sequence (*i.e.*, a germline sequence that is different from the germline sequence from which the antibody was originally derived). Furthermore, the antibodies of the present invention may contain any combination of two or more germline mutations within the framework and/or CDR regions, *e.g.*, wherein certain individual residues are mutated to the corresponding residue of a particular germline sequence while certain other residues that differ from the original germline sequence are maintained or are mutated to the corresponding residue of a different germline sequence. Once obtained, antibodies and antigen-binding fragments that contain one or more germline mutations can be easily tested for one or more desired property such as, improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc. Antibodies and antigen-binding fragments obtained in this general manner are encompassed within the present invention.

[0076] The present invention also includes fully human anti-CTLA-4 monoclonal antibodies comprising variants of any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein having one or more conservative substitutions. For example, the present invention includes anti-CTLA-4 antibodies having HCVR, LCVR, and/or CDR amino acid sequences with, *e.g.*, 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc. conservative amino acid substitutions relative to any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein.

[0077] The terms "human antibody" and "fully human antibody," as used herein, are intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human mAbs of the invention may include amino

acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*), for example in the CDRs and in particular CDR3. However, the terms "human antibody" and "fully human antibody," as used herein, are not intended to include mAbs in which CDR sequences derived from the germline of another mammalian species (e.g., mouse), have been grafted onto human FR sequences. The terms include antibodies recombinantly produced in a non-human mammal, or in cells of a non-human mammal. The terms are not intended to include antibodies isolated from or generated in a human subject.

[0078] The term "recombinant", as used herein, refers to antibodies or antigen-binding fragments thereof of the invention created, expressed, isolated or obtained by technologies or methods known in the art as recombinant DNA technology which include, e.g., DNA splicing and transgenic expression. The term refers to antibodies expressed in a non-human mammal (including transgenic non-human mammals, e.g., transgenic mice), or a cell (e.g., CHO cells) expression system or isolated from a recombinant combinatorial human antibody library.

[0079] The term "multi-specific antigen-binding molecules", as used herein refers to bispecific, tri-specific or multi-specific antigen-binding molecules, and antigen-binding fragments thereof. Multi-specific antigen-binding molecules may be specific for different epitopes of one target polypeptide or may contain antigen-binding domains specific for epitopes of more than one target polypeptide. A multi-specific antigen-binding molecule can be a single multifunctional polypeptide, or it can be a multimeric complex of two or more polypeptides that are covalently or non-covalently associated with one another. The term "multi-specific antigen-binding molecules" includes antibodies of the present invention that may be linked to or co-expressed with another functional molecule, e.g., another peptide or protein. For example, an antibody or fragment thereof can be functionally linked (e.g., by chemical coupling, genetic fusion, non-covalent association or otherwise) to one or more other molecular entities, such as a protein or fragment thereof to produce a bi-specific or a multi-specific antigen-binding molecule with a second binding specificity. According to the present invention, the term "multi-specific antigen-binding molecules" also includes bi-specific, tri-specific or multi-specific antibodies or antigen-binding fragments thereof. In certain embodiments, an antibody of the present invention is functionally linked to another antibody or antigen-binding fragment thereof to produce a bispecific antibody with a second binding specificity. Bispecific and multi-specific antibodies of the present invention are described elsewhere herein.

[0080] The term "specifically binds," or "binds specifically to", or the like, means that an antibody or antigen-binding fragment thereof forms a complex with an antigen that is relatively stable under physiologic conditions. Specific binding can be characterized by an

equilibrium dissociation constant of at least about 1×10^{-8} M or less (e.g., a smaller K_D denotes a tighter binding). Methods for determining whether two molecules specifically bind are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. As described herein, antibodies have been identified by surface plasmon resonance, e.g., BIACORE™, which bind specifically to CTLA-4. Moreover, multi-specific antibodies that bind to one domain in CTLA-4 and one or more additional antigens or a bi-specific that binds to two different regions of CTLA-4 are nonetheless considered antibodies that “specifically bind”, as used herein.

[0081] The term “high affinity” antibody refers to those mAbs having a binding affinity to CTLA-4, expressed as K_D , of at least 10^{-8} M; preferably 10^{-9} M; more preferably 10^{-10} M, even more preferably 10^{-11} M, even more preferably 10^{-12} M, as measured by surface plasmon resonance, e.g., BIACORE™ or solution-affinity ELISA.

[0082] By the term “slow off rate”, “Koff” or “kd” is meant an antibody that dissociates from CTLA-4, with a rate constant of $1 \times 10^{-3} \text{ s}^{-1}$ or less, preferably $1 \times 10^{-4} \text{ s}^{-1}$ or less, as determined by surface plasmon resonance, e.g., BIACORE™.

[0083] The terms “antigen-binding portion” of an antibody, “antigen-binding fragment” of an antibody, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex. The terms “antigen-binding fragment” of an antibody, or “antibody fragment”, as used herein, refers to one or more fragments of an antibody that retain the ability to bind to CTLA-4.

[0084] In specific embodiments, antibody or antibody fragments of the invention may be conjugated to a moiety such a ligand or a therapeutic moiety (“immunoconjugate”), such as a cytotoxin, a second anti-CTLA-4 antibody, an antibody to a tumor-specific antigen, an anti-cancer drug, or any other therapeutic moiety useful for treating a disease or condition including cancer or viral infection including chronic viral infection.

[0085] An “isolated antibody”, as used herein, is intended to refer to an antibody that is substantially free of other antibodies (Abs) having different antigenic specificities (e.g., an isolated antibody that specifically binds CTLA-4, or a fragment thereof, is substantially free of Abs that specifically bind antigens other than CTLA-4).

[0086] A “blocking antibody” or a “neutralizing antibody”, as used herein (or an “antibody that neutralizes CTLA-4 activity” or “antagonist antibody”), is intended to refer to an antibody whose binding to CTLA-4 results in inhibition of at least one biological activity of CTLA-4. For example, an antibody of the invention may prevent or block CTLA-4 binding to CD80 and/or CD86.

[0087] An “activating antibody” or an “enhancing antibody”, as used herein (or an “agonist antibody”), is intended to refer to an antibody whose binding to CTLA-4 results in increasing

or stimulating at least one biological activity of CTLA-4. For example, an antibody of the invention may increase CTLA-4 activity by binding to CTLA-4 in a manner consistent with ligand binding (e.g., CD80 or CD86), resulting in CTLA-4 intracellular signaling.

[0088] The term "surface plasmon resonance", as used herein, refers to an optical phenomenon that allows for the analysis of real-time biomolecular interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIACORE™ system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.).

[0089] The term " K_D ", as used herein, is intended to refer to the equilibrium dissociation constant of a particular antibody-antigen interaction.

[0090] The term "epitope" refers to an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule known as a paratope. A single antigen may have more than one epitope. Thus, different antibodies may bind to different areas on an antigen and may have different biological effects. The term "epitope" also refers to a site on an antigen to which B and/or T cells respond. It also refers to a region of an antigen that is bound by an antibody. Epitopes may be defined as structural or functional. Functional epitopes are generally a subset of the structural epitopes and have those residues that directly contribute to the affinity of the interaction. Epitopes may also be conformational, that is, composed of non-linear amino acids. In certain embodiments, epitopes may include determinants that are chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and, in certain embodiments, may have specific three-dimensional structural characteristics, and/or specific charge characteristics.

[0091] The term "cross-competes", as used herein, means an antibody or antigen-binding fragment thereof binds to an antigen and inhibits or blocks the binding of another antibody or antigen-binding fragment thereof. The term also includes competition between two antibodies in both orientations, *i.e.*, a first antibody that binds and blocks binding of second antibody and vice-versa. In certain embodiments, the first antibody and second antibody may bind to the same epitope. Alternatively, the first and second antibodies may bind to different, but overlapping epitopes such that binding of one inhibits or blocks the binding of the second antibody, e.g., via steric hindrance. Cross-competition between antibodies may be measured by methods known in the art, for example, by a real-time, label-free bio-layer interferometry assay. Cross-competition between two antibodies may be expressed as the binding of the second antibody that is less than the background signal due to self-self binding (wherein first and second antibodies is the same antibody). Cross-competition between 2 antibodies may be expressed, for example, as % binding of the second antibody that is less than the baseline self-self background binding (wherein first and second antibodies is the same antibody).

[0092] The term "substantial identity" or "substantially identical," when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 90%, and more preferably at least about 95%, 96%, 97%, 98% or 99% of the nucleotide bases, as measured by any well-known algorithm of sequence identity, as discussed below. A nucleic acid molecule having substantial identity to a reference nucleic acid molecule may, in certain instances, encode a polypeptide having the same or substantially similar amino acid sequence as the polypeptide encoded by the reference nucleic acid molecule.

[0093] Sequence identity can be calculated using an algorithm, for example, the Needleman Wunsch algorithm (Needleman and Wunsch 1970, J. Mol. Biol. 48: 443-453) for global alignment, or the Smith Waterman algorithm (Smith and Waterman 1981, J. Mol. Biol. 147: 195-197) for local alignment. Another preferred algorithm is described by Dufresne et al in Nature Biotechnology in 2002 (vol. 20, pp. 1269-71) and is used in the software GenePAST (GQ Life Sciences, Inc. Boston, MA).

[0094] As applied to polypeptides, the term "substantial similarity" or "substantially similar" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 90% sequence identity, even more preferably at least 95%, 98% or 99% sequence identity. Preferably, residue positions, which are not identical, differ by conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. See, e.g., Pearson (1994) Methods Mol. Biol. 24: 307-331, which is herein incorporated by reference. Examples of groups of amino acids that have side chains with similar chemical properties include 1) aliphatic side chains: glycine, alanine, valine, leucine and isoleucine; 2) aliphatic-hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartate and glutamate, and 7) sulfur-containing side chains: cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine. Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix

disclosed in Gonnet *et al.* (1992) Science 256: 1443-45, herein incorporated by reference. A "moderately conservative" replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix.

[0095] Sequence similarity for polypeptides is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For instance, GCG software contains programs such as GAP and BESTFIT which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutein thereof. See, *e.g.*, GCG Version 6.1. Polypeptide sequences also can be compared using FASTA with default or recommended parameters; a program in GCG Version 6.1. FASTA (*e.g.*, FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson (2000) *supra*). Another preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer program BLAST, especially BLASTP or TBLASTN, using default parameters. See, *e.g.*, Altschul *et al.* (1990) J. Mol. Biol. 215: 403-410 and (1997) Nucleic Acids Res. 25:3389-3402, each of which is herein incorporated by reference.

[0096] By the phrase "therapeutically effective amount" is meant an amount that produces the desired effect for which it is administered. The exact amount will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, for example, Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding).

[0097] As used herein, the term "subject" refers to an animal, preferably a mammal, in need of amelioration, prevention and/or treatment of a disease or disorder such as viral infection, or cancer. The term includes human subjects who have or are at risk of having cancer, metastatic cancer or viral infection.

[0098] As used herein, "anti-cancer drug" means any agent useful to treat or ameliorate or inhibit cancer including, but not limited to, cytotoxins and agents such as antimetabolites, alkylating agents, anthracyclines, antibiotics, antimetabolic agents, procarbazine, hydroxyurea, asparaginase, corticosteroids, cyclophosphamide, mitotane (O,P'-(DDD)), biologics (*e.g.*, antibodies and interferons) and radioactive agents. As used herein, "a cytotoxin or cytotoxic agent", also refers to a chemotherapeutic agent and means any agent that is detrimental to cells. Examples include Taxol® (paclitaxel), temozolamide, cytochalasin B, gramicidin D, ethidium bromide, emetine, cisplatin, mitomycin, etoposide, teniposide, vincristine, vinblastine, coichicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone,

mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof.

[0099] As used herein, the term “anti-viral drug” refers to any drug or therapy used to treat, prevent, or ameliorate a viral infection in a host subject. The term “anti-viral drug” includes, but is not limited to zidovudine, lamivudine, abacavir, ribavirin, lopinavir, efavirenz, cobicistat, tenofovir, rilpivirine, analgesics and corticosteroids. In the context of the present invention, the viral infections include long-term or chronic infections caused by viruses including, but not limited to, human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), lymphocytic choriomeningitis virus (LCMV), and simian immunodeficiency virus (SIV).

[0100] As used herein, the term “to enhance immune response”, refers to an increase in activity of an immune cell such as T cell or NK cell against a tumor cell or a virally infected cell. In the context of the present invention, the term includes blocking of CTLA-4-mediated inhibition of T cell activity, or rescue or reversal of exhausted state of T cells. It also includes inhibition of regulatory T cell activity. The enhanced immune response, as used in the context of the present invention, results in increased killing of tumor cells and/or inhibition of tumor growth.

[0101] The antibodies and antigen-binding fragments of the present invention specifically bind to CTLA-4 and enhance T cell activation. The anti-CTLA-4 antibodies may bind to CTLA-4 with high affinity or with low affinity. In certain embodiments, the antibodies of the present invention may be blocking antibodies wherein the antibodies may bind to CTLA-4 and inhibit CTLA-4 signaling. In some embodiments, the antibodies of the invention block the binding of CTLA-4 to CD80 and/or CD86 and/or stimulate or enhance T cell activation. In some embodiments, the antibodies bind to CTLA-4 and reverse the anergic state of exhausted T cells. In certain embodiments, the antibodies bind to CTLA-4 and inhibit regulatory T cell activity. In some embodiments, the antibodies may be useful for stimulating or enhancing the immune response and/or for treating a subject suffering from cancer, or a viral infection. The antibodies when administered to a subject in need thereof may reduce chronic infection by a virus such as HIV, LCMV or HBV in the subject. They may be used to inhibit the growth of tumor cells in a subject. They may be used alone or as adjunct therapy with other therapeutic moieties or modalities known in the art for treating cancer, or viral infection.

[0102] In certain embodiments, the anti-CTLA-4 antibodies may be multi-specific antigen-binding molecules, wherein they comprise a first binding specificity to CTLA-4 and a second binding specificity to an antigen selected from the group consisting of another T cell co-inhibitor, and a different epitope of CTLA-4.

[0103] An immunogen comprising any one of the following can be used to generate

antibodies to CTLA-4. In certain embodiments, the antibodies of the invention are obtained from mice immunized with a full length, native CTLA-4 (See NCBI accession number NP_005205.2) (SEQ ID NO: 505), or with a recombinant CTLA-4 peptide. Alternatively, CTLA-4 or a fragment thereof may be produced using standard biochemical techniques and used as immunogen.

[0104] In certain embodiments, the immunogen is the extracellular domain of CTLA-4. In one embodiment of the invention, the immunogen is a fragment of the extracellular domain of CTLA-4.

[0105] In some embodiments, the immunogen may be a recombinant CTLA-4 peptide expressed in *E. coli* or in any other eukaryotic or mammalian cells such as Chinese hamster ovary (CHO) cells.

[0106] In certain embodiments, antibodies that bind specifically to CTLA-4 may be prepared using fragments of the above-noted regions, or peptides that extend beyond the designated regions by about 5 to about 20 amino acid residues from either, or both, the N or C terminal ends of the regions described herein. In certain embodiments, any combination of the above-noted regions or fragments thereof may be used in the preparation of CTLA-4 specific antibodies.

[0107] The peptides may be modified to include addition or substitution of certain residues for tagging or for purposes of conjugation to carrier molecules, such as, KLH. For example, a cysteine may be added at either the N terminal or C terminal end of a peptide, or a linker sequence may be added to prepare the peptide for conjugation to, for example, KLH for immunization.

[0108] Certain anti-CTLA-4 antibodies of the present invention are able to bind to and neutralize the activity of CTLA-4, as determined by *in vitro* or *in vivo* assays. The ability of the antibodies of the invention to bind to and neutralize the activity of CTLA-4 may be measured using any standard method known to those skilled in the art, including binding assays, or activity assays, as described herein.

[0109] Non-limiting, exemplary *in vitro* assays for measuring binding activity are illustrated in Examples herein. In Example 3, the binding affinities and kinetic constants of human anti-CTLA-4 antibodies for human and monkey CTLA-4 were determined by surface plasmon resonance or MASS-1. In Example 4, competition sandwich ELISAs were used to assess the ability of the anti-CTLA-4 antibodies to block CTLA-4 protein binding to its natural ligands B7-1 and B7-2. Example 5 describes the binding of the anti-CTLA-4 antibodies to cells expressing CTLA-4. In Example 6, a luciferase assay and an IL-2 release assay were used to determine the ability of anti-CTLA-4 antibodies to activate T cells and rescue IL-2 release.

[0110] In certain embodiments, the antibodies of the present invention are able to enhance or stimulate T cell activity *in vitro*, in a subject with cancer, or in a subject infected with a

virus such as LCMV. In certain embodiments, the antibodies of the present invention are used in combination with a second therapeutic agent, such as an antibody to a second T cell co-inhibitor, to enhance the immune response and inhibit tumor growth in a subject.

[0111] The antibodies specific for CTLA-4 may contain no additional labels or moieties, or they may contain a label or moiety, e.g., an N-terminal or C-terminal label or moiety. In one embodiment, the label or moiety is biotin. In a binding assay, the location of a label (if any) may determine the orientation of the peptide relative to the surface upon which the peptide is bound. For example, if a surface is coated with avidin, a peptide containing an N-terminal biotin will be oriented such that the C-terminal portion of the peptide will be distal to the surface. In one embodiment, the label may be a radionuclide, a fluorescent dye or a MRI-detectable label. In certain embodiments, such labeled antibodies may be used in diagnostic assays including imaging assays.

Exemplary Embodiments of the Invention

[0112] In one aspect, the present invention provides an antibody or antigen-binding fragment thereof that binds human cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and blocks the interaction between hCTLA-4 and ligands B7-1 and B7-2.

[0113] In certain embodiments, the antibody or antigen-binding fragment induces T-cell activation. In some cases, the T-cell is a cytotoxic T-cell. In some cases, the T-cell is a tumor infiltrating lymphocyte.

[0114] In certain embodiments, the antibody or antigen-binding fragment binds monkey CTLA-4. In some cases, the antibody or antigen-binding fragment binds monkey CTLA-4 expressing cells with an EC₅₀ of less than 0.5 nM.

[0115] In certain embodiments, the antibody or antigen-binding fragment binds hCTLA-4 expressing cells with an EC₅₀ of less than 5 nM, less than 1 nM, or less than 0.5 nM.

[0116] In various embodiments, the antibody or antigen-binding fragment is a fully human antibody.

[0117] In certain embodiments, the antibody or antigen-binding fragment thereof competes for binding to human CTLA-4 with a reference antibody comprising an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/298, 314/322, 330/338, 346/354, 362/370, 378/386, 394/402, 410/418, 426/434, 442/450, 458/466, 474/482, and 490/498.

[0118] In certain embodiments, the antibody or antigen-binding fragment thereof binds to the same epitope on human CTLA-4 as a reference antibody comprising an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26,

34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/298, 314/322, 330/338, 346/354, 362/370, 378/386, 394/402, 410/418, 426/434, 442/450, 458/466, 474/482, and 490/498.

[0119] In certain embodiments, the antibody or antigen-binding fragment comprises: (a) the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 314, 330, 346, 362, 378, 394, 410, 426, 442, 458, 474, and 490; and (b) the CDRs of a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 322, 338, 354, 370, 386, 402, 418, 434, 450, 466, 482, and 498.

[0120] In certain embodiments, the antibody or antigen-binding fragment comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/298, 314/322, 330/338, 346/354, 362/370, 378/386, 394/402, 410/418, 426/434, 442/450, 458/466, 474/482, and 490/498.

[0121] In certain embodiments, the antibody or antigen-binding fragment comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, respectively, selected from the group consisting of SEQ ID NOs: 4-6-8-12-14-16; 20-22-24-28-30-32; 36-38-40-44-46-48; 52-54-56-60-62-64; 68-70-72-76-78-80; 84-86-88-92-94-96; 100-102-104-108-110-112; 116-118-120-124-126-128; 132-134-136-140-142-144; 148-150-152-156-158-160; 164-166-168-172-174-176; 180-182-184-188-190-192; 196-198-200-204-206-208; 212-214-216-220-222-224; 228-230-232-236-238-240; 244-246-248-252-254-256; 260-262-264-268-270-272; 276-278-280-284-286-288; 292-294-296-300-302-304; 308-310-312-300-302-304; 316-318-320-324-326-328; 332-334-336-340-342-344; 348-350-352-356-358-360; 364-366-368-372-374-376; 380-382-384-388-390-392; 396-398-400-404-406-408; 412-414-416-420-422-424; 428-430-432-436-438-440; 444-446-448-452-454-456; 460-462-464-468-470-472; 476-478-480-484-486-488; and 492-494-496-500-502-504.

[0122] In certain embodiments, the antibody or antigen-binding fragment comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/298, 314/322, 330/338, 346/354, 362/370, 378/386, 394/402, 410/418, 426/434, 442/450, 458/466, 474/482, and 490/498.

[0123] In certain embodiments, the present invention provides an antibody or antigen-

binding fragment hereof that is a human, humanized or a chimeric antibody. The antibody or antigen-binding fragment thereof can for instance be an IgG1 or an IgG4 antibody, such as *e.g.*, a human IgG1 or an IgG4 antibody. The constant regions of those antibodies might correspond to wild-type constant regions, or to constant regions into which mutations have been introduced.

[0124] In one aspect, the present invention provides a multi-specific antigen-binding molecule comprising a first antigen-binding specificity that binds specifically to CTLA-4 and a second antigen-binding specificity that specifically binds to a second target epitope.

[0125] In one aspect, the present invention provides a pharmaceutical composition comprising an anti-CTLA-4 antibody or antigen-binding fragment thereof of any of the above embodiments and a pharmaceutically acceptable carrier or diluent.

[0126] In one aspect, the present invention provides isolated polynucleotide molecules and vectors comprising polynucleotide sequences of the antibodies or antigen-binding fragment thereof disclosed herein. In certain embodiments, the present invention provides an isolated polynucleotide molecule and/or a vector comprising a polynucleotide sequence that encodes a HCVR of an antibody as set forth herein. In certain embodiments, the present invention provides an isolated polynucleotide molecule and/or a vector comprising a polynucleotide sequence that encodes a LCVR of an antibody as set forth herein. In certain embodiments, the present invention provides a cell expressing the vectors discussed above or herein.

[0127] In one aspect, the present invention provides a method for treating a disease or disorder that is treatable by antagonizing CTLA-4 via administration to a subject in need thereof a therapeutically effective amount of an anti-CTLA-4 antibody or antigen-binding fragment thereof as disclosed herein, or a pharmaceutical composition comprising such antibodies or antigen-binding fragments. In some cases, the disease or disorder is a chronic viral infection caused by a virus selected from the group consisting of human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human papilloma virus (HPV), lymphocytic choriomeningitis virus (LCMV) and simian immunodeficiency virus (SIV). In some cases, the disease or disorder is selected from the group consisting of blood cancer, brain cancer, renal cell cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, skin cancer, cervical cancer, kidney cancer, stomach cancer, pancreatic cancer, hepatic cell carcinoma, bone cancer, colon cancer, non-small-cell lung cancer, squamous cell carcinoma of head and neck, colorectal cancer, mesothelioma, B cell lymphoma, and melanoma.

[0128] In one aspect, the present invention provides methods of enhancing an immune response in a subject, the method comprising administering a pharmaceutical composition comprising an isolated anti-CTLA-4 antibody or antigen-binding fragment thereof as disclosed herein. In certain embodiments, the present invention provides methods of

inhibiting a T-regulatory (Treg) cell in a subject comprising administering a pharmaceutical composition comprising an isolated anti-CTLA-4 antibody or antigen-binding fragment thereof as disclosed herein. In certain embodiments, the present invention provides methods of enhancing T cell activation in a subject, the method comprising administering a pharmaceutical composition comprising an isolated anti-CTLA-4 antibody or antigen-binding fragment thereof as disclosed herein. In certain embodiments, the subject has a disease or disorder selected from the group consisting of blood cancer, brain cancer, renal cell carcinoma (e.g., clear cell renal carcinoma), ovarian cancer, bladder cancer, prostate cancer, breast cancer (e.g., triple negative breast cancer), skin cancer, cervical cancer, stomach cancer, kidney cancer, pancreatic cancer, hepatic cell carcinoma, bone cancer, colon cancer, non-small-cell lung cancer, squamous cell carcinoma of head and neck, colorectal cancer, mesothelioma, lymphoma (e.g., B cell lymphoma, diffuse large B cell lymphoma) and melanoma. In certain embodiments, the subject has a chronic viral infection caused by a virus selected from the group consisting of human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human papilloma virus (HPV), lymphocytic choriomeningitis virus (LCMV) and simian immunodeficiency virus (SIV). In certain embodiments, the anti-CTLA-4 antibody is administered to the subject in combination with a second therapeutic agent selected from the group consisting of a PD-1 inhibitor, a LAG3 inhibitor, an antibody to a tumor specific antigen, an antibody to a virally-infected-cell antigen, a PD-L1 inhibitor, a CD20 inhibitor, a bispecific antibody against CD20 and CD3, a dietary supplement such as an antioxidant, a VEGF antagonist, a cancer vaccine, a chemotherapeutic agent, a cytotoxic agent, surgery, radiation, a NSAID, a corticosteroid, and any other therapy useful for ameliorating at least one symptom associated with the disease or disorder.

[0129] In one aspect, the present invention provides methods of inhibiting growth of a tumor or a tumor cell in a subject comprising administering to the subject in need thereof a therapeutically effective amount of an anti-CTLA-4 antibody or antigen-binding fragment thereof as disclosed herein, or a pharmaceutical composition comprising such antibodies or antigen-binding fragments. In certain embodiments, the tumor is primary or recurrent. In certain embodiments, the tumor is an established tumor. In certain embodiments, the subject has metastatic disease and/or has been treated with prior therapy. In certain embodiments, the tumor is present in a subject with a disease or disorder selected from the group consisting of blood cancer, brain cancer, renal cell cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, hepatic cell carcinoma, bone cancer, colon cancer, non-small-cell lung cancer, squamous cell carcinoma of head and neck, colorectal cancer, mesothelioma, lymphoma, and melanoma. In certain embodiments, the anti-CTLA-4 antibody or antigen-binding fragment thereof is administered as one or more doses wherein

each dose is administered 1 to 12 weeks after the immediately preceding dose. In certain embodiments, the anti-CTLA-4 antibody or antigen-binding fragment thereof is administered at a dose of about 0.1 mg/kg of body weight to about 100 mg/kg of body weight of the subject. In certain embodiments, each dose comprises from about 50 mg to about 1000 mg of the antibody. In certain embodiments, the anti-CTLA-4 antibody is administered to the subject in combination with a second therapeutic agent selected from the group consisting of a PD-1 inhibitor, a LAG3 inhibitor, an antibody to a tumor specific antigen, a PD-L1 inhibitor, a CD20 inhibitor, a bispecific antibody against CD20 and CD3, a dietary supplement such as an antioxidant, a VEGF antagonist, a cancer vaccine, a chemotherapeutic agent, a cytotoxic agent, surgery, radiation, a NSAID, a corticosteroid, and any other therapy useful for ameliorating at least one symptom associated with the disease or disorder. In one embodiment, the second therapeutic agent is a PD-1 inhibitor wherein the PD-1 inhibitor is an antibody or antigen-binding fragment thereof that specifically binds to PD-1. In some embodiments, the PD-1 inhibitor is REGN2810, nivolumab or pembrolizumab. In certain embodiments, the anti-CTLA-4 antibody or antigen-binding fragment thereof is administered subcutaneously, intravenously, intratumorally, peritumorally, intradermally, intraperitoneally, orally, intramuscularly, or intracranially.

[0130] In one aspect, the present invention provides methods of rescuing CTLA-4-mediated inhibition of T cell activity comprising contacting the T cell with an anti-CTLA-4 antibody or antigen-binding fragment thereof as disclosed herein. In one embodiment, the T cell is contacted by an anti-CTLA-4 antibody of the present invention in combination with an anti-PD-1 antibody (e.g., REGN2810).

[0131] In one aspect, the present invention provides a use of an anti-CTLA-4 antibody or antigen-binding fragment thereof as disclosed herein, or a pharmaceutical composition comprising such antibodies or antigen-binding fragments, in the treatment of a disease or disorder that is treatable by antagonizing CTLA-4. In some cases, the disease or disorder is cancer.

[0132] In one aspect, the present invention provides a use of an anti-CTLA-4 antibody or antigen-binding fragment thereof as disclosed herein, or a pharmaceutical composition comprising such antibodies or antigen-binding fragments, in the manufacture of a medicament for treating a disease or disorder that is treatable by antagonizing CTLA-4. In some cases, the disease or disorder is cancer.

Antigen-Binding Fragments of Antibodies

[0133] Unless specifically indicated otherwise, the term "antibody," as used herein, shall be understood to encompass antibody molecules comprising two immunoglobulin heavy chains and two immunoglobulin light chains (*i.e.*, "full antibody molecules") as well as

antigen-binding fragments thereof. The terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex. The terms "antigen-binding fragment" of an antibody, or "antibody fragment", as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to CTLA-4. An antibody fragment may include a Fab fragment, a F(ab')₂ fragment, a Fv fragment, a dAb fragment, a fragment containing a CDR, or an isolated CDR. In certain embodiments, the term "antigen-binding fragment" refers to a polypeptide fragment of a multi-specific antigen-binding molecule. Antigen-binding fragments of an antibody may be derived, *e.g.*, from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and (optionally) constant domains. Such DNA is known and/or is readily available from, *e.g.*, commercial sources, DNA libraries (including, *e.g.*, phage-antibody libraries), or can be synthesized. The DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and/or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, etc.

[0134] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')₂ fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (*e.g.*, an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (*e.g.* monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed within the expression "antigen-binding fragment," as used herein.

[0135] An antigen-binding fragment of an antibody will typically comprise at least one variable domain. The variable domain may be of any size or amino acid composition and will generally comprise at least one CDR, which is adjacent to or in frame with one or more framework sequences. In antigen-binding fragments having a V_H domain associated with a V_L domain, the V_H and V_L domains may be situated relative to one another in any suitable arrangement. For example, the variable region may be dimeric and contain V_H - V_H, V_H - V_L or V_L - V_L dimers. Alternatively, the antigen-binding fragment of an antibody may contain a monomeric V_H or V_L domain.

[0136] In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting, exemplary configurations of variable and constant domains that may be found within an antigen-binding fragment of an antibody of the present invention include: (i) V_H-C_H1; (ii) V_H-C_H2; (iii) V_H-C_H3; (iv) V_H-C_H1-C_H2; (v) V_H-C_H1-C_H2-C_H3; (vi) V_H-C_H2-C_H3; (vii) V_H-C_L; (viii) V_L-C_H1; (ix) V_L-C_H2; (x) V_L-C_H3; (xi) V_L-C_H1-C_H2; (xii) V_L-C_H1-C_H2-C_H3; (xiii) V_L-C_H2-C_H3; and (xiv) V_L-C_L. In any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be either directly linked to one another or may be linked by a full or partial hinge or linker region. A hinge region may consist of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids, which result in a flexible or semi-flexible linkage between adjacent variable and/or constant domains in a single polypeptide molecule. Moreover, an antigen-binding fragment of an antibody of the present invention may comprise a homo-dimer or hetero-dimer (or other multimer) of any of the variable and constant domain configurations listed above in non-covalent association with one another and/or with one or more monomeric V_H or V_L domain (e.g., by disulfide bond(s)).

[0137] As with full antibody molecules, antigen-binding fragments may be mono-specific or multi-specific (e.g., bi-specific). A multi-specific antigen-binding fragment of an antibody will typically comprise at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Any multi-specific antibody format, including the exemplary bi-specific antibody formats disclosed herein, may be adapted for use in the context of an antigen-binding fragment of an antibody of the present invention using routine techniques available in the art.

Preparation of Human Antibodies

[0138] Methods for generating human antibodies in transgenic mice are known in the art. Any such known methods can be used in the context of the present invention to make human antibodies that specifically bind to CTLA-4.

[0139] Using VELOCIMMUNE® technology (see, for example, US 6,596,541, Regeneron Pharmaceuticals, VELOCIMMUNE®) or any other known method for generating monoclonal antibodies, high affinity chimeric antibodies to CTLA-4 are initially isolated having a human variable region and a mouse constant region. The VELOCIMMUNE® technology involves generation of a transgenic mouse having a genome comprising human heavy and light chain variable regions operably linked to endogenous mouse constant region loci such that the mouse produces an antibody comprising a human variable region and a mouse constant region in response to antigenic stimulation. The DNA encoding the variable regions of the heavy and light chains of the antibody are isolated and operably linked to DNA encoding the

human heavy and light chain constant regions. The DNA is then expressed in a cell capable of expressing the fully human antibody.

[0140] Generally, a VELOCIMMUNE® mouse is challenged with the antigen of interest, and lymphatic cells (such as B-cells) are recovered from the mice that express antibodies. The lymphatic cells may be fused with a myeloma cell line to prepare immortal hybridoma cell lines, and such hybridoma cell lines are screened and selected to identify hybridoma cell lines that produce antibodies specific to the antigen of interest. DNA encoding the variable regions of the heavy chain and light chain may be isolated and linked to desirable isotypic constant regions of the heavy chain and light chain. Such an antibody protein may be produced in a cell, such as a CHO cell. Alternatively, DNA encoding the antigen-specific chimeric antibodies or the variable domains of the light and heavy chains may be isolated directly from antigen-specific lymphocytes.

[0141] Initially, high affinity chimeric antibodies are isolated having a human variable region and a mouse constant region. As in the experimental section below, the antibodies are characterized and selected for desirable characteristics, including affinity, selectivity, epitope, etc. The mouse constant regions are replaced with a desired human constant region to generate the fully human antibody of the invention, for example wild-type or modified IgG1 or IgG4. While the constant region selected may vary according to specific use, high affinity antigen-binding and target specificity characteristics reside in the variable region.

Bioequivalents

[0142] The anti-CTLA-4 antibodies and antibody fragments of the present invention encompass proteins having amino acid sequences that vary from those of the described antibodies, but that retain the ability to bind CTLA-4. Such variant antibodies and antibody fragments comprise one or more additions, deletions, or substitutions of amino acids when compared to parent sequence, but exhibit biological activity that is essentially equivalent to that of the described antibodies. Likewise, the antibody-encoding DNA sequences of the present invention encompass sequences that comprise one or more additions, deletions, or substitutions of nucleotides when compared to the disclosed sequence, but that encode an antibody or antibody fragment that is essentially bioequivalent to an antibody or antibody fragment of the invention.

[0143] Two antigen-binding proteins, or antibodies, are considered bioequivalent if, for example, they are pharmaceutical equivalents or pharmaceutical alternatives whose rate and extent of absorption do not show a significant difference when administered at the same molar dose under similar experimental conditions, either single dose or multiple doses. Some antibodies will be considered equivalents or pharmaceutical alternatives if they are

equivalent in the extent of their absorption but not in their rate of absorption and yet may be considered bioequivalent because such differences in the rate of absorption are intentional and are reflected in the labeling, are not essential to the attainment of effective body drug concentrations on, e.g., chronic use, and are considered medically insignificant for the particular drug product studied.

[0144] In one embodiment, two antigen-binding proteins are bioequivalent if there are no clinically meaningful differences in their safety, purity, or potency.

[0145] In one embodiment, two antigen-binding proteins are bioequivalent if a patient can be switched one or more times between the reference product and the biological product without an expected increase in the risk of adverse effects, including a clinically significant change in immunogenicity, or diminished effectiveness, as compared to continued therapy without such switching.

[0146] In one embodiment, two antigen-binding proteins are bioequivalent if they both act by a common mechanism or mechanisms of action for the condition or conditions of use, to the extent that such mechanisms are known.

[0147] Bioequivalence may be demonstrated by *in vivo* and/or *in vitro* methods.

Bioequivalence measures include, e.g., (a) an *in vivo* test in humans or other mammals, in which the concentration of the antibody or its metabolites is measured in blood, plasma, serum, or other biological fluid as a function of time; (b) an *in vitro* test that has been correlated with and is reasonably predictive of human *in vivo* bioavailability data; (c) an *in vivo* test in humans or other mammals in which the appropriate acute pharmacological effect of the antibody (or its target) is measured as a function of time; and (d) in a well-controlled clinical trial that establishes safety, efficacy, or bioavailability or bioequivalence of an antibody.

[0148] Bioequivalent variants of the antibodies of the invention may be constructed by, for example, making various substitutions of residues or sequences or deleting terminal or internal residues or sequences not needed for biological activity. For example, cysteine residues not essential for biological activity can be deleted or replaced with other amino acids to prevent formation of unnecessary or incorrect intramolecular disulfide bridges upon renaturation. In other contexts, bioequivalent antibodies may include antibody variants comprising amino acid changes, which modify the glycosylation characteristics of the antibodies, e.g., mutations that eliminate or remove glycosylation.

Anti-CTLA-4 Antibodies Comprising Fc Variants

[0149] According to certain embodiments of the present invention, anti-CTLA-4 antibodies are provided comprising an Fc domain comprising one or more mutations which enhance or diminish antibody binding to the FcRn receptor, e.g., at acidic pH as compared to neutral pH.

For example, the present invention includes anti-CTLA-4 antibodies comprising a mutation in the C_H2 or a C_H3 region of the Fc domain, wherein the mutation(s) increases the affinity of the Fc domain to FcRn in an acidic environment (e.g., in an endosome where pH ranges from about 5.5 to about 6.0). Such mutations may result in an increase in serum half-life of the antibody when administered to an animal. Non-limiting examples of such Fc modifications include, e.g., a modification at position 250 (e.g., E or Q); 250 and 428 (e.g., L or F); 252 (e.g., L/Y/F/W or T), 254 (e.g., S or T), and 256 (e.g., S/R/Q/E/D or T); or a modification at position 428 and/or 433 (e.g., H/L/R/S/P/Q or K) and/or 434 (e.g., A, W, H, F or Y [N434A, N434W, N434H, N434F or N434Y]); or a modification at position 250 and/or 428; or a modification at position 307 or 308 (e.g., 308F, V308F), and 434. In one embodiment, the modification comprises a 428L (e.g., M428L) and 434S (e.g., N434S) modification; a 428L, 259I (e.g., V259I), and 308F (e.g., V308F) modification; a 433K (e.g., H433K) and a 434 (e.g., 434Y) modification; a 252, 254, and 256 (e.g., 252Y, 254T, and 256E) modification; a 250Q and 428L modification (e.g., T250Q and M428L); and a 307 and/or 308 modification (e.g., 308F or 308P). In yet another embodiment, the modification comprises a 265A (e.g., D265A) and/or a 297A (e.g., N297A) modification.

[0150] For example, the present invention includes anti-CTLA-4 antibodies comprising an Fc domain comprising one or more pairs or groups of mutations selected from the group consisting of: 250Q and 248L (e.g., T250Q and M248L); 252Y, 254T and 256E (e.g., M252Y, S254T and T256E); 428L and 434S (e.g., M428L and N434S); 257I and 311I (e.g., P257I and Q311I); 257I and 434H (e.g., P257I and N434H); 376V and 434H (e.g., D376V and N434H); 307A, 380A and 434A (e.g., T307A, E380A and N434A); and 433K and 434F (e.g., H433K and N434F). In one embodiment, the present invention includes anti-CTLA-4 antibodies comprising an Fc domain comprising a S108P mutation in the hinge region of IgG4 to promote dimer stabilization. All possible combinations of the foregoing Fc domain mutations, and other mutations within the antibody variable domains disclosed herein, are contemplated within the scope of the present invention.

[0151] The present invention also includes anti-CTLA-4 antibodies comprising a chimeric heavy chain constant (C_H) region, wherein the chimeric C_H region comprises segments derived from the C_H regions of more than one immunoglobulin isotype. For example, the antibodies of the invention may comprise a chimeric C_H region comprising part or all of a C_H2 domain derived from a human IgG1, human IgG2 or human IgG4 molecule, combined with part or all of a C_H3 domain derived from a human IgG1, human IgG2 or human IgG4 molecule. According to certain embodiments, the antibodies of the invention comprise a chimeric C_H region having a chimeric hinge region. For example, a chimeric hinge may comprise an "upper hinge" amino acid sequence (amino acid residues from positions 216 to 227 according to EU numbering) derived from a human IgG1, a human IgG2 or a human

IgG4 hinge region, combined with a "lower hinge" sequence (amino acid residues from positions 228 to 236 according to EU numbering) derived from a human IgG1, a human IgG2 or a human IgG4 hinge region. According to certain embodiments, the chimeric hinge region comprises amino acid residues derived from a human IgG1 or a human IgG4 upper hinge and amino acid residues derived from a human IgG2 lower hinge. An antibody comprising a chimeric C_H region as described herein may, in certain embodiments, exhibit modified Fc effector functions without adversely affecting the therapeutic or pharmacokinetic properties of the antibody. (See, e.g., US Patent Publication No. 20140243504, the disclosure of which is hereby incorporated by reference in its entirety).

Biological Characteristics of the Antibodies

[0152] In general, the antibodies of the present invention function by binding to CTLA-4. The present invention includes anti-CTLA-4 antibodies and antigen-binding fragments thereof that bind soluble monomeric or dimeric CTLA-4 molecules with high affinity. For example, the present invention includes antibodies and antigen-binding fragments of antibodies that bind dimeric human and monkey CTLA-4 (e.g., at 25°C) with a K_D of less than about 20nM as measured by surface plasmon resonance, e.g., using the assay format as defined in Example 3 herein. In certain embodiments, the antibodies or antigen-binding fragments thereof bind monomeric CTLA-4 with a K_D of less than about 10nM, less than about 5nM, less than about 2nM, or less than about 1nM, as measured by surface plasmon resonance, e.g., using the assay format as defined in Example 3 herein, or a substantially similar assay.

[0153] The present invention also includes antibodies and antigen-binding fragments thereof that bind CTLA-4 with a dissociative half-life (t_{1/2}) of greater than about 4 minutes as measured by surface plasmon resonance at 25°C, e.g., using an assay format as defined in Example 3 herein, or a substantially similar assay. In certain embodiments, the antibodies or antigen-binding fragments of the present invention bind CTLA-4 with a t_{1/2} of greater than about 5 minutes, greater than about 10 minutes, greater than about 15 minutes, greater than about 20 minutes, greater than about 30 minutes, greater than about 40 minutes, greater than about 100 minutes, greater than about 200 minutes, greater than about 300 minutes, or greater than about 500 minutes, as measured by surface plasmon resonance at 25°C, e.g., using an assay format as defined in Example 3 herein (e.g., mAb-capture format), or a substantially similar assay.

[0154] The present invention also includes antibodies or antigen-binding fragments thereof that block hCTLA-4 binding to hB7-1 (CD80) and/or hB7-2 (CD86) with an IC₅₀ of less than about 320 nM as determined using an Enzyme-linked Immunosorbent Assay (ELISA), e.g., as shown in Example 4, or a substantially similar assay. In certain embodiments, the

antibodies or antigen-binding fragments thereof block hCTLA-4 binding to human B7-1 and/or human B7-2 with an IC_{50} less than about 200nM, less than about 100nM, less than about 70nM, less than about 20nM, less than about 10nM, less than about 5nM, less than about 1nM, or less than about 0.5nM, as measured by a competition sandwich ELISA, e.g., as defined in Example 4 herein, or a substantially similar assay.

[0155] The present invention also includes antibodies or antigen-binding fragment thereof that block binding of hCTLA-4 to human B7-1 and/or human B7-2 by at least 85% as measured by a competition sandwich ELISA, e.g., as defined in Example 4 herein, or a substantially similar assay.

[0156] The present invention also includes antibodies or antigen-binding fragments thereof that bind to a human CTLA-4-expressing cell with an EC_{50} less than about 6nM as measured by an electrochemiluminescence assay as defined in Example 5 herein, or a substantially similar assay. In certain embodiments, the antibodies or antigen-binding fragments thereof bind to a hCTLA-4-expressing cell with an EC_{50} less than about 4nM, less than about 2nM, less than about 1nM, or less than about 0.5nM, as measured by an electrochemiluminescence assay, e.g., using the assay format in Example 5 herein, or a substantially similar assay. In certain embodiments, the antibodies or antigen-binding fragments thereof bind to a hCTLA-4-expressing cell at a ratio of more than about 10-fold above binding to control cells, at a ratio of more than about 15-fold, or at a ratio of more than about 20-fold above binding to control cells, as measured by an electrochemiluminescence assay, e.g., using the assay format in Example 5 herein, or a substantially similar assay.

[0157] The present invention also includes antibodies or antigen-binding fragments thereof that bind to a cynomolgus monkey CTLA-4-expressing cell with an EC_{50} less than about 0.5nM as measured by an electrochemiluminescence assay as defined in Example 5 herein, or a substantially similar assay. In certain embodiments, the antibodies or antigen-binding fragments thereof bind to a mfCTLA-4-expressing cell with an EC_{50} less than about 0.5nM, or less than about 0.2nM, as measured by an electrochemiluminescence assay, e.g., using the assay format as defined in Example 5 herein, or a substantially similar assay.

[0158] The present invention also includes antibodies or antigen-binding fragments thereof that block CTLA-4-induced T cell down-regulation (by blocking the CTLA-4/CD80 and CTLA-4/CD86 interactions) with an EC_{50} less than 8nM as measured by a T cell/APC luciferase reporter assay as defined in Example 6 herein, or a substantially similar assay. In certain embodiments, the antibodies or antigen-binding fragments thereof block CTLA-4-induced T cell down-regulation with an EC_{50} less than about 6nM, less than about 5nM, less than about 3nM, less than about 2.5nM, or less than about 2nM, as measured by a T cell/APC luciferase reporter assay, e.g., using the assay format as defined in Example 6 herein, or a substantially similar assay. In certain embodiments, the antibodies or antigen-binding

fragments thereof block CTLA-4-induced T cell down-regulation of both human and monkey CTLA-4.

[0159] The present invention also includes antibodies or antigen-binding fragments thereof that rescues CTLA-4-mediated inhibition of IL-2 release (by blocking the CTLA-4/CD80 and CTLA-4/CD86 interactions) with an EC_{50} less than about 50nM as measured by a T cell/APC IL-2 release assay as defined in Example 6 herein, or a substantially similar assay. In certain embodiments, the antibodies or antigen-binding fragments thereof rescues CTLA-4-mediated inhibition of IL-2 release with an EC_{50} less than about 45nM, less than about 35nM, less than about 25nM, or less than about 20nM, as measured by a T cell/APC IL-2 release assay, *e.g.*, using the assay format as defined in Example 6 herein, or a substantially similar assay. In certain embodiments, the antibodies or antigen-binding fragments thereof block CTLA-4-induced T cell down-regulation and/or CTLA-4-mediated inhibition of IL-2 release for both human and monkey CTLA-4. In certain embodiments, the antibodies or antigen-binding fragments thereof block CTLA-4-induced T cell down-regulation, as demonstrated by IL-2 production, at a rate of from 4 to 6 fold above that observed for an isotype control antibody.

[0160] In certain embodiments, the antibodies of the present invention are useful in inhibiting the growth of a tumor or delaying the progression of cancer when administered prophylactically to a subject in need thereof and may increase survival of the subject. For example, the administration of an antibody of the present invention may lead to shrinking of a primary tumor and may prevent metastasis or development of secondary tumors. In certain embodiments, the antibodies of the present invention are useful in inhibiting the growth of a tumor when administered therapeutically to a subject in need thereof and may increase survival of the subject. For example, the administration of a therapeutically effective amount of an antibody of the invention to a subject may lead to shrinking and disappearance of an established tumor in the subject. In certain embodiments, one or more antibodies of the present invention are administered locally (intratumorally or peritumorally) and lead to inhibition of tumor growth in the injected tumor lesion and in distant tumor lesions (abscopal effect).

[0161] In various embodiments, the invention provides an isolated recombinant monoclonal antibody or antigen-binding fragment thereof that binds to CTLA-4, wherein the antibody or antigen-binding fragment thereof exhibits one or more of the following characteristics: (i) comprises a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 314, 330, 346, 362, 378, 394, 410, 426, 442, 458, 474, and 490, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; (ii) comprises a LCVR having an amino acid

sequence selected from the group consisting of SEQ ID NO: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 322, 338, 354, 370, 386, 402, 418, 434, 450, 466, 482, and 498, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; (iii) comprises a HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 232, 248, 264, 280, 296, 312, 320, 336, 352, 368, 384, 400, 416, 432, 448, 464, 480, and 496, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; and a LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 224, 240, 256, 272, 288, 304, 328, 344, 360, 376, 392, 408, 424, 440, 456, 472, 488, and 504, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; (iv) comprises a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 228, 244, 260, 276, 292, 308, 316, 332, 348, 364, 380, 396, 412, 428, 444, 460, 476, and 492, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 230, 246, 262, 278, 294, 310, 318, 334, 350, 366, 382, 398, 414, 430, 446, 462, 478, and 494, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; a LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 220, 236, 252, 268, 284, 300, 324, 340, 356, 372, 388, 404, 420, 436, 452, 468, 484, and 500, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; and a LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 222, 238, 254, 270, 286, 302, 326, 342, 358, 374, 390, 406, 422, 438, 454, 470, 486, and 502, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; (v) binds dimeric human and monkey CTLA-4 with a binding dissociation equilibrium constant (K_D) of less than about 20nM as measured in a surface plasmon resonance assay at 25°C; (vi) binds dimeric human and monkey CTLA-4 with a dissociative half-life ($t_{1/2}$) of greater than about 4 minutes as measured in a surface plasmon resonance assay at 25°C; (vii) blocks hCTLA-4 binding to hB7-1 (CD80) and/or hB7-2 (CD86) with an IC₅₀ of less than about 320 nM as determined using a cell adherence assay; (viii) blocks the binding of hCTLA-4 to human B7-1 and/or human B7-2 by at least 85% as measured by a competition sandwich ELISA; (ix) binds to a human CTLA-4-expressing cell

with an EC₅₀ less than about 6 nM as measured by an electrochemiluminescence assay; (x) binds to a hCTLA-4-expressing cell at a ratio of more than 10-fold about binding to control cells; (xi) binds to a monkey CTLA-4-expressing cell with an EC₅₀ less than about 0.5 nM as measured by an electrochemiluminescence assay; (xii) blocks CTLA-4-induced T cell down regulation with an EC₅₀ less than 8 nM as measured by a T cell/APC luciferase reporter assay; (xiii) blocks CTLA-4-induced T cell down regulation of both human and monkey CTLA-4; (xiv) rescues CTLA-4-mediated inhibition of IL-2 release with EC₅₀ less than about 50nM as determined in a T cell/APC IL-2 release assay; (xv) blocks CTLA-4-induced T cell down-regulation and/or CTLA-4-mediated inhibition of IL-2 release for both human and monkey CTLA-4; (xvi) blocks CTLA-4-induced T cell down-regulation, as demonstrated by IL-2 production, at a rate of from 4 to 6 fold above that observed for an isotype control antibody; (xvii) suppresses tumor growth and increases survival in a subject with cancer, and (xviii) is fully human.

[0162] The antibodies of the present invention may possess one or more of the aforementioned biological characteristics, or any combinations thereof. Other biological characteristics of the antibodies of the present invention will be evident to a person of ordinary skill in the art from a review of the present disclosure including the working examples herein.

Species Selectivity and Species Cross-Reactivity

[0163] According to certain embodiments of the invention, the anti-CTLA-4 antibodies bind to human CTLA-4 but not to CTLA-4 from other species. Alternatively, the anti-CTLA-4 antibodies of the invention, in certain embodiments, bind to human CTLA-4 and to CTLA-4 from one or more non-human species. For example, the anti-CTLA-4 antibodies of the invention may bind to human CTLA-4 and may bind or not bind, as the case may be, to one or more of mouse, rat, guinea pig, hamster, gerbil, pig, cat, dog, rabbit, goat, sheep, cow, horse, camel, cynomolgus, marmoset, rhesus or chimpanzee CTLA-4. In certain embodiments, the anti-CTLA-4 antibodies of the invention may bind to human and cynomolgus CTLA-4 with the same affinities or with different affinities, but do not bind to rat and mouse CTLA-4.

Epitope Mapping and Related Technologies

[0164] The present invention includes anti-CTLA-4 antibodies which interact with one or more amino acids found within one or more domains of the CTLA-4 molecule including, e.g., an extracellular domain, a transmembrane domain, and a cytoplasmic domain. The epitope to which the antibodies bind may consist of a single contiguous sequence of 3 or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) amino acids located

within any of the aforementioned domains of the CTLA-4 molecule (e.g. a linear epitope in a domain). Alternatively, the epitope may consist of a plurality of non-contiguous amino acids (or amino acid sequences) located within any or all of the aforementioned domains of the CTLA-4 molecule (e.g. a conformational epitope).

[0165] Various techniques known to persons of ordinary skill in the art can be used to determine whether an antibody "interacts with one or more amino acids" within a polypeptide or protein. Exemplary techniques include, for example, routine cross-blocking assays, such as that described in *Antibodies*, Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harbor, NY). Other methods include alanine scanning mutational analysis, peptide blot analysis (Reineke (2004) *Methods Mol. Biol.* 248: 443-63), peptide cleavage analysis, crystallographic studies and NMR analysis. In addition, methods such as epitope excision, epitope extraction and chemical modification of antigens can be employed (Tomer (2000) *Prot. Sci.* 9: 487-496). Another method that can be used to identify the amino acids within a polypeptide with which an antibody interacts is hydrogen/deuterium exchange detected by mass spectrometry. In general terms, the hydrogen/deuterium exchange method involves deuterium-labeling the protein of interest, followed by binding the antibody to the deuterium-labeled protein. Next, the protein/antibody complex is transferred to water and exchangeable protons within amino acids that are protected by the antibody complex undergo deuterium-to-hydrogen back-exchange at a slower rate than exchangeable protons within amino acids that are not part of the interface. As a result, amino acids that form part of the protein/antibody interface may retain deuterium and therefore exhibit relatively higher mass compared to amino acids not included in the interface. After dissociation of the antibody, the target protein is subjected to protease cleavage and mass spectrometry analysis, thereby revealing the deuterium-labeled residues which correspond to the specific amino acids with which the antibody interacts. See, e.g., Ehring (1999) *Analytical Biochemistry* 267: 252-259; Engen and Smith (2001) *Anal. Chem.* 73: 256A-265A.

[0166] The term "epitope" refers to a site on an antigen to which B and/or T cells respond. B-cell epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation.

[0167] Modification-Assisted Profiling (MAP), also known as Antigen Structure-based Antibody Profiling (ASAP) is a method that categorizes large numbers of monoclonal antibodies (mAbs) directed against the same antigen according to the similarities of the binding profile of each antibody to chemically or enzymatically modified antigen surfaces

(see US 2004/0101920, herein specifically incorporated by reference in its entirety). Each category may reflect a unique epitope either distinctly different from or partially overlapping with epitope represented by another category. This technology allows rapid filtering of genetically identical antibodies, such that characterization can be focused on genetically distinct antibodies. When applied to hybridoma screening, MAP may facilitate identification of rare hybridoma clones that produce mAbs having the desired characteristics. MAP may be used to sort the antibodies of the invention into groups of antibodies binding different epitopes.

[0168] In certain embodiments, the anti-CTLA-4 antibodies or antigen-binding fragments thereof bind an epitope within any one or more of the regions exemplified in CTLA-4, either in natural form, as exemplified in SEQ ID NO: 505, or recombinantly produced, or to a fragment thereof.

[0169] The present invention includes anti-CTLA-4 antibodies that bind to the same epitope, or a portion of the epitope, as any of the specific exemplary antibodies described herein in Table 1, or an antibody having the CDR sequences of any of the exemplary antibodies described in Table 1. Likewise, the present invention also includes anti-CTLA-4 antibodies that compete for binding to CTLA-4 or a CTLA-4 fragment with any of the specific exemplary antibodies described herein in Table 1, or an antibody having the CDR sequences of any of the exemplary antibodies described in Table 1. For example, the present invention includes anti-CTLA-4 antibodies that cross-compete for binding to CTLA-4 with one or more antibodies as exemplified herein (e.g., H1H19303P or H1H19319P2).

[0170] One can easily determine whether an antibody binds to the same epitope as, or competes for binding with, a reference anti-CTLA-4 antibody by using routine methods known in the art. For example, to determine if a test antibody binds to the same epitope as a reference anti-CTLA-4 antibody of the invention, the reference antibody is allowed to bind to a CTLA-4 protein or peptide under saturating conditions. Next, the ability of a test antibody to bind to the CTLA-4 molecule is assessed. If the test antibody is able to bind to CTLA-4 following saturation binding with the reference anti-CTLA-4 antibody, it can be concluded that the test antibody binds to a different epitope than the reference anti-CTLA-4 antibody. On the other hand, if the test antibody is not able to bind to the CTLA-4 protein following saturation binding with the reference anti-CTLA-4 antibody, then the test antibody may bind to the same epitope as the epitope bound by the reference anti-CTLA-4 antibody of the invention.

[0171] To determine if an antibody competes for binding with a reference anti-CTLA-4 antibody, the above-described binding methodology is performed in two orientations: In a first orientation, the reference antibody is allowed to bind to a CTLA-4 protein under saturating conditions followed by assessment of binding of the test antibody to the CTLA-4

molecule. In a second orientation, the test antibody is allowed to bind to a CTLA-4 molecule under saturating conditions followed by assessment of binding of the reference antibody to the CTLA-4 molecule. If, in both orientations, only the first (saturating) antibody is capable of binding to the CTLA-4 molecule, then it is concluded that the test antibody and the reference antibody compete for binding to CTLA-4. As will be appreciated by a person of ordinary skill in the art, an antibody that competes for binding with a reference antibody may not necessarily bind to the identical epitope as the reference antibody, but may sterically block binding of the reference antibody by binding an overlapping or adjacent epitope.

[0172] Two antibodies bind to the same or overlapping epitope if each competitively inhibits (blocks) binding of the other to the antigen. That is, a 1-, 5-, 10-, 20- or 100-fold excess of one antibody inhibits binding of the other by at least 50% but preferably 75%, 90% or even 99% as measured in a competitive binding assay (see, *e.g.*, Junghans *et al.*, Cancer Res. 1990 50:1495-1502). Alternatively, two antibodies have the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other. Two antibodies have overlapping epitopes if some amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.

[0173] Additional routine experimentation (*e.g.*, peptide mutation and binding analyses) can then be carried out to confirm whether the observed lack of binding of the test antibody is in fact due to binding to the same epitope as the reference antibody or if steric blocking (or another phenomenon) is responsible for the lack of observed binding. Experiments of this sort can be performed using ELISA, RIA, surface plasmon resonance, flow cytometry or any other quantitative or qualitative antibody-binding assay available in the art.

Immunoconjugates

[0174] The invention encompasses a human anti-CTLA-4 monoclonal antibody conjugated to a therapeutic moiety ("immunoconjugate"), such as a cytotoxin or a chemotherapeutic agent to treat cancer. As used herein, the term "immunoconjugate" refers to an antibody which is chemically or biologically linked to a cytotoxin, a radioactive agent, a cytokine, an interferon, a target or reporter moiety, an enzyme, a toxin, a peptide or protein or a therapeutic agent. The antibody may be linked to the cytotoxin, radioactive agent, cytokine, interferon, target or reporter moiety, enzyme, toxin, peptide or therapeutic agent at any location along the molecule so long as it is able to bind its target. Examples of immunoconjugates include antibody drug conjugates and antibody-toxin fusion proteins. In one embodiment, the agent may be a second different antibody to CTLA-4. In certain embodiments, the antibody may be conjugated to an agent specific for a tumor cell or a virally infected cell. In one embodiment, the antibody is conjugated to an agent specific for a

T-cell. The type of therapeutic moiety that may be conjugated to the anti-CTLA-4 antibody and will take into account the condition to be treated and the desired therapeutic effect to be achieved. Examples of suitable agents for forming immunoconjugates are known in the art; see for example, WO 05/103081.

Multi-specific Antibodies

[0175] The antibodies of the present invention may be mono-specific, bi-specific, or multi-specific. Multi-specific antibodies may be specific for different epitopes of one target polypeptide or may contain antigen-binding domains specific for more than one target polypeptide. See, e.g., Tutt et al., 1991, J. Immunol. 147:60-69; Kufer et al., 2004, Trends Biotechnol. 22:238-244.

[0176] In one aspect, the present invention includes multi-specific antigen-binding molecules or antigen-binding fragments thereof wherein one specificity of an immunoglobulin is specific for the extracellular domain of CTLA-4, or a fragment thereof, and the other specificity of the immunoglobulin is specific for binding outside the extracellular domain of CTLA-4, or a second therapeutic target, or is conjugated to a therapeutic moiety.

[0177] Any of the multi-specific antigen-binding molecules of the invention, or variants thereof, may be constructed using standard molecular biological techniques (e.g., recombinant DNA and protein expression technology), as will be known to a person of ordinary skill in the art.

[0178] In some embodiments, CTLA-4-specific antibodies are generated in a bi-specific format (a "bi-specific") in which variable regions binding to distinct domains of CTLA-4 are linked together to confer dual-domain specificity within a single binding molecule.

Appropriately designed bi-specifics may enhance overall CTLA-4 inhibitory efficacy through increasing both specificity and binding avidity. Variable regions with specificity for individual domains, (e.g., segments of the N-terminal domain), or that can bind to different regions within one domain, are paired on a structural scaffold that allows each region to bind simultaneously to the separate epitopes, or to different regions within one domain. In one example for a bi-specific, heavy chain variable regions (V_H) from a binder with specificity for one domain are recombined with light chain variable regions (V_L) from a series of binders with specificity for a second domain to identify non-cognate V_L partners that can be paired with an original V_H without disrupting the original specificity for that V_H . In this way, a single V_L segment (e.g., V_{L1}) can be combined with two different V_H domains (e.g., V_{H1} and V_{H2}) to generate a bi-specific comprised of two binding "arms" (V_{H1} - V_{L1} and V_{H2} - V_{L1}). Use of a single V_L segment reduces the complexity of the system and thereby simplifies and increases efficiency in cloning, expression, and purification processes used to generate the bi-specific (See, for example, USSN13/022759 and US2010/0331527).

[0179] Alternatively, antibodies that bind more than one domains and a second target, such as, but not limited to, for example, a second different anti-CTLA-4 antibody, may be prepared in a bi-specific format using techniques described herein, or other techniques known to those skilled in the art. Antibody variable regions binding to distinct regions may be linked together with variable regions that bind to relevant sites on, for example, the extracellular domain of CTLA-4, to confer dual-antigen specificity within a single binding molecule. Appropriately designed bi-specifics of this nature serve a dual function. Variable regions with specificity for the extracellular domain are combined with a variable region with specificity for outside the extracellular domain and are paired on a structural scaffold that allows each variable region to bind to the separate antigens.

[0180] An exemplary bi-specific antibody format that can be used in the context of the present invention involves the use of a first immunoglobulin (Ig) C_H3 domain and a second Ig C_H3 domain, wherein the first and second Ig C_H3 domains differ from one another by at least one amino acid, and wherein at least one amino acid difference reduces binding of the bi-specific antibody to Protein A as compared to a bi-specific antibody lacking the amino acid difference. In one embodiment, the first Ig C_H3 domain binds Protein A and the second Ig C_H3 domain contains a mutation that reduces or abolishes Protein A binding such as an H95R modification (by IMGT exon numbering; H435R by EU numbering). The second C_H3 may further comprise a Y96F modification (by IMGT; Y436F by EU). Further modifications that may be found within the second C_H3 include: D16E, L18M, N44S, K52N, V57M, and V82I (by IMGT; D356E, L358M, N384S, K392N, V397M, and V422I by EU) in the case of IgG1 antibodies; N44S, K52N, and V82I (IMGT; N384S, K392N, and V422I by EU) in the case of IgG2 antibodies; and Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I (by IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I by EU) in the case of IgG4 antibodies. Variations on the bi-specific antibody format described above are contemplated within the scope of the present invention.

[0181] Other exemplary bispecific formats that can be used in the context of the present invention include, without limitation, *e.g.*, scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, Quadroma, knobs-into-holes, common light chain (*e.g.*, common light chain with knobs-into-holes, etc.), CrossMab, CrossFab, (SEED)body, leucine zipper, Duobody, IgG1/IgG2, dual acting Fab (DAF)-IgG, and Mab² bispecific formats (see, *e.g.*, Klein *et al.* 2012, mAbs 4:6, 1-11, and references cited therein, for a review of the foregoing formats). Bispecific antibodies can also be constructed using peptide/nucleic acid conjugation, *e.g.*, wherein unnatural amino acids with orthogonal chemical reactivity are used to generate site-specific antibody-oligonucleotide conjugates which then self-assemble into multimeric complexes with defined composition, valency and geometry. (See, *e.g.*, Kazane *et al.*, *J. Am. Chem. Soc.* [Epub: Dec. 4, 2012]).

Therapeutic Administration and Formulations

[0182] The invention provides therapeutic compositions comprising the anti-CTLA-4 antibodies or antigen-binding fragments thereof of the present invention. Therapeutic compositions in accordance with the invention will be administered with suitable carriers, excipients, and other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTIN™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell *et al.* "Compendium of excipients for parenteral formulations" PDA (1998) J Pharm Sci Technol 52:238-311.

[0183] The dose of antibody may vary depending upon the age and the size of a subject to be administered, target disease, conditions, route of administration, and the like. When an antibody of the present invention is used for treating a disease or disorder in an adult patient, or for preventing such a disease, it is advantageous to administer the antibody of the present invention normally at a single dose of about 0.1 to about 60 mg/kg body weight, more preferably about 5 to about 60, about 20 to about 50, about 10 to about 50, about 1 to about 10, or about 0.8 to about 11 mg/kg body weight. Depending on the severity of the condition, the frequency and the duration of the treatment can be adjusted. In certain embodiments, the antibody or antigen-binding fragment thereof of the invention can be administered as an initial dose of at least about 0.1 mg to about 800 mg, about 1 to about 500 mg, about 5 to about 300 mg, or about 10 to about 200 mg, to about 100 mg, or to about 50 mg. In certain embodiments, the initial dose may be followed by administration of a second or a plurality of subsequent doses of the antibody or antigen-binding fragment thereof in an amount that can be approximately the same or less than that of the initial dose, wherein the subsequent doses are separated by at least 1 day to 3 days; at least one week, at least 2 weeks; at least 3 weeks; at least 4 weeks; at least 5 weeks; at least 6 weeks; at least 7 weeks; at least 8 weeks; at least 9 weeks; at least 10 weeks; at least 12 weeks; or at least 14 weeks.

[0184] Various delivery systems are known and can be used to administer the pharmaceutical composition of the invention, *e.g.*, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, *e.g.*, Wu *et al.* (1987) J. Biol. Chem. 262:4429-4432). Methods of introduction include, but are not limited to, intradermal, transdermal,

intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural and oral routes. The composition may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (*e.g.*, oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. The pharmaceutical composition can be also delivered in a vesicle, in particular a liposome (see, for example, Langer (1990) Science 249:1527-1533).

[0185] The use of nanoparticles to deliver the antibodies of the present invention is also contemplated herein. Antibody-conjugated nanoparticles may be used both for therapeutic and diagnostic applications. Antibody-conjugated nanoparticles and methods of preparation and use are described in detail by Arruebo, M., et al. 2009 ("Antibody-conjugated nanoparticles for biomedical applications" in J. Nanomat. Volume 2009, Article ID 439389, 24 pages, doi: 10.1155/2009/439389), incorporated herein by reference. Nanoparticles may be developed and conjugated to antibodies contained in pharmaceutical compositions to target tumor cells or autoimmune tissue cells or virally infected cells. Nanoparticles for drug delivery have also been described in, for example, US 8257740, or US 8246995, each incorporated herein in its entirety.

[0186] In certain situations, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump may be used. In another embodiment, polymeric materials can be used. In yet another embodiment, a controlled release system can be placed in proximity of the composition's target, thus requiring only a fraction of the systemic dose.

[0187] The injectable preparations may include dosage forms for intravenous, subcutaneous, intratumoral, peritumoral, intracutaneous, intracranial, intraperitoneal and intramuscular injections, drip infusions, etc. These injectable preparations may be prepared by methods publicly known. For example, the injectable preparations may be prepared, *e.g.*, by dissolving, suspending or emulsifying the antibody or its salt described above in a sterile aqueous medium or an oily medium conventionally used for injections. As the aqueous medium for injections, there are, for example, physiological saline, an isotonic solution containing glucose and other auxiliary agents, etc., which may be used in combination with an appropriate solubilizing agent such as an alcohol (*e.g.*, ethanol), a polyalcohol (*e.g.*, propylene glycol, polyethylene glycol), a nonionic surfactant [*e.g.*, polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc. As the oily medium, there are employed, *e.g.*, sesame oil, soybean oil, etc., which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc. The injection thus prepared is preferably filled in an appropriate ampoule.

[0188] A pharmaceutical composition of the present invention can be delivered

subcutaneously or intravenously with a standard needle and syringe. In addition, with respect to subcutaneous delivery, a pen delivery device readily has applications in delivering a pharmaceutical composition of the present invention. Such a pen delivery device can be reusable or disposable. A reusable pen delivery device generally utilizes a replaceable cartridge that contains a pharmaceutical composition. Once all of the pharmaceutical composition within the cartridge has been administered and the cartridge is empty, the empty cartridge can readily be discarded and replaced with a new cartridge that contains the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, the disposable pen delivery device comes prefilled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.

[0189] Numerous reusable pen and autoinjector delivery devices have applications in the subcutaneous delivery of a pharmaceutical composition of the present invention. Examples include, but certainly are not limited to AUTOPEN™ (Owen Mumford, Inc., Woodstock, UK), DISETRONIC™ pen (Disetronic Medical Systems, Burghdorf, Switzerland), HUMALOG MIX 75/25™ pen, HUMALOG™ pen, HUMALIN 70/30™ pen (Eli Lilly and Co., Indianapolis, IN), NOVOPEN™ I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR™ (Novo Nordisk, Copenhagen, Denmark), BD™ pen (Becton Dickinson, Franklin Lakes, NJ), OPTIPEN™, OPTIPEN PRO™, OPTIPEN STARLET™, and OPTICLIK™ (Sanofi-Aventis, Frankfurt, Germany), to name only a few. Examples of disposable pen delivery devices having applications in subcutaneous delivery of a pharmaceutical composition of the present invention include, but certainly are not limited to the SOLOSTAR™ pen (Sanofi-Aventis), the FLEXPEN™ (Novo Nordisk), and the KWIKPEN™ (Eli Lilly), the SURECLICK™ Autoinjector (Amgen, Thousand Oaks, CA), the PENLET™ (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey, L.P.) and the HUMIRA™ Pen (Abbott Labs, Abbott Park, IL), to name only a few.

[0190] Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared into dosage forms in a unit dose suited to fit a dose of the active ingredients. Such dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc. The amount of the antibody contained is generally about 5 to about 500 mg per dosage form in a unit dose; especially in the form of injection, it is preferred that the antibody is contained in about 5 to about 100 mg and in about 10 to about 250 mg for the other dosage forms.

Therapeutic Uses of the Antibodies

[0191] The antibodies of the invention are useful, *inter alia*, for the treatment, prevention

and/or amelioration of any disease or disorder associated with or mediated by CTLA-4 expression, signaling or activity, or treatable by blocking the interaction between CTLA-4 and the CTLA-4 ligands B7-1/CD80 and/or B7-2/CD86, or otherwise inhibiting CTLA-4 activity and/or signaling. One or more antibodies of the present invention may be administered to relieve or prevent or decrease the severity of one or more of the symptoms or conditions of the disease or disorder. For example, the present invention provides methods for treating cancer (tumor growth inhibition) and/or viral infections by administering an anti-CTLA-4 antibody (or pharmaceutical composition comprising an anti-CTLA-4 antibody) as described herein to a patient in need of such treatment, and anti-CTLA-4 antibodies (or pharmaceutical composition comprising an anti-CTLA-4 antibody) for use in the treatment of cancer (tumor growth inhibition) and/or viral infections. The antibodies of the present invention are useful for the treatment, prevention, and/or amelioration of disease or disorder or condition such as cancer or a viral infection and/or for ameliorating at least one symptom associated with such disease, disorder or condition. In the context of the methods of treatment described herein, the anti-CTLA-4 antibody may be administered as a monotherapy (*i.e.*, as the only therapeutic agent) or in combination with one or more additional therapeutic agents (examples of which are described elsewhere herein).

[0192] In some embodiments of the invention, the antibodies described herein are useful for treating subjects suffering from primary or recurrent cancer, including, but not limited to, blood cancer, brain cancer (*e.g.*, glioblastoma multiforme), renal cell carcinoma (*e.g.*, clear cell renal cancer), ovarian cancer, bladder cancer, prostate cancer, breast cancer (*e.g.*, triple negative breast cancer), kidney cancer, cervical cancer, skin cancer, liver cancer, stomach cancer, pancreatic cancer, hepatic cell carcinoma, bone cancer, colon cancer, non-small-cell lung cancer, squamous cell carcinoma of head and neck, colorectal cancer, mesothelioma, and melanoma.

[0193] As used herein, the term “blood cancer” includes a hematologic malignancy that affects blood, bone marrow, lymph or lymphatic system. As such, the term includes malignancies of cells from the lymphoid and myeloid cell lineages. The myeloid cell line normally produces granulocytes, erythrocytes, thrombocytes, macrophages, and mast cells; the lymphoid cell line produces B, T, NK and plasma cells. The term, therefore, includes malignancies of the above-mentioned cells, *viz.* lymphomas, myelomas, lymphoid leukemias and myelogenous leukemias. Examples include, but are not limited to, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute monocytic leukemia, Hodgkin’s lymphomas, non-Hodgkin’s lymphomas (*e.g.*, B cell lymphoma, diffuse large B cell lymphoma), and myeloma (including multiple myeloma).

[0194] The antibodies may be used to treat early stage or late-stage symptoms of cancer.

In one embodiment, an antibody or fragment thereof of the invention may be used to treat advanced or metastatic cancer. The antibodies are useful in reducing or inhibiting or shrinking tumor growth of both solid tumors and blood cancers. In certain embodiments, treatment with an antibody or antigen-binding fragment thereof of the invention leads to more than 40% regression, more than 50% regression, more than 60% regression, more than 70% regression, more than 80% regression or more than 90% regression of a tumor in a subject. In certain embodiments, the antibodies may be used to prevent relapse of a tumor. In certain embodiments, the antibodies are useful in extending progression-free survival or overall survival in a subject with cancer. In some embodiments, the antibodies are useful in reducing toxicity due to chemotherapy or radiotherapy while maintaining long-term survival in a patient suffering from cancer. In certain embodiments, one or more antibodies of the present invention are injected locally into one or more tumor lesions (intratumorally or peritumorally), and lead to inhibition of tumor growth in the injected tumor as well as in one or more adjacent or distant tumors in the subject (abscopal effect).

[0195] In certain embodiments, the antibodies of the invention are useful to treat subjects suffering from a chronic viral infection. In some embodiments, the antibodies of the invention are useful in decreasing viral titers in the host and/or rescuing exhausted T cells. In certain embodiments, an antibody or fragment thereof of the invention may be used to treat chronic viral infection by lymphocytic choriomeningitis virus (LCMV). In some embodiments, an antibody or antigen-binding fragment thereof of the invention may be administered at a therapeutic dose to a patient with an infection by human immunodeficiency virus (HIV) or human papilloma virus (HPV) or hepatitis B/C virus (HBV/HCV). In a related embodiment, an antibody or antigen-binding fragment thereof of the invention may be used to treat an infection by simian immunodeficiency virus (SIV) in a simian subject such as cynomolgus.

[0196] In certain embodiments, a blocking antibody of the present invention may be administered in a therapeutically effective amount to a subject suffering from a cancer or a viral infection.

[0197] In certain embodiments, one or more antibodies of the present invention are administered locally into a tumor or near a tumor lesion (intratumorally or peritumorally) in a subject with cancer to minimize systemic exposure and to prevent/ameliorate toxicity due to systemic exposure of the antibody.

[0198] It is also contemplated herein to use one or more antibodies of the present invention prophylactically to patients at risk for developing a disease or disorder such as cancer, and viral infection.

[0199] In a further embodiment of the invention, the present antibodies are used for the preparation of a pharmaceutical composition for treating patients suffering from cancer, or viral infection. In another embodiment of the invention, the present antibodies are used as

adjunct therapy with any other agent or any other therapy known to those skilled in the art useful for treating cancer or viral infection.

Combination Therapies and Formulations

[0200] Combination therapies may include an anti-CTLA-4 antibody of the invention and any additional therapeutic agent that may be advantageously combined with an antibody of the invention, or with a biologically active fragment of an antibody of the invention.

[0201] The antibodies of the present invention may be combined synergistically with one or more anti-cancer drugs or therapy used to treat or inhibit cancer, including, for example, blood cancer, brain cancer (e.g., glioblastoma multiforme), renal cell carcinoma, ovarian cancer, bladder cancer, prostate cancer, breast cancer, hepatic cell carcinoma, bone cancer, skin cancer, cervical cancer, stomach cancer, kidney cancer, colon cancer, non-small-cell lung cancer, squamous cell carcinoma of head and neck, colorectal cancer, mesothelioma, and melanoma. It is contemplated herein to use anti-CTLA-4 antibodies of the invention in combination with immunostimulatory and/or immunosupportive therapies to inhibit tumor growth, and/or enhance survival of cancer patients. The immunostimulatory therapies include direct immunostimulatory therapies to augment immune cell activity by either “releasing the brake” on suppressed immune cells or “stepping on the gas” to activate an immune response. Examples include targeting other checkpoint receptors, vaccination and adjuvants. The immunosupportive modalities may increase antigenicity of the tumor by promoting immunogenic cell death, inflammation or have other indirect effects that promote an anti-tumor immune response. Examples include radiation, chemotherapy, anti-angiogenic agents, and surgery.

[0202] In various embodiments, one or more antibodies of the present invention may be used in combination with a PD-1 inhibitor (e.g., an anti-PD-1 antibody such as nivolumab, pembrolizumab, pidilizumab, BGB-A317 or REGN2810), a PD-L1 inhibitor (e.g., an anti-PD-L1 antibody such as avelumab, atezolizumab, durvalumab, MDX-1105, or REGN3504), a LAG3 inhibitor, a TIM3 inhibitor, a BTLA inhibitor, a TIGIT inhibitor, a CD47 inhibitor, a CD28 inhibitor, a CSF1R inhibitor, a CXCR inhibitor, a CCR4 inhibitor, a CCR8 inhibitor, a CD40 inhibitor, a OX40 inhibitor, a GITR inhibitor, an antagonist of another T cell co-inhibitor or ligand (e.g., an antibody to CD-28, 2B4, LY108, LAIR1, ICOS, CD160 or VISTA), an indoleamine-2,3-dioxygenase (IDO) inhibitor, a vascular endothelial growth factor (VEGF) antagonist [e.g., a “VEGF-Trap” such as aflibercept or other VEGF-inhibiting fusion protein as set forth in US 7,087,411, or an anti-VEGF antibody or antigen binding fragment thereof (e.g., bevacizumab, or ranibizumab) or a small molecule kinase inhibitor of VEGF receptor (e.g., sunitinib, sorafenib, or pazopanib)], an Ang2 inhibitor (e.g., nesvacumab), a transforming growth factor beta (TGF β) inhibitor, an epidermal growth factor receptor

(EGFR) inhibitor (e.g., erlotinib, cetuximab), a CD20 inhibitor (e.g., an anti-CD20 antibody such as rituximab), an antibody to a tumor-specific antigen [e.g., CA9, CA125, melanoma-associated antigen 3 (MAGE3), carcinoembryonic antigen (CEA), vimentin, tumor-M2-PK, prostate-specific antigen (PSA), mucin-1, MART-1, and CA19-9], a vaccine (e.g., Bacillus Calmette-Guerin, a cancer vaccine), an adjuvant to increase antigen presentation (e.g., granulocyte-macrophage colony-stimulating factor), a bispecific antibody (e.g., CD3xCD20 bispecific antibody, or PSMAxCD3 bispecific antibody), a cytotoxin, a chemotherapeutic agent (e.g., dacarbazine, temozolomide, cyclophosphamide, docetaxel, doxorubicin, daunorubicin, cisplatin, carboplatin, gemcitabine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, and vincristine), cyclophosphamide, surgery, radiotherapy, an IL-6R inhibitor (e.g., sarilumab), an IL-4R inhibitor (e.g., dupilumab), an IL-10 inhibitor, a cytokine such as IL-2, IL-7, IL-21, and IL-15, an antibody-drug conjugate (ADC) (e.g., anti-CD19-DM4 ADC, and anti-DS6-DM4 ADC), an anti-inflammatory drug (e.g., corticosteroids, and non-steroidal anti-inflammatory drugs), a dietary supplement such as anti-oxidants or any other therapy care to treat cancer. In certain embodiments, the anti-CTLA-4 antibodies of the present invention may be used in combination with cancer vaccines including dendritic cell vaccines, oncolytic viruses, tumor cell vaccines, etc. to augment the anti-tumor response. Examples of cancer vaccines that can be used in combination with anti-CTLA-4 antibodies of the present invention include MAGE3 vaccine for melanoma and bladder cancer, MUC1 vaccine for breast cancer, EGFRv3 (e.g., Rindopepimut) for brain cancer (including glioblastoma multiforme), or ALVAC-CEA (for CEA+ cancers).

[0203] In certain embodiments, the anti-CTLA-4 antibodies of the invention may be administered in combination with radiation therapy in methods to generate long-term durable anti-tumor responses and/or enhance survival of patients with cancer. In some embodiments, the anti-CTLA-4 antibodies of the invention may be administered prior to, concomitantly or after administering radiation therapy to a cancer patient. For example, radiation therapy may be administered in one or more doses to tumor lesions followed by administration of one or more doses of anti-CTLA-4 antibodies of the invention. In some embodiments, radiation therapy may be administered locally to a tumor lesion to enhance the local immunogenicity of a patient's tumor (adjuvating radiation) and/or to kill tumor cells (ablative radiation) followed by systemic administration of an anti-CTLA-4 antibody of the invention. For example, intracranial radiation may be administered to a patient with brain cancer (e.g., glioblastoma multiforme) in combination with systemic administration of an anti-CTLA-4 antibody of the invention. In certain embodiments, the anti-CTLA-4 antibodies of the invention may be administered in combination with radiation therapy and a chemotherapeutic agent (e.g., temozolomide) or a VEGF antagonist (e.g., aflibercept). In certain embodiments, the anti-CTLA-4 antibodies of the invention may be administered in

combination with radiation therapy and a chemotherapeutic agent (e.g., temozolomide) or a PD-1 inhibitor (e.g., an anti-PD-1 antibody such as REGN2810, nivolumab, or pembrolizumab).

[0204] In certain embodiments, the anti-CTLA-4 antibodies of the invention may be administered in combination with one or more anti-viral drugs to treat chronic viral infection caused by LCMV, HIV, HPV, HBV or HCV. Examples of anti-viral drugs include, but are not limited to, zidovudine, lamivudine, abacavir, ribavirin, lopinavir, efavirenz, cobicistat, tenofovir, rilpivirine and corticosteroids.

[0205] The additional therapeutically active agent(s)/component(s) may be administered prior to, concurrent with, or after the administration of the anti-CTLA-4 antibody of the present invention. For purposes of the present disclosure, such administration regimens are considered the administration of an anti-CTLA-4 antibody "in combination with" a second therapeutically active component.

[0206] The additional therapeutically active component(s) may be administered to a subject prior to administration of an anti-CTLA-4 antibody of the present invention. For example, a first component may be deemed to be administered "prior to" a second component if the first component is administered 1 week before, 72 hours before, 60 hours before, 48 hours before, 36 hours before, 24 hours before, 12 hours before, 6 hours before, 5 hours before, 4 hours before, 3 hours before, 2 hours before, 1 hour before, 30 minutes before, 15 minutes before, 10 minutes before, 5 minutes before, or less than 1 minute before administration of the second component. In other embodiments, the additional therapeutically active component(s) may be administered to a subject after administration of an anti-CTLA-4 antibody of the present invention. For example, a first component may be deemed to be administered "after" a second component if the first component is administered 1 minute after, 5 minutes after, 10 minutes after, 15 minutes after, 30 minutes after, 1 hour after, 2 hours after, 3 hours after, 4 hours after, 5 hours after, 6 hours after, 12 hours after, 24 hours after, 36 hours after, 48 hours after, 60 hours after, 72 hours after administration of the second component. In yet other embodiments, the additional therapeutically active component(s) may be administered to a subject concurrent with administration of an anti-CTLA-4 antibody of the present invention. "Concurrent" administration, for purposes of the present invention, includes, e.g., administration of an anti-CTLA-4 antibody and an additional therapeutically active component to a subject in a single dosage form (e.g., co-formulated), or in separate dosage forms administered to the subject within about 30 minutes or less of each other. If administered in separate dosage forms, each dosage form may be administered via the same route (e.g., both the anti-CTLA-4 antibody and the additional therapeutically active component may be administered intravenously, subcutaneously, etc.); alternatively, each dosage form may be administered

via a different route (e.g., the anti-CTLA-4 antibody may be administered intravenously, and the additional therapeutically active component may be administered subcutaneously). In any event, administering the components in a single dosage form, in separate dosage forms by the same route, or in separate dosage forms by different routes are all considered "concurrent administration," for purposes of the present disclosure. For purposes of the present disclosure, administration of an anti-CTLA-4 antibody "prior to", "concurrent with," or "after" (as those terms are defined herein above) administration of an additional therapeutically active component is considered administration of an anti-CTLA-4 antibody "in combination with" an additional therapeutically active component).

[0207] The present invention includes pharmaceutical compositions in which an anti-CTLA-4 antibody of the present invention is co-formulated with one or more of the additional therapeutically active component(s) as described elsewhere herein using a variety of dosage combinations.

[0208] In exemplary embodiments in which an anti-CTLA-4 antibody of the invention is administered in combination with a PD-1 inhibitor (e.g., an anti-PD-1 antibody as disclosed in US 2015/0203579, herein incorporated by reference in its entirety), including administration of co-formulations comprising an anti-CTLA-4 antibody and a PD-1 inhibitor, the individual components may be administered to a subject and/or co-formulated using a variety of dosage combinations. Thus, the present invention includes a combination of (i) an anti-CTLA-4 antibody of the invention, and (ii) a PD-1 inhibitor (e.g., an anti-PD-1 antibody as disclosed in US 2015/0203579, herein incorporated by reference in its entirety), for simultaneous, separate and/or sequential use in the treatment of cancer or viral infections. For example, the anti-CTLA-4 antibody and the PD-1 inhibitor (e.g., an anti-PD-1 antibody) each may be administered to a subject and/or contained in a co-formulation in an amount selected from the group consisting of 0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.7 mg/kg, 0.8 mg/kg, 0.9 mg/kg, 1.0 mg/kg, 1.5 mg/kg, 2.0 mg/kg, 2.5 mg/kg, 3.0 mg/kg, 3.5 mg/kg, 4.0 mg/kg, 4.5 mg/kg, 5.0 mg/kg, 6.0 mg/kg, 7.0 mg/kg, 8.0 mg/kg, 9.0 mg/kg, and 10.0 mg/kg. In one embodiment, the anti-CTLA-4 antibody and the PD-1 inhibitor (e.g., an anti-PD-1 antibody) each may be administered to a subject and/or contained in a co-formulation in an amount from about 50mg to about 600mg, e.g., an amount selected from the group consisting of 50mg, 100mg, 200mg, 250mg, 300mg, 350mg, 400mg, 450mg, 500mg, 550mg, and 600mg. The combinations/co-formulations may be administered to a subject according to any of the administration regimens disclosed elsewhere herein, including, e.g., twice a week, once every week, once every 2 weeks, once every 3 weeks, once every month, once every 2 months, once every 3 months, once every 4 months, once every 5 months, once every 6 months, etc. The anti-CTLA-4 antibody of the invention might, for

instance, be administered at a dose of about 0.8 to about 11, about 1 to about 10, about 3 to about 10, about 1, about 3 or about 10 mg/kg, simultaneously with an PD-1 inhibitor (e.g. an anti-PD-1 antibody as disclosed in US 2015/0203579) at a dose of about 3 to 5, or about 3.0 mg/kg. The simultaneous administration might for instance occur every 14 days, 21 days or 28 days.

[0209] In exemplary embodiments in which an anti-CTLA-4 antibody of the invention is administered in combination with an anti-PD-1 antibody and a VEGF antagonist (e.g., a VEGF trap such as aflibercept), including administration of co-formulations comprising an anti-CTLA-4 antibody, an anti-PD-1 antibody, and a VEGF antagonist, the individual components may be administered to a subject and/or co-formulated using a variety of dosage combinations. For example, the anti-CTLA-4 antibody and/or anti-PD-1 antibody may be administered to a subject and/or contained in a co-formulation in an amount selected from the group consisting of 0.01 mg, 0.02 mg, 0.03 mg, 0.04 mg, 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 6.0 mg, 7.0 mg, 8.0 mg, 9.0 mg, and 10.0 mg; and the VEGF antagonist (e.g., a VEGF trap such as aflibercept) may be administered to the subject and/or contained in a co-formulation in an amount selected from the group consisting of 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg, 2.0 mg, 2.1 mg, 2.2 mg, 2.3 mg, 2.4 mg, 2.5 mg, 2.6 mg, 2.7 mg, 2.8 mg, 2.9 mg and 3.0 mg. The combinations/co-formulations may be administered to a subject according to any of the administration regimens disclosed elsewhere herein, including, e.g., twice a week, once every week, once every 2 weeks, once every 3 weeks, once every month, once every 2 months, once every 3 months, once every 4 months, once every 5 months, once every 6 months, etc.

Administrative Regimens

[0210] According to certain embodiments of the present invention, multiple doses of an anti-CTLA-4 antibody (or a pharmaceutical composition comprising a combination of an anti-CTLA-4 antibody and any of the additional therapeutically active agents mentioned herein) may be administered to a subject over a defined time course. The methods according to this aspect of the invention comprise sequentially administering to a subject multiple doses of an anti-CTLA-4 antibody of the invention. As used herein, "sequentially administering" means that each dose of anti-CTLA-4 antibody is administered to the subject at a different point in time, e.g., on different days separated by a predetermined interval (e.g., hours, days, weeks or months). The present invention includes methods which comprise sequentially administering to the patient a single initial dose of an anti-CTLA-4 antibody, followed by one or more secondary doses of the anti-CTLA-4 antibody, and optionally followed by one or

more tertiary doses of the anti-CTLA-4 antibody. The anti-CTLA-4 antibody may be administered at a dose between 0.1 mg/kg to 100 mg/kg body weight of the subject.

[0211] The terms "initial dose," "secondary doses," and "tertiary doses," refer to the temporal sequence of administration of the anti-CTLA-4 antibody of the invention. Thus, the "initial dose" is the dose which is administered at the beginning of the treatment regimen (also referred to as the "baseline dose"); the "secondary doses" are the doses which are administered after the initial dose; and the "tertiary doses" are the doses which are administered after the secondary doses. The initial, secondary, and tertiary doses may all contain the same amount of anti-CTLA-4 antibody, but generally may differ from one another in terms of frequency of administration. In certain embodiments, however, the amount of anti-CTLA-4 antibody contained in the initial, secondary and/or tertiary doses varies from one another (e.g., adjusted up or down as appropriate) during the course of treatment. In certain embodiments, two or more (e.g., 2, 3, 4, or 5) doses are administered at the beginning of the treatment regimen as "loading doses" followed by subsequent doses that are administered on a less frequent basis (e.g., "maintenance doses").

[0212] In certain embodiments, the amount of anti-CTLA-4 antibody contained in the initial, secondary and/or tertiary doses may be sub-optimal or sub-therapeutic. As used herein, the terms "sub-therapeutic" or "sub-optimal" refer to an antibody dose administered at too low a level to produce a therapeutic effect or below the level necessary to treat a disease such as cancer.

[0213] In certain exemplary embodiments of the present invention, each secondary and/or tertiary dose is administered 1 to 26 (e.g., 1, 1½, 2, 2½, 3, 3½, 4, 4½, 5, 5½, 6, 6½, 7, 7½, 8, 8½, 9, 9½, 10, 10½, 11, 11½, 12, 12½, 13, 13½, 14, 14½, 15, 15½, 16, 16½, 17, 17½, 18, 18½, 19, 19½, 20, 20½, 21, 21½, 22, 22½, 23, 23½, 24, 24½, 25, 25½, 26, 26½, or more) weeks after the immediately preceding dose. The phrase "the immediately preceding dose," as used herein, means, in a sequence of multiple administrations, the dose of anti-CTLA-4 antibody which is administered to a patient prior to the administration of the very next dose in the sequence with no intervening doses.

[0214] The methods according to this aspect of the invention may comprise administering to a patient any number of secondary and/or tertiary doses of an anti-CTLA-4 antibody. For example, in certain embodiments, only a single secondary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) secondary doses are administered to the patient. Likewise, in certain embodiments, only a single tertiary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) tertiary doses are administered to the patient.

[0215] In embodiments involving multiple secondary doses, each secondary dose may be administered at the same frequency as the other secondary doses. For example, each

secondary dose may be administered to the patient 1 to 2 weeks or 1 to 2 months after the immediately preceding dose. Similarly, in embodiments involving multiple tertiary doses, each tertiary dose may be administered at the same frequency as the other tertiary doses. For example, each tertiary dose may be administered to the patient 2 to 12 weeks after the immediately preceding dose. In certain embodiments of the invention, the frequency at which the secondary and/or tertiary doses are administered to a patient can vary over the course of the treatment regimen. The frequency of administration may also be adjusted during the course of treatment by a physician depending on the needs of the individual patient following clinical examination.

Diagnostic Uses of the Antibodies

[0216] The anti-CTLA-4 antibodies of the present invention may be used to detect and/or measure CTLA-4 in a sample, e.g., for diagnostic purposes. Some embodiments contemplate the use of one or more antibodies of the present invention in assays to detect a disease or disorder such as cancer, autoimmune disease or viral infection. Exemplary diagnostic assays for CTLA-4 may comprise, e.g., contacting a sample, obtained from a subject (e.g., a patient), with an anti-CTLA-4 antibody of the invention, wherein the anti-CTLA-4 antibody is labeled with a detectable label or reporter molecule or used as a capture ligand to selectively isolate CTLA-4 from subject samples. Alternatively, an unlabeled anti-CTLA-4 antibody can be used in diagnostic applications in combination with a secondary antibody which is itself detectably labeled. The detectable label or reporter molecule can be a radioisotope, such as ^3H , ^{14}C , ^{32}P , ^{35}S , or ^{125}I ; a fluorescent or chemiluminescent moiety such as fluorescein isothiocyanate, or rhodamine; or an enzyme such as alkaline phosphatase, β -galactosidase, horseradish peroxidase, or luciferase. Specific exemplary assays that can be used to detect or measure CTLA-4 in a sample include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence-activated cell sorting (FACS).

[0217] Samples that can be used in CTLA-4 diagnostic assays according to the present invention include any tissue or fluid sample obtainable from a subject, which contains detectable quantities of either CTLA-4 protein, or fragments thereof, under normal or pathological conditions. Generally, levels of CTLA-4 in a particular sample obtained from a healthy patient (e.g., a patient not afflicted with cancer or an autoimmune disease) will be measured to initially establish a baseline, or standard, level of CTLA-4. This baseline level of CTLA-4 can then be compared against the levels of CTLA-4 measured in samples obtained from individuals suspected of having a cancer-related condition, or symptoms associated with such condition.

[0218] The antibodies specific for CTLA-4 may contain no additional labels or moieties, or

they may contain an N-terminal or C-terminal label or moiety. In one embodiment, the label or moiety is biotin. In a binding assay, the location of a label (if any) may determine the orientation of the peptide relative to the surface upon which the peptide is bound. For example, if a surface is coated with avidin, a peptide containing an N-terminal biotin will be oriented such that the C-terminal portion of the peptide will be distal to the surface.

[0219] Aspects of the invention relate to use of the disclosed antibodies as markers for predicting prognosis of cancer or a viral infection in patients. Antibodies of the present invention may be used in diagnostic assays to evaluate prognosis of cancer in a patient and to predict survival.

EXAMPLES

[0220] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Centigrade, room temperature is about 25°C, and pressure is at or near atmospheric.

Example 1: Generation of Human Antibodies to CTLA-4

[0221] Human antibodies to CTLA-4 were generated using either a human CTLA-4 protein (Cat. No.: 7268-CT, R&D Systems) or DNA encoding hCTLA-4 (Accession No: NM_005214.4). The immunogen was administered directly, with an adjuvant to stimulate the immune response, to a VELOCIMMUNE® mouse (*i.e.*, an engineered mouse comprising DNA encoding human Immunoglobulin heavy and kappa light chain variable regions), as described in US 8502018 B2. The antibody immune response was monitored by a CTLA-4-specific immunoassay. When a desired immune response was achieved splenocytes were harvested and fused with mouse myeloma cells to preserve their viability and form hybridoma cell lines. The hybridoma cell lines were screened and selected to identify cell lines that produce CTLA-4-specific antibodies. Using this technique, and the immunogen described above, several anti-CTLA-4 chimeric antibodies (*i.e.*, antibodies possessing human variable domains and mouse constant domains) were obtained; exemplary antibodies generated in this manner from the VELOCIMMUNE® mice were designated as H1M20370N, H1M20372N, H1M20393N, H2M20361N, H2M20368N, H2M20369N, H2M20373N, H2M20375N, H2M20379N, H2M20385N, H2M20386N, and H2M20387N.

[0222] Anti-CTLA-4 antibodies were also isolated directly from antigen-positive B cells

(from either of the immunized mice) without fusion to myeloma cells, as described in U.S. Patent 7,582,298, herein specifically incorporated by reference in its entirety. Using this method, several fully human anti-CTLA-4 antibodies (*i.e.*, antibodies possessing human variable domains and human constant domains) were obtained; exemplary antibodies generated in this manner were designated as follows: H1H19264P, H1H19269P, H1H19273P, H1H19274P, H1H19278P, H1H19279P, H1H19280P, H1H19281P, H1H19283P, H1H19284P, H1H19291P, H1H19294P, H1H19303P, H1H19305P, H1H19307P, H1H19312P, H1H19313P, H1H19314P2, H1H19319P2, and H1H19327P2.

[0223] The biological properties of the exemplary antibodies generated in accordance with the methods of this Example are described in detail in the Examples set forth below.

Example 2: Heavy and Light Chain Variable Region Amino Acid and Nucleotide Sequences

[0224] Table 1 sets forth the amino acid sequence identifiers of the heavy and light chain variable regions and CDRs of selected anti-CTLA-4 antibodies of the invention. The corresponding nucleic acid sequence identifiers are set forth in Table 2.

[0225] Table 1: Amino Acid Sequence Identifiers

Antibody Designation	SEQ ID NOs:							
	HCVR	HCDR1	HCDR2	HCDR3	LCVR	LCDR1	LCDR2	LCDR3
H1H19264P	2	4	6	8	10	12	14	16
H1H19269P	18	20	22	24	26	28	30	32
H1H19273P	34	36	38	40	42	44	46	48
H1H19274P	50	52	54	56	58	60	62	64
H1H19278P	66	68	70	72	74	76	78	80
H1H19279P	82	84	86	88	90	92	94	96
H1H19280P	98	100	102	104	106	108	110	112
H1H19281P	114	116	118	120	122	124	126	128
H1H19283P	130	132	134	136	138	140	142	144
H1H19284P	146	148	150	152	154	156	158	160
H1H19291P	162	164	166	168	170	172	174	176
H1H19294P	178	180	182	184	186	188	190	192
H1H19303P	194	196	198	200	202	204	206	208
H1H19305P	210	212	214	216	218	220	222	224
H1H19307P	226	228	230	232	234	236	238	240
H1H19312P	242	244	246	248	250	252	254	256
H1H19313P	258	260	262	264	266	268	270	272

H1H19314P2	274	276	278	280	282	284	286	288
H1H19319P2	290	292	294	296	298	300	302	304
H1H19327P2	306	308	310	312	298	300	302	304
H1M20370N	314	316	318	320	322	324	326	328
H1M20372N	330	332	334	336	338	340	342	344
H1M20393N	346	348	350	352	354	356	358	360
H2M20361N	362	364	366	368	370	372	374	376
H2M20368N	378	380	382	384	386	388	390	392
H2M20369N	394	396	398	400	402	404	406	408
H2M20373N	410	412	414	416	418	420	422	424
H2M20375N	426	428	430	432	434	436	438	440
H2M20379N	442	444	446	448	450	452	454	456
H2M20385N	458	460	462	464	466	468	470	472
H2M20386N	474	476	478	480	482	484	486	488
H2M20387N	490	492	494	496	498	500	502	504

[0226] Table 2: Nucleic Acid Sequence Identifiers

	SEQ ID NOs:							
Antibody Designation	HCVR	HCDR1	HCDR2	HCDR3	LCVR	LCDR1	LCDR2	LCDR3
H1H19264P	1	3	5	7	9	11	13	15
H1H19269P	17	19	21	23	25	27	29	31
H1H19273P	33	35	37	39	41	43	45	47
H1H19274P	49	51	53	55	57	59	61	63
H1H19278P	65	67	69	71	73	75	77	79
H1H19279P	81	83	85	87	89	91	93	95
H1H19280P	97	99	101	103	105	107	109	111
H1H19281P	113	115	117	119	121	123	125	127
H1H19283P	129	131	133	135	137	139	141	143
H1H19284P	145	147	149	151	153	155	157	159
H1H19291P	161	163	165	167	169	171	173	175
H1H19294P	177	179	181	183	185	187	189	191
H1H19303P	193	195	197	199	201	203	205	207
H1H19305P	209	211	213	215	217	219	221	223
H1H19307P	225	227	229	231	233	235	237	239
H1H19312P	241	243	245	247	249	251	253	255
H1H19313P	257	259	261	263	265	267	269	271
H1H19314P2	273	275	277	279	281	283	285	287
H1H19319P2	289	291	293	295	297	299	301	303

H1H19327P2	305	307	309	311	297	299	301	303
H1M20370N	313	315	317	319	321	323	325	327
H1M20372N	329	331	333	335	337	339	341	343
H1M20393N	345	347	349	351	353	355	357	359
H2M20361N	361	363	365	367	369	371	373	375
H2M20368N	377	379	381	383	385	387	389	391
H2M20369N	393	395	397	399	401	403	405	407
H2M20373N	409	411	413	415	417	419	421	423
H2M20375N	425	427	429	431	433	435	437	439
H2M20379N	441	443	445	447	449	451	453	455
H2M20385N	457	459	461	463	465	467	469	471
H2M20386N	473	475	477	479	481	483	485	487
H2M20387N	489	491	493	495	497	499	501	503

[0227] Antibodies are typically referred to herein according to the following nomenclature: Fc prefix (e.g. "H1M," "H4H," etc.), followed by a numerical identifier (e.g. "19264," "20370," etc., as shown in Table 1), followed by a "P," "P2," or "N" suffix. Thus, according to this nomenclature, an antibody may be referred to herein as, e.g., "H1M20370N," "H1H19264P," "H1H19314P2," etc. The H1H prefix on the antibody designations used herein indicates the particular Fc region isotype of the antibody. For example, an "H1H" antibody has a human IgG1 Fc, an "H1M" antibody has a mouse IgG1 Fc, and an "H2M" antibody has a mouse IgG2 Fc (all variable regions are fully human as denoted by the first 'H' in the antibody designation). As will be appreciated by a person of ordinary skill in the art, an antibody having a particular Fc isotype can be converted to an antibody with a different Fc isotype (e.g., an antibody with a mouse IgG1 Fc can be converted to an antibody with a human IgG1 or a human IgG4, etc.), but in any event, the variable domains (including the CDRs) – which are indicated by the numerical identifiers shown in Table 1 – will remain the same, and the binding properties to antigen are expected to be identical or substantially similar regardless of the nature of the Fc domain.

[0228] Control Constructs:

Two control constructs (anti-CTLA4 antibodies) were included in the following experiments for comparative purposes:

COMP1: a human anti-CTLA-4 antibody with heavy and light chain variable domains having the amino acid sequences of the corresponding domains of "10D1", as set forth in WO 01/14424 A2 (Bristol Myers Squibb) and produced with a hIgG1 Fc.

COMP2: a human anti-CTLA-4 antibody with heavy and light chain variable domains having the amino acid sequences of the corresponding domains of "11.2.1", as set forth in US 2014/099325 A1 (Pfizer) and produced with a hIgG2 Fc.

Example 3: Surface Plasmon Resonance Derived Binding Affinities and Kinetic Constants of Human Monoclonal anti-CTLA-4 Antibodies

[0229] Binding affinities and kinetic constants of human anti-CTLA-4 antibodies were determined by surface plasmon resonance (Biacore 4000 (GE, Pittsburgh, PA) or MASS-1 (Sierra Sensors, Greenville, RI)) at 25°C (Tables 3 and 4). Antibodies expressed as human IgG1, (i.e., “H1H”) were captured onto a CM5 sensor surface (GE) derivatized by amine coupling with a monoclonal mouse-anti-human Fc antibody (GE). Antibodies expressed as mouse IgG1 or mouse IgG2 (i.e., “H1M”, “H2M”) were captured onto a high-capacity amine sensor surface (Sierra Sensors) derivatized by amine coupling with a polyclonal goat anti-mouse Fc antibody (GE). Various concentrations of soluble human (h) CTLA-4 (SEQ ID NO: 506) or *Macaca fascicularis* (mf) CTLA-4 (SEQ ID NO: 507) proteins expressed with a c-terminus myc-myc-polyhistidine tag (mmh) were injected over the anti-CTLA-4 mAb captured sensor surfaces at a flow rate of 30 or 50uL/ minute. CTLA-4 is a homodimer interconnected by one disulfide bond in the extracellular domain at cysteine residue 157.

[0230] All binding studies were performed in a buffer composed of 0.01M HEPES pH 7.4, 0.15M NaCl, 3mM EDTA, 0.05% v/v Surfactant P20 (HBS-ET running buffer). Association of hCTLA4.mmh or mfCTLA4.mmh to the captured monoclonal antibody was monitored for 4 or 5 min and the dissociation of hCTLA4.mmh or mfCTLA4.mmh in HBS-ET running buffer was monitored for 10 min.

[0231] Kinetic association (k_a) and dissociation (k_d) rate constants were determined by fitting the real-time sensorgrams to a 1:1 binding model using Scrubber 2.0c curve fitting software. Binding equilibrium dissociation constants (K_D) and dissociative half-lives ($t_{1/2}$) were calculated from the kinetic rate constants as:

$$K_D (M) = \frac{k_d}{k_a}, \quad \text{and} \quad t_{1/2} (\text{min}) = \frac{\ln(2)}{60 \cdot k_d}$$

[0232] As shown in Table 3, all the anti-CTLA-4 antibodies of this invention bound to human CTLA-4, many with nanomolar affinity to hCTLA-4.mmh, and displayed cross-reactivity to cynomolgus CTLA-4 protein. Cross reactivity to mouse or rat CTLA-4 protein was not observed (data not shown).

[0233] Table 3: Biacore binding affinities of human Fc mAbs at 25°C

Binding at 25C/ Mab Capture Format					
AbPID	Analyte *	ka (1/Ms)	kd (1/s)	KD (M)	t1/2 (min)
H1H19264P	hCTLA-4.mmh	6.04E+04	7.31E-04	1.21E-08	15.8
	mf CTLA-4. mmh	4.90E+04	9.94E-04	2.03E-08	11.6
H1H19269P	hCTLA-4.mmh	3.94E+05	4.74E-04	1.20E-09	24.4
	mf CTLA-4. mmh	3.56E+05	4.35E-04	1.22E-09	26.6

H1H19273P	hCTLA-4.mmh	3.74E+05	3.62E-04	9.66E-10	31.9
	mf CTLA-4. mmh	3.62E+05	3.46E-04	9.56E-10	33.4
H1H19274P	hCTLA-4.mmh	5.30E+05	7.60E-04	1.43E-09	15.2
	mf CTLA-4. mmh	5.22E+05	4.63E-04	8.87E-10	25
H1H19278P	hCTLA-4.mmh	1.79E+05	4.02E-04	2.25E-09	28.8
	mf CTLA-4. mmh	1.66E+05	1.01E-03	6.11E-09	11.4
H1H19279P	hCTLA-4.mmh	3.46E+05	2.61E-04	7.52E-10	44.3
	mf CTLA-4. mmh	3.40E+05	2.59E-04	7.63E-10	44.6
H1H19280P	hCTLA-4.mmh	3.37E+05	3.46E-04	1.03E-09	33.4
	mf CTLA-4. mmh	3.20E+05	3.09E-04	9.64E-10	37.4
H1H19281P	hCTLA-4.mmh	4.84E+05	7.41E-04	1.53E-09	15.6
	mf CTLA-4. mmh	4.72E+05	1.01E-03	2.14E-09	11.5
H1H19283P	hCTLA-4.mmh	2.21E+05	8.28E-04	3.75E-09	14
	mf CTLA-4. mmh	2.20E+05	6.83E-04	3.11E-09	16.9
H1H19284P	hCTLA-4.mmh	1.48E+05	3.69E-04	2.49E-09	31.3
	mf CTLA-4. mmh	1.94E+05	3.05E-04	1.57E-09	37.9
H1H19291P	hCTLA-4.mmh	8.88E+04	1.23E-03	1.38E-08	9.4
	mf CTLA-4. mmh	9.31E+04	1.21E-03	1.30E-08	9.6
H1H19294P	hCTLA-4.mmh	2.85E+05	3.23E-04	1.13E-09	35.7
	mf CTLA-4. mmh	2.63E+05	2.69E-04	1.02E-09	43
H1H19303P	hCTLA-4.mmh	1.21E+05	1.99E-03	1.64E-08	5.8
	mf CTLA-4. mmh	1.56E+05	2.45E-03	1.57E-08	4.7
H1H19305P	hCTLA-4.mmh	2.89E+05	1.21E-03	4.19E-09	9.5
	mf CTLA-4. mmh	2.84E+05	9.02E-04	3.18E-09	12.8
H1H19307P	hCTLA-4.mmh	2.17E+05	2.84E-04	1.31E-09	40.6
	mf CTLA-4. mmh	2.09E+05	2.92E-04	1.40E-09	39.5
H1H19312P	hCTLA-4.mmh	3.20E+05	1.05E-03	3.29E-09	11
	mf CTLA-4. mmh	3.33E+05	7.60E-04	2.28E-09	15.2
H1H19313P	hCTLA-4.mmh	4.89E+05	7.58E-04	1.55E-09	15.2
	mf CTLA-4. mmh	4.75E+05	4.64E-04	9.76E-10	24.9
H1H19314P2	hCTLA-4.mmh	1.15E+05	1.13E-03	9.87E-09	10.2
	mf CTLA-4. mmh	1.07E+05	9.13E-04	8.57E-09	12.6
H1H19319P2	hCTLA-4.mmh	1.43E+05	1.46E-03	1.02E-08	7.9
	mf CTLA-4. mmh	2.03E+05	2.61E-03	1.29E-08	4.4
H1H19327P2	hCTLA-4.mmh	8.81E+03	5.85E-04	6.63E-08	19.8
	mf CTLA-4. mmh	1.88E+05	1.17E-02	6.24E-08	1
H1H20361N	hCTLA-4.mmh	6.21E+04	1.99E-03	3.21E-08	5.8
	mf CTLA-4. mmh	ND	ND	ND	ND
H1H20361N2	hCTLA-4.mmh	5.39E+04	2.51E-03	4.65E-08	4.6
	mf CTLA-4. mmh	ND	ND	ND	ND
H1H20370N	hCTLA-4.mmh	1.72E+05	5.88E-04	3.43E-09	19.6
	mf CTLA-4. mmh	ND	ND	ND	ND

H1H20370N2	hCTLA-4.mmh	5.13E+04	1.21E-03	2.36E-08	9.5
	mf CTLA-4. mmh	ND	ND	ND	ND
H1H20372N	hCTLA-4.mmh	8.05E+04	3.67E-04	4.55E-09	31.5
	mf CTLA-4. mmh	ND	ND	ND	ND
H1H20373N	hCTLA-4.mmh	5.23E+05	4.01E-04	7.66E-10	28.8
	mf CTLA-4. mmh	ND	ND	ND	ND
H1H20375N	hCTLA-4.mmh	4.19E+04	2.79E-03	6.65E-08	4.1
	mf CTLA-4. mmh	ND	ND	ND	ND
H1H20380N2	hCTLA-4.mmh	1.37E+06	3.20E-04	2.33E-10	36.2
	mf CTLA-4. mmh	ND	ND	ND	ND
H1H20386N	hCTLA-4.mmh	1.85E+05	1.94E-03	1.05E-08	6
	mf CTLA-4. mmh	ND	ND	ND	ND
H1H20386N2	hCTLA-4.mmh	1.35E+05	1.68E-03	1.24E-08	6.9
	mf CTLA-4. mmh	ND	ND	ND	ND

* h and mf CTLA-4 mmh proteins were flown over mAb-captured surfaces at concentrations ranging from 0.37nM to 90nM in 3-fold dilutions; ND=Not Determined

Example 4: Anti-CTLA-4 Antibodies Block the Interaction Between Human CTLA-4 and its Natural Ligands, B7-1 and B7-2

[0234] CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a type I transmembrane T cell inhibitory checkpoint receptor expressed on conventional and regulatory T cells. CTLA-4 negatively regulates T cell activation by outcompeting the stimulatory receptor CD28 from binding to its natural ligands, B7-1 (CD80) and B7-2 (CD86). In this example, the ability of anti-CTLA-4 antibodies to block CTLA-4 protein binding to plate-bound B7-1 and B7-2 was assessed using competition sandwich Enzyme-linked Immunosorbent Assays (ELISA). Various concentrations of anti-CTLA-4 antibody were pre-mixed with a constant amount of dimeric CTLA-4 protein and the reduction of the CTLA-4 binding to the plate immobilized B7-1 or B7-2, due to the presence of the antibody, was monitored.

[0235] Briefly, assays were performed using the following procedure: Human B7-1 and B7-2 proteins, expressed with c-terminal human IgG1 and 6x Histidine (hIgG1-6xHis; R&D Systems, Minneapolis, MN) were separately coated at 2 µg/mL in PBS on a 96-well microtiter plate overnight (ON) at 4°C. Nonspecific binding sites were subsequently blocked using a 0.5% (w/v) solution of BSA in PBS. Separately, a constant amount of 200pM or 400pM of recombinant hCTLA-4-mFc protein (human CTLA-4 extracellular domain expressed with a c-terminal Fc portion of mouse IgG2a, SEQ ID NO: 508) was added to serially diluted anti-CTLA-4 antibodies, or solutions with no antibody present. In this example, anti-CTLA-4 antibody doses ranged from 1.7pM to a maximum of either 100nM or 1.0 µM. Next, after 1h at room temperature (RT), antibody-protein complexes with 200pM constant concentration of hCTLA-4-mFc protein were transferred to microtiter plates coated

with hB7-1-hIgG1-6His, and antibody-protein complexes with 400pM constant concentration of hCTLA-4-mFc were transferred to hB7-2-hIgG1-6His coated plates. After a subsequent 1h incubation at RT, wells were washed, and plate-bound hCTLA-4-mFc was detected with anti-mouse Fcγ-fragment specific goat polyclonal antibodies conjugated with horseradish peroxidase (HRP) (JacksonImmunoResearch, West Grove, PA). Plates were developed using TMB substrate solution (BD Biosciences, San Jose, CA) according to manufacturer's instructions and absorbance was measured at 450nm on a Victor plate reader (PerkinElmer™, Waltham, MA).

[0236] All data analysis was performed using a sigmoidal dose-response model within Prism™ software (GraphPad, LaJolla, CA). Calculations were performed as follows: IC₅₀, defined as the concentration of antibody required to reduce 50% of hCTLA-4 binding to hB7-1 or B7-2, was used as an indicator of blocking potency. Percent blockade at maximum concentration of the antibody tested (100nM or 1.0 uM) was calculated as the ability of antibodies to block the binding of 200pM or 400pM of hCTLA-4-mFc to hB7-1 or hB7-2, respectively, relative to the baseline of the assay. The binding signal of samples with 200pM or 400pM of hCTLA-4-mFc in the absence of antibody was referenced as 100% binding or 0% blocking; and the baseline signal of the sample buffer without hCTLA-4-mFc or antibody was referenced as 0% binding or 100% blocking.

[0237] As the results in Table 4 show, the anti-CTLA-4 antibodies of this invention display a wide range of ability to block the binding of human CTLA-4 to its natural ligands, B7-1 or B7-2. Exemplary antibodies H1H19273P and H1H19313P potently block the binding of CTLA-4 to B7-1 or B7-2 with picomolar IC₅₀ values and with percent blockade of ~100% at 1.0uM maximum antibody concentration. Several antibodies, such as H1H20373N were stronger blockers of CTLA-4 binding to B7-2 than B7-1, while some antibodies showed minimal blocking ability of either ligand (H1H19314P2).

[0238] Table 4: Anti-CTLA-4 Antibodies Block the Binding of hCTLA-4 to ligands hB7-1 or hB7-2

	Ab blocking of 200pM hCTLA-4-mFc binding to plate-coated hB7-1/CD80-hIgG1-6His		Ab blocking of 400pM hCTLA-4-mFc binding to plate-coated hB7-2/CD86-hIgG1-6His	
AbPID	Maximum Ab concentration: 100nM			
	IC ₅₀ (M)	% Blockade	IC ₅₀ (M)	% Blockade
Blocking ability of Human Fc anti-CTLA-4 antibodies				
H1H19264P	-	8	-	43
H1H19269P	1.0E-10	98	1.9E-10*	100
H1H19274P	1.3E-10	99	2.5E-10	100
H1H19278P	3.2E-10	99	5.4E-10	100

H1H19279P	2.1E-10	97	2.2E-10	100
H1H19280P	1.1E-10	99	2.0E-10	100
H1H19281P	9.4E-11*	99	1.9E-10*	100
H1H19283P	9.7E-09	96	1.2E-09	99
H1H19284P	1.7E-10	98	3.1E-10	99
H1H19291P	2.0E-09	98	2.5E-09	99
H1H19294P	1.5E-10	99	2.5E-10	99
H1H19305P	1.9E-10	98	3.6E-10	99
H1H19307P	1.8E-10	99	2.9E-10	99
H1H19312P	2.0E-10	97	5.1E-10	99
H1H19314P2	-	0	-	7
H1H19327P2	-	7	-	38
H1H19273P	2.5E-10	98	5.4E-10	98
H1H19303P	1.8E-07	90	3.9E-08	97
H1H19313P	4.0E-10	98	7.7E-10	99
H1H19319P2	3.2E-07	85	4.3E-08	97
H1H20370N	8.6E-10	95	9.9E-10	96
H1H20370N2	1.1E-08	85	9.8E-09	92
H1H20372N	2.5E-09	98	9.9E-10	98
H1H20361N	6.9E-08	73	6.5E-08	82
H1H20361N2	1.2E-07	53	1.1E-07	70
H1H20373N	-	22	3.4E-08	91
H1H20375N	-	13	-	29
H1H20380N2	5.0E-10	98	3.8E-10	98
H1H20386N	1.8E-08	94	7.7E-09	96
H1H20386N2	INC	59	1.7E-07	87
Controls				
mIgG2a Isotype	-	-6	-	1
hIgG1 Isotype	-	15	-	14

Negative Max % Blocking (ie -8) indicates an increase of hCTLA-4 binding detected in the presence of antibody.

(-) indicates IC₅₀ values not quantitative for antibodies blocking <50% at the highest concentration tested.

(INC): inconclusive: sigmoidal binding curve was not fitted by Prism™ software to calculate IC₅₀ value.

(*) Indicates IC₅₀ value below the theoretical bottom of assay (0.1x10⁻⁰⁹ M for hCTLA-4 binding to hB7-1/CD80, or 0.2x10⁰⁹ M for hCTLA-4 binding to hB7-2/CD86)

Example 5: Anti-CTLA-4 Antibodies Display Specific and Potent Binding to Human CTLA-4 Engineered Cell Lines

[0239] In this example, the ability of anti-human (h) CTLA-4 antibodies to bind specifically

to human-CTLA-4 expressing cell lines was determined using electrochemiluminescence (ECL) based detection.

[0240] Briefly, mouse embryonic fibroblast cells isolated from Velocimmune® mice (VI-fibroblasts) were stably transfected with human CTLA-4 (amino acids M1-N223, NCBI Accession # NM_005214.4). The non-transfected VI-fibroblast cells have no detectable expression of CTLA-4 by fluorescence activated cell sorting (FACS) and were included as binding controls. Additionally, a reporter T cell line generated by transducing immortal human Jurkat T-cells (ATCC, Manassas, VA) with an NFAT-Luc lentivirus reporter (Qiagen, Germantown, MD) and h, m or mf CTLA-4 chimeric constructs was also assessed in this assay. The chimeric constructs comprised the extracellular domain of either hCTLA-4 (aa 1-161; accession number NP_005205.2), mouse CTLA-4 (ms CTLA-4, amino acids 1-161, accession number NM_009843.4) or mf CTLA-4 (aa from 1-161; accession number XP_005574071.1) fused to the trans-membrane and cytoplasmic domain of hCD300a (aa 181-299; accession number NP_009192.2).

[0241] Approximately 2.0×10^4 VI-fibroblast/hCTLA-4 cells or 1.0×10^4 Jurkat/NFAT chimera cells were seeded separately onto 96-well carbon electrode plates (MULTI-ARRAY high bind plate, Meso Scale Discovery (MSD; Rockville, MD)) and incubated for 1 hour (h) at 37°C. Nonspecific binding sites were blocked by 2% BSA (w/v) in PBS for 1 hour at room temperature (RT). Serial dilutions of anti-CTLA-4 or isotype control antibodies, ranging from 1.7 pM to 150 nM, or buffer containing no-antibody was added to plate-bound cells for 1 h, RT. Plates were then washed to remove unbound antibodies using an AquaMax2000 plate washer with a cell washing head (MDS Analytical Technologies, Sunnyvale, CA). The plate-bound antibodies were detected with either SULFO-TAG™-conjugated goat polyclonal anti-human IgG antibody specific for heavy and light chains (Jackson ImmunoResearch, West Grove, PA) or a SULFO-TAG™-conjugated goat polyclonal anti-mouse IgG antibody specific for Fc γ fragment (Jackson ImmunoResearch) for 1h, RT.

[0242] After washes, plates were developed with Read Buffer (MSD) according to manufacturer's recommended procedure and luminescent signals were recorded with a SECTOR Imager 600 (MSD). Luminescence intensity, measured in relative light units (RLU), was recorded to indicate the binding intensity of each antibody at the range of concentrations. The ratio of signal detected with 0.4nM or 0.6nM antibody binding to the CTLA-4 engineered cells compared to parental cells at the same concentration was reported as an indication of specificity of CTLA-4 binding.

[0243] In addition, direct binding signals (RLU) were analyzed as a function of the antibody concentration and the data were fitted with a sigmoidal (four-parameter logistic) dose-response model using GraphPad Prism™ software (GraphPad, LaJolla, CA). The EC₅₀ value, defined as the concentration of antibody at which 50% of the maximal binding signal

is detected, was determined to indicate binding potency to CTLA-4 engineered cells.

[0244] As the results in Table 5 show, a majority of the anti-CTLA-4 antibodies of this invention bound specifically to the hCTLA-4 engineered cell lines. Several exemplary antibodies, such as H1H19303P and H1H19280P bound with picomolar EC₅₀ values and with ratios 20-23-fold above binding to control cell lines.

[0245] A selection of antibodies were further assessed for cross reactivity to mouse and cynomolgus monkey engineered cell lines. As the results in Table 6 show, anti-CTLA-4 antibodies H1H19303P, H1H19273P, H1H19319P2 and H1H19319P potentially bind to Jurkat/NFAT Luc/human and cynomolgus CTLA-4/hCD300 chimera cell lines, with picomolar EC₅₀ values. No cross-reactivity to mouse CTLA-4 chimera cells was observed.

[0246] Table 5: Anti-CTLA-4 Antibodies Specifically Bind to Cell Lines Engineered to Express Human CTLA-4

Ab PID	Cell Binding Potency to VI-fibroblast/hCTLA-4 , EC50 (M)	Ratio of RLU Signal binding to VI fibroblast/hCTLA-4 relative to parental VI-fibroblast
		Ratio at 0.4nM Ab concentration
Cell Binding Properties of Human Fc anti-CTLA-4 antibodies		
H1H19264P	NB	1
H1H19269P (*)	4.0E-10	15
H1H19273P	INC	11
H1H19274P (*)	3.9E-10	18
H1H19278P	2.2E-10	19
H1H19279P	2.4E-10	18
H1H19280P	1.3E-09	15
H1H19281P	7.5E-11	23
H1H19283P	7.9E-10	7
H1H19284P	INC	7
H1H19291P	INC	5
H1H19294P	6.8E-10	10
H1H19303P (*)	2.1E-10	20
H1H19305P (*)	8.4E-10	12
H1H19307P	3.7E-09	7
H1H19312P (*)	7.0E-10	14
H1H19313P (*)	1.6E-10	11
H1H19314P2 (*)	3.4E-09	8
H1H19319P2	2.4E-10	16
H1H19327P2	2.9E-10	16

CONTROLS		
hIgG1 Isotype Control	NB	1
Cell binding properties of Hybridoma CTLA-4 antibodies (H1M, H2M)		
		Ratio at 0.6nM Ab concentration
H1M20370N	2.2E-10	23
H1M20372N	8.8E-10	14
H1M20393N (*)	7.3E-09	12
H2M20361N	3.2E-10	19
H2M20368N	2.6E-10	25
H2M20369N	9.0E-10	18
H2M20373N	6.2E-11	22
H2M20375N	1.9E-10	18
H2M20379N	9.2E-11	28
H2M20380N	1.2E-10	28
H2M20385N	5.5E-09	8
H2M20386N	INC	3
H2M20387N	INC	3
CONTROLS		
COMP1	INC	11
mIgG2 Isotype Control	NB	1

NB = non-binder; antibodies with a binding ratio of less than 3 were classified as non-binders
 (*) RLU value for highest two antibody concentrations were excluded to calculate EC50 values.

INC = inconclusive, GraphPad Prism™ cannot fit 4 parameters sigmoidal curve for EC50 value calculation, but antibody specifically bound to CTLA-4 expressing cells with ratios 3-fold or greater above the parental cells.

[0247] Table 6: Selected Anti-CTLA-4 antibodies Display Specificity of Binding to Engineered Jurkat Human and Monkey Cell Lines

Ab PID	Potency of cell binding on Jurkat/NFAT Luc / CTLA-4 hCD300a Chimera, EC50 (M)		Ratio of RLU Signal binding to Jurkat/NFAT Luc / CTLA-4 hC300a Chimera for binding to Jurkat/NFAT Luc/cl.3C7		
	hCTLA-4	mf CTLA-4	hCTLA-4	mf CTLA-4	ms CTLA-4
			0.4nM	0.4nM	0.4nM
H1H19303P (*)	2.9E-10	1.1E-10	13	17	1
H1H19273P (*)	5.2E-10	2.2E-10	14	20	1
H1H19319P2 (*)	2.8E-10	1.7E-10	13	15	1

H1H19313P (*)	1.1E-10	1.4E-10	16	25	1
CONTROLS					
COMP1	INC	INC	6	8	1
hIgG1 Isotype Control	NB	NB	1	1	1

Monkey = *Macaca fascicularis*.

NB = non-binder; antibodies with a binding ratio of less than 3 were classified as non-binders

(*) RLU value for highest two antibody concentrations were excluded to calculate EC50 values.

INC = inconclusive, GraphPad Prism™ cannot fit 4 parameters sigmoidal curve for EC50 value calculation, but antibody specifically bound to CTLA-4 expressing cells with ratios 3-fold or greater above the parental cells.

Example 6: Anti-CTLA-4 Antibodies Induce T-cell Activation in Engineered Reporter T-cell / APC Bioassay Systems

[0248] In this example, T-cell/ Antigen Presenting Cell (APC)-based luciferase reporter bioassays were developed to evaluate the effects of blocking CTLA-4/CD80 or CTLA-4/CD86 interaction and T-cell activation. In one bioassay format, the effect of anti-CTLA-4 antibody administration on the T-cell/APC system was assessed by measuring luciferase activity. In a second assay, the ability of anti-CTLA-4 antibodies to induce Interleukin (IL)-2 release was assessed.

[0249] As described in the examples above, the anti-CTLA-4 antibodies tested in this example demonstrated binding to human and cynomolgus monkey (*Macaca fascicularis*) CTLA-4 via surface plasmon resonance (SPR) and exhibited specific and potent binding to cell lines engineered to express human CTLA-4. These selected CTLA-4 antibodies were also previously shown to block the binding of CTLA-4 to B7-1(CD80) and B7-2 (CD86).

Background

[0250] T-cell activation is achieved by stimulating T-cell receptors (TCR) that recognize specific peptides presented by major histocompatibility complex class I or II (MHC I or MHC II) proteins on antigen-presenting cells (APC) (Goldrath *et al.* 1999). An activated TCR in turn initiates a cascade of signaling events, which can be monitored by reporter genes, driven by various transcription factors such as activator-protein 1 (AP-1), Nuclear Factor of Activated T-cells (NFAT) or Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB). The T-cell response is then further refined via engagement of co-receptors expressed either constitutively or inducible on T-cells such as CD28, CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4), PD-1 (Programmed Cell Death Protein 1), LAG-3 (Lymphocyte-Activation Gene 3) or other molecules (Sharpe *et al.* 2002). The co-receptors, CD28 and CTLA-4 compete for the same ligands, CD80 and CD86 expressed on antigen-presenting

cells (APC) to which CTLA-4 has a higher affinity than CD28. CTLA-4 functions as a decoy and inhibits the activation of CD28 by sequestering away the ligands leading to reduced T-cell activation. (Alegre *et al.* 2001 and Walker *et al.* 2011).

NFAT-Luciferase Activity

[0251] Cell line engineering: Reporter T-cells were engineered by transducing immortal human Jurkat T-cells (ATCC), which endogenously express a TCR and CD28 on the cell surface, with an NFAT-Luc lentivirus reporter (Qiagen, Rockville, MD) as per manufacturer's instructions. The lentivirus encodes the firefly luciferase gene under the control of a minimal CMV (Cytomegalovirus) promoter and tandem repeats of the NFAT transcriptional response element (TRE) and a puromycin resistance gene.

[0252] After antibiotic selection and single cloning, the Jurkat/NFAT-Luc clonal line 3C7 (Jurkat/NFAT-Luc cl.3C7) was transduced with lentiviral encoding human (h) or monkey (mf - *Macaca fascicularis*) CTLA-4 chimeric proteins. The chimeric construct comprises the extracellular domain of hCTLA-4 (aa 1-161; accession number NP_005205.2) or mfCTLA-4 (aa from 1-161; accession number XP_005574071.1) fused to the trans-membrane and cytoplasmic domain of hCD300a (aa 181-299; accession number NP_009192.2). CD300a is found on immune cells and transmits inhibitory signals via its immuno-receptor tyrosine based inhibition motifs (ITIM) (DeBell *et al.* 2012). The resulting stable T-cell lines, Jurkat/NFAT-Luc/ hCTLA-4-hCD300a and Jurkat/NFAT-Luc/mfCTLA-4-hCD300a, were selected and maintained in RPMI + 10% FBS + penicillin + streptomycin + glutamine supplemented with 500µg/mL G418 and 1µg/mL puromycin.

[0253] Human Raji B-cells (ATCC, Manassas, VA), which endogenously express CD20, Fc gamma receptors (FcγR), CD80 and CD86 on the cell surface, were used as APC cells in the luciferase-based bioassay. Raji cells were maintained in RPMI + 10% FBS + penicillin + streptomycin + glutamine supplemented with HEPES and sodium pyruvate.

[0254] T-cell/APC stimulation: Reporter T-cells are stimulated via a T-cell activating anti-CD20xCD3 bispecific antibody (REGN2281), which targets CD3 expressed on Jurkat T-cells and CD20 on Raji B-cells. The bispecific mode of binding of REGN2281 leads to an increase of the NFAT coupled reporter gene, luciferase, in the Jurkat/NFAT-Luc T-cells.

[0255] In Jurkat/NFAT-Luc/CTLA-hCD300a chimera cells however, maximal activation of the reporter gene with REGN2281 is attenuated due to inhibitory signaling transmitted by the interaction of CTLA-4-hCD300a chimeric receptors with its ligands, CD80/CD86, expressed on Raji cells. In this bioassay, anti-CTLA-4 antibodies blocking the CTLA-4/CD80 and CD86 axis would, in theory, rescue NFAT-Luc activity in the Jurkat reporter cells by disabling the inhibitory signal delivered via the CD300a tail of the chimeric CTLA-4 protein.

[0256] In this assay format, anti-CTLA-4 antibodies could simultaneously induce an agonistic signal in Jurkats, triggered by the anchoring of the antibody Fc to FcγR on Raji

cells. The blocking of FcγR with saturating levels of IgG molecules or FcγR specific antibodies can reduce the agonistic effect of CTLA-4 antibodies. Therefore, an Fc block step was included in the assay to inhibit the binding of CTLA-4 mabs to FcγR on Raji cells.

[0257] Luciferase Assay: 24 h prior to screening, 5×10^5 reporter T-cells and 7.5×10^5 Raji APCs were cultured in assay medium (RPMI1640 supplemented with 10% FBS and penicillin + streptomycin + glutamine (PSG)). The following day, anti-CTLA-4 antibodies and isotype matched negative controls (serially diluted 1:3; dose-range 15 pM to 100 nM) were tested in the presence of 100pM REGN2281 and 10nM of Fc Block or 10nM of a human IgG4 isotype control to occupy endogenous FcγRIIb receptors on Raji cells. Serially diluted antibodies were added to corresponding wells in 96 well white flat bottom plates (Nunc/Thermo Fisher, Pittsburgh, PA) containing a fixed concentration of 100pM REGN2281/10nM Fc Block or 100pM REGN2281/10 nM hIgG4 isotype control. Reporter T-cells and Raji APCs were re-suspended at 2×10^6 /mL and T-cells were first added to plates with a final concentration 5×10^4 cells/well. Plates were incubated for 15-30 minutes at 37°C/5% CO₂, followed by the addition of Raji cells with a final concentration of 5×10^4 cells/well. Samples were incubated for another 4-6 h at 37°C/5% CO₂, before the addition of 100μL ONE-Glo™ (Promega, Madison WI) to detect NFAT-Luc activity. The emitted light was captured in relative light units (RLU) on the multilabel plate reader Victor (PerkinElmer, Waltham, MA). All serial dilutions were tested in duplicates.

[0258] The EC₅₀ values of CTLA-4 antibodies were determined from a four-parameter logistic equation over a 10-point dose-response curve using GraphPad Prism software (GraphPad, La Jolla, CA). Fold induction was calculated by normalizing the relative RLU values of each sample to the mean of samples containing no CTLA-4 antibody, which was set to 1.

[0259] Results: As recorded in Table 7, no increase in reporter gene activity (luciferase) was observed when anti-CTLA-4 antibodies were added to parental Jurkat/NFAT-Luc cl 3C7 cells plus Raji APCs, in the presence of REGN2281 +/- Fc block. However, increasing luciferase activity was recorded when anti-CTLA-4 antibodies were added to the Jurkat/NFAT-Luc/h and mf CTLA-4/hCD300 chimera cell lines/Raji APC system, in the presence of REGN2281 +/- Fc block. In this bioassay format, anti-CTLA-4 antibodies block the interaction of CTLA-4 on the Jurkat reporter cells with CD80/CD86 expressed endogenously on Raji cells, leading to the induction of the luciferase protein. The anti-CTLA-4 antibodies tested in this assay increase luciferase activity, with maximal values observed in the presence of Fc block, with EC₅₀s ranging from 1.77nM to 7.67nM. As shown in Table 7, H1H19303P performed better than comparators 1 and 2 as tested.

CTLA-4 T-cell/APC human Interleukin 2 (hIL-2) release assay

[0260] Cell line engineering: The Jurkat/NFAT-Luc clonal line 3C7 (as described above)

was transduced with in house made lentiviral sup encoding hCTLA-4 full length protein (accession number NP_005205.2). The resulting stable T-cell line (Jurkat/NFAT-Luc/hCTLA-4 wt) was sorted for high expression by flow cytometry and maintained in RPMI + 10% FBS + PSG supplemented with 500 µg/mL G418 and 1µg/mL puromycin.

[0261] Human Embryonic Kidney (HEK) 293 cells (ATCC) were transfected with human CD20 and used for the transduction with lentiviral sups to overexpress hCD80 (aa 1-288; accession number NP_005182.1) or hCD86 (aa 1-329; accession number NP_787058.4) fused to green fluorescent protein (GFP; aa 2-240; accession number WP_031943942.1) with a 4xG4S linker between. After single cloning by limiting dilution, the following resulting clonal lines were generated: HEK293/hCD20/hCD80-GFP clone 1F4 and HEK293/hCD20/hCD86-GFP clone 4G5. Cell lines were maintained in DME + 10% FBS + PSG + non-essential-amino-acids (NEAA, Irvine Scientific, Santa Ana, CA) supplemented with 500 µg/mL G418.

[0262] T-cell/APC stimulation: Engineered T-cells are stimulated via a T-cell activating bispecific antibody REGN2281, as described above. Binding of REGN2281 to CD3 leads to the clustering of CD3 subunits in complex with the TCR and activates the T-cell, which in turn releases hIL-2. The release of IL-2 can be further mounted by CD28 interaction with its ligands, CD80 or CD86 located on the engineered HEK293 cells. The maximal activation of Jurkat/NFAT-Luc/hCTLA-4 cells is attenuated, due to the competition of CTLA-4 with CD28 for the binding of the ligands CD80/CD86 on HEK293 cells (Carreno *et al.* 2000).

[0263] In this bioassay, antibodies blocking the CTLA-4/CD80 or CD86 interaction would rescue the IL-2 release in engineered Jurkat cells by disabling the inhibitory CTLA-4 arm.

[0264] IL-2 release Assay: 24 h prior to screening, engineered T-cells were cultured to 5×10^5 cells/mL in assay medium (RPMI1640 + 10% FBS+ PSG). The following day, HEK293 cells were washed with D-PBS (Irvine Scientific), detached with trypsin (Specialty Media) and blocked with assay medium. Next, HEK293 cells were treated with assay medium containing 50 µg/mL of Mitomycin C to arrest cell growth, for 1 h at 37°C/5% CO₂. Cells were subsequently washed thoroughly with assay medium to remove free Mitomycin C.

[0265] The anti-CTLA-4 antibodies and their isotype controls were serially diluted 1:3 in assay medium, with a 10-point dilution ranging from 15 pM to 100 nM. Serially diluted antibodies were added to corresponding wells in a 96 well round bottom plates (Nunc) containing a fixed concentration of 300pM REGN2281. Reporter T-cells were added to plates with a final concentration 1×10^5 cells/well. Plates were incubated for 15-30 min at 37°C/5% CO₂, followed by the addition of HEK293 cells with a final concentration of 2.5×10^3 cells/well. Plates were incubated for 72 h at 37°C/5% CO₂ and supernatants were collected and used for IL-2 measurements. IL-2 levels were measured using the AlphaLISA kit (PerkinElmer) according to manufacturer's protocol. The measurements were acquired on

the multilabel plate reader Envision (PerkinElmer). All serial dilutions were tested in duplicates.

[0266] The EC₅₀ values of the CTLA-4 mAbs were determined from a four-parameter logistic equation over a 10-point dose-response curve using GraphPad Prism. The fold induction was calculated by normalizing the relative IL-2 values of each sample to the samples containing no anti-CTLA-4 antibody. Table 9 shows the fold induction reached at 100nM and the calculated EC₅₀ values reached in the hIL-2 release assay.

[0267] *Results:* As the results in Table 8 show, the anti-CTLA-4 antibodies tested in this assay induce IL-2 production in the Jurkat/NFAT-Luc/CTLA-4 chimera//Raji APC system. At 100 nM concentration, anti-CTLA-4 antibodies induce IL-2 production with fold activities ranging from 4 to 6x above that observed in the assay system using CTLA-4 negative reporter T-cells. As shown in Table 8, H1H19303P performed better than comparators 1 and 2 as tested.

Summary

[0268] In summary, selected anti-CTLA-4 antibodies were tested in two engineered T cell/APC bioassay systems designed to assess the activity of the antibodies on T-cell activation. In one format, anti-CTLA-4 antibodies activated T-cells as measured by an increase in NFAT-Luciferase activity, indicating that the antibodies block the interaction between CTLA-4 and ligands CD80 and CD86. In a second format, the anti-CTLA-4 antibodies induced production of IL-2, indicating that anti-CTLA-4 antibodies can block the CTLA-4/CD80 and CTLA-4/CD86 interaction, thereby rescuing IL-2 release.

[0269] Table 7: EC₅₀ of CTLA-4 mabs in CTLA-4 T-cell/APC luciferase assay

Assay System	T cell: Parental Jurkat/NFATLuc cl.3C7 [M]		T cell : Jurkat/NFAT-Luc hCTLA-44/hCD300 [M]		T cell : Jurkat/NFAT-Luc mfCTLA-4/hCD300 [M]	
	APC: Raji		APC: Raji		APC: Raji	
Antibody 100nM	- Fc Block	+ Fc Block	- Fc Block	+ Fc Block	- Fc Block	+ Fc Block
H1H19273P	-	-	2.74E-09	3.83E-09	3.05E-09	1.83E-09
H1H19291P	-	-	2.36E-09	3.92E-09	-	7.67E-09
H1H19313P	-	-	1.69E-09	3.47E-09	1.34E-09	1.84E-09
H1H19303P	-	-	1.61E-09	1.73E-09	1.28E-09	1.77E-09
H1H19319P2	-	-	2.47E-09	4.18E-09	-	4.91E-09
H1H19327P2	-	-	4.20E-09	5.49E-09	-	5.76E-09
COMP1			3.20E-09	3.30E-09	-	3.00E-09
COMP2			1.97E-09	2.07E-09	1.11E-09	1.70E-09
hIgG1 Isotype	-	-	-	-	-	-
hIgG2 Isotype	-	-	-	-	-	-

(-) indicates EC₅₀ values could not be determined from the fitted curve

[0270] Table 8: Fold induction at 100nM CTLA-4 mabs and EC₅₀ of CTLA-4 mabs in CTLA-4 T-cell/APC IL-2 release assay

Assay System	T cell: Parental Jurkat/NFATLuc cl.3C7		T cell: Jurkat/NFAT-Luc hCTLA-44/hCD300		T cell: Jurkat/NFAT-Luc mfCTLA-4/hCD300	
	APC: HEK293/hCD20		APC: HEK293/hCD20/hCD80		APC: HEK293/hCD20/hCD86	
Antibody 100nM	EC50 [M]	Fold at 100 nM	EC50 [M]	Fold at 100 nM	EC50 [M]	Fold at 100 nM
H1H19273P	-	0.9	3.33E-08	5.1	1.14E-08	6.5
H1H19303P	-	1.1	4.09E-08	5.4	4.09E-08	4.4
H1H19313P	-	0.9	2.19E-08	5.7	2.19E-08	6.1
H1H19319P2	-	1.6	1.56E-08	4.2	1.56E-08	6.4
COMP1	-	1.3	1.83E-08	4.1	4.63E-08	6.3
COMP2	-	0.9	1.17E-08	5.0	9.71E-08	5.0
hIgG1 Isotype	-	1.2	-	0.8	-	1.1
hIgG2 Isotype	-	0.8	-	1.0	-	1.0

(-) indicates EC₅₀ values could not be determined from the fitted curve

Example 7: Efficacy of Anti-CTLA-4 Antibodies Against Tumors

[0271] This Example describes the anti-tumor efficacy of exemplary anti-CTLA-4 antibodies of the invention against MC38.Ova tumors grown in mice humanized for the CTLA-4 gene.

[0272] Human *CTLA-4*^{hum/hum} knock-in mice were engineered on a C57BL/6 strain background using VelociGene™ technology, wherein the mice express a chimeric protein comprising the human CTLA-4 extracellular domain fused to mouse CTLA-4 transmembrane and cytoplasmic domains from the endogenous *Ctla4* locus (Valenzuela *et al* 2003; Nat. Biotechnol. 21: 652-659). The MC38.Ova cell line was engineered by stable lentiviral transduction of MC38 cells to express transmembrane chicken ovalbumin antigen (Ova).

Study (A)

[0273] *CTLA-4*^{hum/hum} knock-in mice were implanted subcutaneously (SC) with MC38.Ova cells (10⁶ cells/mouse) on day 0 and received 10 mg/kg of either H1H19273P, or H1H19303P, or H1H19319 or 10 mg/kg of hIgG1 isotype control IP on days 3, 7, 10, 14 and 17. Tumor volumes and tumor-free animals were monitored for up to 37 days.

[0274] All three anti-CTLA-4 antibodies showed partial tumor growth inhibition tested at 10 mg/kg compared to treatment with isotype control (Figure 1). Treatment with H1H19303P resulted in 8 out of 9 (89%) mice tumor-free in 10 mg/kg dose group by day 24 (Figure 2). Treatments with either H1H19319P or H1H19273P were similarly efficacious, resulting in complete tumor growth inhibition in 7 out of 9 mice (78 %) and 5 out of 9 mice (56 %) respectively by day 24. None of the animals was tumor-free in the isotype control treated group at day 24. Tumor volumes at day 24 were significantly smaller (p<0.0001) for each

anti-CTLA-4 antibody treatment group compared to the group administered the isotype control.

[0275] Mice observed to be tumor-free at day 24 were monitored for 37 days post-implantation. The survival rate was significantly higher in mice treated with either of anti-human CTLA-4 antibodies ($p < 0.0001$) compared to mice administered an isotype control (Figure 3). No tumor recurrence was observed in all tumor-free mice from anti-CTLA-4 antibody groups. No evidence of body weight loss was observed as a result of antibody treatment.

[0276] In summary, treatment with each of the three anti-human CTLA-4 antibodies (H1H19273P, H1H19303P, and H1H19319) resulted in reduced tumor growth, improved tumor clearance and improved survival compared to isotype control. Efficacy of each of the three anti-human CTLA-4 antibodies in this model was comparable.

Study (B)

[0277] The exemplary anti-CTLA-4 antibody used for this study is a fully human antibody that binds specifically to human CTLA-4 and comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 of SEQ ID NOS: 196-198-200-204-206-208 and HCVR/LCVR of SEQ ID Nos: 194/202 (also known as H1H19303P). The full-length heavy chain amino acid sequence of H1H19303P (also known as REGN4659) is shown in SEQ ID NO: 509, and the full-length light chain amino acid sequence of H1H19303P is shown in SEQ ID NO: 510 (Table 9).

[0278] Table 9: Amino acid sequences of H1H19303P

Ab region	Amino acid sequence
HCVR	SEQ ID NO: 194 EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYEMSWVRQAPGKGLEWSSIRTSGTT KYYADSMKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAGGGTFLHYWGQGTLVTVSS
LCVR	SEQ ID NO: 202 DIQMTQSPSSVSASVGDRVTITCRASQGIASYLAWYQQKPGKAPKLLIYAASSLQTGVP SRFSGSGYGTDFLTISLQPEDFATYYCQAKSFPMYTFGQGTGLEIK
HCDR1	SEQ ID NO: 196 GFTFSNYE
HCDR2	SEQ ID NO: 198 IRTSGTTK
HCDR3	SEQ ID NO: 200 AGGGTFLHY
LCDR1	SEQ ID NO: 204 QGIASY
LCDR2	SEQ ID NO: 206 AAS
LCDR3	SEQ ID NO: 208

	QQAQSFPMYT
HC	SEQ ID NO: 509 <u>*EVQLVESGGGLVQPGGSLRLS</u> <u>CAASGFTFSNYEMSWWRQAPGKGLEWVSSIRTS</u> <u>GTT</u> <u>KYYADSMKGRFTISRDN</u> <u>AKNSLYLQMN</u> <u>SLRAEDTAVYYCAGGGTFLHYWGQGT</u> <u>LVTVSS</u> ASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP SRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVD KSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK
LC	SEQ ID NO: 510 <u>*DIQMTQSPSSVSASV</u> <u>GDRVIT</u> <u>CRASQGIAS</u> <u>YLAWYQQKPGKAPKLLIYAASSL</u> <u>QTGVP</u> <u>SRFSGSGYGTDF</u> <u>TLTISSLPEDFATYYC</u> <u>QQAQSFPMYTFGQGT</u> <u>KLKIR</u> <u>TVAAPSVFI</u> FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC

*the underlined sequence is the variable region

Administration and Analysis of Anti-tumor Activity of Anti-CTLA-4 Antibodies

[0279] The anti-tumor activity of H1H19303P was tested at different doses in MC38.Ova tumor-bearing *CTLA-4^{hum/hum}* knock-in mice. A hlgG1 isotype control was included as a negative control. *CTLA-4^{hum/hum}* knock-in mice were implanted SC in the hind flank with 1×10^6 MC38.Ova cells on day 0 and separated into four treatment groups (Table 10). Mice were administered H1H19303P, or a hlgG1 isotype control IP on days 3, 6, 9, 13 and 16. Tumor volumes were measured by caliper twice per week for 37 days. Tumor-bearing mice were sacrificed with CO₂ either at day 37 or at the following endpoints: tumor volumes > 2000 mm³ or tumor ulceration. Tumor-free mice were followed for up to 107 days for a survival study.

[0280] Table 10: Dosing scheme for efficacy study in *CTLA-4^{hum/hum}* knock-in mice implanted with MC38.Ova Cells

Treatment Groups	Dose	No. of Mice/ Group	Route of Administration	Dosing Schedule	Bleed Schedule ^a
H1H19303P	2 mg/kg	8	IP	Days 3, 6, 9, 13, and 16	Days -2, 6, 13, 20
H1H19303P	5 mg/kg	8			
H1H19303P	10 mg/kg	8			
hlgG1 Isotype Control	10 mg/kg	7			

^a Serum samples were analyzed for antibody levels by ELISA. Samples collected at days 6, 13, and 20 were analyzed for the 10 mg/kg H1H19303P and hlgG1 control groups, and samples collected at days 6 and 20 were analyzed for the 2 mg/kg and 5 mg/kg dose groups for H1H19303P.

[0281] Blood samples were collected from the submandibular vein two days before the start of the experiment (day -2) and two hours before antibody administration on days 6, 13 and 20. Serum samples were frozen and stored for subsequent measurements of serum antibody levels.

[0282] Statistical analysis was performed using GraphPad Prism software (Version 6). Statistical significance for differences in tumor volumes between animal groups was determined by one-way ANOVA with Dunnett's multiple comparisons post-hoc test. Statistical significance for tumor-free survival was determined by log-rank (Mantel-Cox) test. To determine whether each group was significantly different from the control group, the two group Mantel-Cox analysis was run with the significance level ($\alpha=0.05$) adjusted for number of comparisons ($k=6$) using the Bonferroni method ($\alpha_{\text{adjusted}}=0.05/6$).

Serum Concentration of Total Human IgG Antibody

[0283] The serum concentration of total H1H19303P and hIgG1 isotype control antibody was determined using a sandwich ELISA specific for the detection of human Fc γ . Serum samples collected at days 6, 13, and 20 were analyzed for the 10 mg/kg H1H19303P and hIgG1 control groups, and samples collected at days 6 and 20 were analyzed for the 2 mg/kg and 5 mg/kg dose groups for H1H19303P. Briefly, goat anti-human Fc γ polyclonal antibody at 1 $\mu\text{g/mL}$ in PBS was passively adsorbed to a microtiter plate overnight at 4°C followed by a nonspecific binding block with 5% BSA in PBS. The standard used for calibration in this assay was H1H19303P, or isotype control antibody at concentrations ranging from 2.7 to 350 ng/mL (1:2 serial dilution). Serial dilutions of standards and serum samples were prepared in dilution buffer (0.5% BSA in PBS). Samples were then added to the anti-hFc γ -coated plate (100 μL /well) and incubated for 1 hour at room temperature. Subsequently, plate-captured human IgG antibodies were detected using 160 ng/mL of an HRP-conjugated anti-hFc γ polyclonal antibody in dilution buffer. The chromogenic HRP-substrate, 3,3',5,5'-tetramethylbenzidine (TMB) was used to detect HRP activity, and the resultant OD₄₅₀ was read on a Perkin Elmer Victor X4 Multimode Plate Reader. The lowest concentration of standard (H1H19303P, or isotype control antibody) used for calibration (2.7 ng/mL) was within the dynamic range of the assay and was defined as this assay's LLOQ. Data were analyzed by non-linear regression using GraphPad Prism software. Average concentrations from 2 replicate experiments were used for analysis.

Serum Concentration of Mouse Anti-Human Antibodies

[0284] Anti- H1H19303P or anti-IgG1 control antibody mouse IgG titers were determined using a sandwich ELISA specific for the detection of each of the antibodies injected. Serum samples collected at days 6, 13, and 20 were analyzed for the 10 mg/kg H1H19303P and hIgG1 control groups, and samples collected at days 6 and 20 were analyzed for the 2 mg/kg and 5 mg/kg dose groups for H1H19303P. Briefly, H1H19303P or anti-IgG1 control antibody at 1 $\mu\text{g/mL}$ in PBS were passively adsorbed to a microtiter plate overnight at 4°C followed by a nonspecific binding block with 5% bovine serum albumin (BSA) in PBS. Serial dilutions of serum samples were prepared in dilution buffer (0.5% BSA in PBS) starting from 1:500. Therefore, the corresponding dilution factor (500) was defined as the assay's lower

limit of detection (LOD). Samples were then added to the H1H19303P or anti-IgG1 control antibody -coated plates (100 μ L/well) and incubated 16-18 hours at 4°C. Wells with addition of dilution buffer only were included to determine the assay background. Subsequently, plate-captured mouse IgG was detected using horseradish peroxidase (HRP)-conjugated goat anti-mouse Fc γ polyclonal antibody at 40 ng/mL. The chromogenic HRP-substrate, TMB was used to detect HRP activity, and the resultant optical density at 450nm (OD₄₅₀) was read on a Perkin Elmer Victor X4 Multimode Plate Reader. Data of binding signal versus dilution factor were analyzed by non-linear regression using GraphPad Prism software and titers were calculated. The MAHA titer was defined as the calculated dilution factor of the serum sample corresponding to a binding signal equivalent to twice the background signal of the assay.

Results

[0285] CTLA-4^{hum/hum} knock-in mice were implanted SC with MC38.Ova cells on day 0 and received 2, 5, or 10 mg/kg H1H19303P or 10 mg/kg hlgG1 isotype control IP on days 3, 6, 9, 13 and 16. Tumor volumes were monitored for 37 days, and tumor-free animals were monitored for up to 107 days.

[0286] H1H19303P showed partial tumor growth inhibition at all doses tested (Figure 4) compared to treatment with isotype control. Treatment with H1H19303P resulted in 5 out of 8 (63%) mice tumor-free in both the 5 mg/kg and 10 mg/kg dose groups and 2 out of 8 (25%) mice tumor-free in the 2 mg/kg dose group by day 20. Tumor volumes at day 20 were significantly smaller ($p < 0.0001$) for H1H19303P treatment groups compared to the group administered the isotype control (Figure 5).

[0287] Mice observed to be tumor-free at day 20 were monitored for up to 107 days post-implantation. The survival rate was significantly higher in mice treated with H1H19303P ($p < 0.0001$) compared to mice administered an isotype control (Figure 6). No tumor recurrence was observed in 24 out of 25 tumor-free mice from all dose groups. No evidence of body weight loss was observed as a result of antibody treatment.

[0288] In summary, prophylactic treatment with H1H19303P significantly reduced tumor growth in a dose-dependent manner, improved tumor clearance and improved survival compared to isotype control.

Evaluation of Serum Antibody Concentrations and MAHA by ELISA

[0289] Serum samples collected on days 6, 13 and 20 were analyzed for concentrations of H1H19303P and isotype control, as well as for MAHA titers using ELISA. The concentration of H1H19303P and hlgG1 isotype control antibody in serum was determined using a sandwich ELISA specific for the detection of human IgG (Figure 7). Specific mouse IgG titers to H1H19303P or IgG1 control antibody were determined using a sandwich ELISA specific for the detection of each antibody (Figure 8).

[0290] At day 6, H1H19303P and isotype control were detected in serum at all doses tested, with average serum concentrations of 39.8 ± 24 , 33.5 ± 8.9 , and 10.4 ± 2.9 observed for the 10, 5, and 2 mg/kg doses of H1H19303P, respectively (Table 11).

[0291] Table 11: Serum concentrations of H1H19303P and isotype control

Dose	Antibody Administered	Average Serum Concentration ($\mu\text{g/mL}$) ^a		
		Day 6	Day 13	Day 20
10 mg/kg	H1H19303P	39.8 ± 24	12.0 ± 13	0.21 ± 0.254
	Isotype Control	130 ± 10.4	255 ± 43.4	279 ± 64.4
5 mg/kg	H1H19303P	33.5 ± 8.9	NT	$\leq \text{LLOQ}$
2 mg/kg	H1H19303P	10.4 ± 2.9	NT	$\leq \text{LLOQ}$

^aData shown are average serum concentrations with standard deviation.

NT: Not tested; LLOQ: Lower limit of quantification

[0292] Table 12: Average titer of mouse anti- H1H19303P and anti-isotype control antibodies

Dose	Antibody Administered	Average Titer ^a		
		Day 6	Day 13	Day 20
10 mg/kg	H1H19303P	$\leq \text{LOD}$	39831 ± 24087	711076 ± 352075
	hIgG1 Control	$\leq \text{LOD}$	$\leq \text{LOD}$	564 ± 658
5 mg/kg	H1H19303P	$\leq \text{LOD}$	NT	779150 ± 514583
2 mg/kg	H1H19303P	$\leq \text{LOD}$	NT	878074 ± 409564

^aData shown are average titers with standard deviation.

NT: Not tested; LOD: Limit of detection

[0293] After day 6, reductions in serum concentrations were observed for H1H19303P for all dose groups by day 20, despite additional administration of antibody at days 6, 9, 13, and 16 (Table 11). Rapid antibody clearance was observed compared to isotype control for the 10mg/kg dose groups. The reduction in serum concentrations of H1H19303P are likely attributed to the development of MAHA (Figure 8, Table 12). MAHA titers were observed at all time-points measured after day 6 for all doses of H1H19303P. However, MAHA titers for isotype control were at the limit of detection at all time-points tested.

Conclusion

[0294] Intraperitoneal administration of H1H19303P at doses of 10 mg/kg, 5 mg/kg or 2 mg/kg resulted in reduction of tumor growth, improved tumor clearance, and improved survival compared to hIgG1 control in *CTLA-4^{hum/hum}* knock-in mice implanted with MC38.Ova tumor cells. Serum concentrations of H1H19303P decreased over time, corresponding with development of anti- H1H19303P MAHA at time-points after day 6.

Example 8: Efficacy of the combination treatment with anti-mouse CTLA-4 antibodies and anti-human PD-1 antibodies (REGN2810) in *PD-1^{hum/hum}* Knock-in Mice Bearing MC38.Ova Tumor

[0295] This Example describes the anti-tumor efficacy of an anti-CTLA-4 antibody in

combination with an anti-PD-1 antibody in mice humanized for the PD-1 gene. The anti-PD-1 antibody used in this study is REGN2810 (also known as cemiplimab), and is described in US Patent 9,987,500 as H4H7798N. *PD-1^{hum/hum}* knock-in mice have been described in US Patent Application Publication US2015/0203579.

[0296] *PD-1^{hum/hum}* knock-in mice were implanted subcutaneously with MC38.Ova cells (5×10^5 cells/mouse). Mice were randomized into 4 treatment groups when mean tumor size reached 100 mm^3 (day 0 of treatment). Mice were administered 10 mg/kg of either isotype control antibody, an anti-mouse CTLA-4-mIgG2a antibody (clone 9D9), anti-human PD-1 antibody (REGN2810) or a combination of anti-mouse CTLA-4 and anti-human PD-1 antibodies (10 mg/kg + 10 mg/kg) IP on days 0, 3, 7, 10 and 14. Tumor volumes and tumor-free animals were monitored for up to 22 days. Tumor volumes were monitored by caliper measurements twice per week for 22 days. Monotherapy with anti-CTLA-4 antibodies or anti-PD-1 antibodies showed partial tumor growth inhibition tested at 10 mg/kg compared to treatment with isotype control (Figure 9). Individual tumor volumes at day 10 after treatment initiation (Figure 10) were used for statistical analysis, as this was the last time point in the study where all animals in all groups were alive. Statistical significance was determined by one-way ANOVA with Dunnett's multiple comparisons post-test (** $p < 0.01$, **** $p < 0.0001$). Combination of anti-CTLA-4 and anti-PD-1 antibodies treatment resulted in more efficacious tumor growth inhibition compared to monotherapy with either antibody with statistically significant smaller tumors at day 10 in a combo treated group than in an anti-PD-1 treated group (**** $p < 0.0001$, Figure 10). One out of eight animals in anti-CTLA-4 treatment group and 2 out of eight animals in a combo treated group became tumor-free by day 22. Treatment with a combination of anti-CTLA-4 and anti-PD-1 antibodies also resulted in a significant difference in animal survival rate compared to control group (Mantel-Cox test, **** $p < 0.0001$, Figure 11). No evidence of body weight loss was observed as a result of antibody treatment.

[0297] In summary, treatment with a combination of anti-mCTLA-4 and anti-PD-1 (REGN2810) antibodies resulted in reduced tumor growth and improved survival compared to monotherapy with either antibody.

Example 9: Anti-Tumor Efficacy of REGN4659 Treatment in Established MC38.Ova Tumor Model in Human CTLA-4^{hum/hum} Mice

Experimental design

[0298] Sixty CTLA-4^{hum/hum} mice were subcutaneously implanted with 5×10^5 MC38.Ova cells in the flank on day 0. On day 10, thirty mice with average tumor volume of 100 mm^3 were selected and randomized into 3 treatment groups (N=10/group). On days 10,13 and 17 mice were dosed with antibodies as follows: group 1, hIgG1 isotype control Ab (REGN1932)

at 25 mg/kg; group 2, anti-hCTLA-4 Ab (REGN4659; H1H19303P) at 25 mg/kg; group 3, anti-hCTLA-4 Ab (REGN4659; H1H19303P) at 10 mg/kg.

[0299] All antibodies were administered by IP injection. Tumor volumes were monitored by caliper measurements for the duration of the experiment (27 days).

Results

[0300] REGN4569 treatment of established MC38.Ova tumors resulted in partial tumor growth inhibition (Figure 12).

[0301] REGN4659 monotherapy was similarly efficacious at both doses, 10 mg/kg and at 25 mg/kg, in reducing tumor growth (Figure 13).

[0302] One-way analysis of variance (ANOVA) with Tukey's multiple comparison post-test revealed a significant difference in mean tumor volumes between each REGN4569 monotherapy group and hlgG1 isotype control group ($p < 0.05$) at day 21, the last day when the animals in all treated groups were alive (Figure 13).

Example 10: Analysis of Intratumoral and Peripheral T Cells After REGN4659 Treatment of Established Subcutaneous MC38.Ova Tumors in CTLA-4^{hum/hum} Mice

Experimental design

[0303] Forty CTLA-4^{hum/hum} mice were subcutaneously implanted with 5×10^5 MC38.Ova cells in the flank on day 0. On day 10, twenty mice with average tumor volume of 100 mm^3 were selected and randomized into 2 treatment groups ($N=10/\text{group}$). On days 10 and 13 mice were dosed with antibodies as follows: group 1, hlgG1 isotype control Ab (REGN1932) at 25 mg/kg; group 2, anti-hCTLA-4 Ab (REGN4659; H1H19303P) at 25 mg/kg. All antibodies were administered by IP injection. Tumor volumes were monitored by caliper measurements. On day 17, when tumors reached $355 \pm 35 \text{ mm}^3$ (mean $\pm$ SEM) in hlgG1 group and $180 \pm 43 \text{ mm}^3$ (mean $\pm$ SEM) in REGN4659 treated group, all mice were sacrificed. Tumors and spleens were harvested for lymphocyte analysis by flow cytometry. Single cells suspensions of tumors and spleens were prepared. Cells were treated with 24G.2 (Bioxcell), which blocks Fc binding to FcγRIIb and FcγRIII, and subsequently stained for viability with LIVE/DEAD™ Fixable Aqua Dead Cell dye (Invitrogen) and then with a cocktail of antibodies against CD45 (clone 30-F11; Biolegend), C90.2 (clone 30-H12; Biolegend), CD8 (clone 53-6.7; Biolegend), CD4 (GK1.5; Biolegend), CD11b (clone M1/70; Biolegend) and human CTLA-4 (clone BNI3, BD). For intracellular staining, samples were fixed, permeabilized, and stained with antibodies to FoxP3 (clone FJK-16s, Invitrogen) and human CTLA-4. Samples were then analyzed on a FACS Canto flow cytometer (BD).

Results

[0304] T-cell subsets were analyzed in tumors and spleens of MC38.Ova tumor bearing mice at day 17 after implantation and REGN4659 antibody treatment. Assessment of T_{eff}

and Treg population at the tumor site and in the periphery in the spleens showed that REGN4659, which possesses hlgG1 isotype (SEQ ID NO: 509 is the full-length heavy chain amino acid sequence of H1H19303P, also known as REGN4659), mediates reduction of Tregs in the tumor site after just two administrations of therapeutic antibody in MC38.Ova tumor bearing CTLA-4^{hum/hum} mice (Table 12). Expansion of CD4⁺ effector cells and CD8⁺ cells at the tumor site is observed whereas treatment with REGN4659 expanded Tregs in the spleens. These data show that REGN4659 promotes anti-tumor activity in MC38.Ova tumor model in CTLA-4^{hum/hum} mice by selectively reducing intratumoral Tregs along with activation of intratumoral effector T cells. The different outcome of REGN4659 on intratumoral Treg numbers compared to splenic Tregs or T effector cells could be attributed to differences in the expression levels of CTLA-4. To answer this question, CTLA-4 expression level (surface and intracellular) on T-cells was measured by FACS from the hlgG1 control treated group. The expression of total CTLA-4 on intratumoral Tregs was about 3 times higher than on intratumoral CD8⁺ and CD4⁺ effector cells and about 8 times higher than on Tregs from spleen (Figure 14). This difference in expression may explain selective loss of tumor Tregs by FcγR dependent mechanism, given high binding affinity of antibodies with human IgG1 constant region to murine Fcγ receptors.

[0305] Table 13: CTLA-4 blockade with REGN4659 expands intratumoral CD4⁺ effector and CD8⁺ cells, but reduces Tregs.

	Tumor		
	CD4 ⁺ Effector (**)	CD4 ⁺ Treg (**)	CD8 ⁺ (**)
hIgG1	2.12 ± 0.72	56.82 ± 5.14	6.12 ± 0.64
REGN4659	5.83 ± 0.87	35.38 ± 3.08	11.83 ± 1.49
	Spleen		
	CD4 ⁺ Effector (***)	CD4 ⁺ Treg (**)	CD8 ⁺
hIgG1	10.11 ± 1.33	30.6 ± 1.60	8.73 ± 0.74
REGN4659	14.67 ± 0.78	40.4 ± 0.93	6.99 ± 0.52

[0306] Table 13 shows the percentage of CD45⁺ cells that are CD4⁺FoxP3⁻ (CD4⁺effector), percentage of CD45⁺ that are CD8⁺ and percentage of CD4⁺ cells that are FoxP3⁺ (CD4⁺Treg). Unpaired T-test analysis revealed significant difference in CD4⁺ effector, CD8⁺, CD4⁺Tregs in tumors and in CD4⁺effector and CD4⁺ Tregs in spleens between REGN4659 group and isotype control treated group (**p<0.005, *** p<0.001).

Example 11: Changes in T Cell Function and Overall Systemic Immune Activation in Spleens of Tumor Bearing Mice Treated with REGN4659

Experimental design

[0307] Twenty CTLA-4^{hum/hum} mice were subcutaneously implanted with 5x10⁵ MC38.Ova cells in the flank on day 0 and randomized into 2 treatment groups (N=9/group). On days 3, 7, 11, 14 and 17 mice were dosed either with hIgG1 isotype control Ab (REGN1932) at 10 mg/kg or with anti-hCTLA-4 Ab (REGN4659; H1H19303P) at 10 mg/kg. All antibodies were administered by IP injection. Tumor volumes were monitored by caliper measurements. Mice were sacrificed starting from day 24 (when tumor grew too big) to day 37 (end of the experiment). In REGN4659 group, 8 out of 9 mice became tumor free, while in the control group none of the mice was tumor free at day 24. Expression levels of murine genes (normalized to murine cyclophilin B RNA expression) was measured by Taqman real-time PCR. Unpaired t-test showed statistically significant increase in relative levels of FoxP3, CD3e, Perforin, IFN γ , TNF α , PD-L1, PD-L2 in REGN4659 group compared to isotype control group.

Results

[0308] Taqman analysis of spleens of REGN4659-treated mice revealed increased transcript levels for FoxP3, CD3e, Perforin, IFN γ , TNF α , PD-L1, PD-L2, suggesting increase in T cells effector function and overall immune-enhancing function of REGN4659. The expression levels of the murine genes (normalized to murine cyclophilin B RNA expression) is shown in Table 14. Unpaired t-test showed statistically significant increase in relative levels of FoxP3, CD3e, Perforin, IFN γ , TNF α , PD-L1 and PD-L2 in REGN4659 group compared to isotype control group.

[0309] Table 14: REGN4659 therapy enhanced adaptive immune responses *in vivo*.

	FOXP3 (***)	CD3e (***)	Perforin (***)	IFN γ (***)	TNF α (***)	PD-L1 (*)	PD-L2 (***)
hIgG1	3.12 $\pm$ 0.54	2.72 $\pm$ 0.39	2.46 $\pm$ 0.35	0.962 $\pm$ 0.16	1.98 $\pm$ 0.34	2.81 $\pm$ 0.59	1.98 $\pm$ 0.30
REGN 4659	9.15 $\pm$ 1.28	11.48 $\pm$ 1.57	10.65 $\pm$ 1.45	4.33 $\pm$ 0.61	6.42 $\pm$ 0.88	5.33 $\pm$ 0.61	7.46 $\pm$ 1.02

Reported average $\pm$ SEM; Unpaired t test, two-tailed; *p<0.05, **p $\leq$ 0.01, ***p $\leq$ 0.001.

Example 12: Human Clinical Trial of Anti-CTLA-4 Antibody (REGN4659) in Combination with Cemiplimab (Anti-PD-1 Antibody) in the Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

[0310] This study is an open-label, phase I, first-in-human (FIH) study evaluating REGN4659 (*i.e.*, H1H19303P of Examples 1-7 and 9-11) alone, high dose cemiplimab alone (cohort C), and the combination of REGN4659 with cemiplimab in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). The study comprises both a dose escalation phase and a dose expansion phase.

[0311] Cemiplimab (REGN2810; Example 8) is a high-affinity, fully human, hinge-stabilized IgG4P antibody directed to the PD-1 receptor that potently blocks the interaction of

PD-1 with its ligands, PD-L1 and PD-L2.

Study Objectives

[0312] The primary objective of the dose escalation phase is to assess safety, tolerability, and pharmacokinetics (PK) of REGN4659 alone, high-dose cemiplimab alone, and the combination of REGN4659 with cemiplimab in treatment-experienced patients with non-small cell lung cancer (NSCLC). The primary objectives of the dose expansion phase are to assess preliminary anti-tumor activity of the combination of REGN4659 with cemiplimab as measured by the objective response rate (ORR) in anti-PD-1/PD-L1 immunotherapy experienced NSCLC patients, and to assess the safety, tolerability, and PK of REGN4659 and cemiplimab in anti-PD-1/PD-L1 immunotherapy experienced NSCLC patients.

[0313] The secondary objectives of the study are (i) to assess preliminary anti-tumor activity of high-dose cemiplimab monotherapy and the combination of REGN4659 with cemiplimab as measured by the ORR in treatment-experienced patients with NSCLC in the dose escalation phase, (ii) to assess anti-tumor activity of REGN4659 with cemiplimab via multiple criteria during dose escalation and expansion, and (iii) to assess systemic pharmacodynamic effects of REGN4659 and cemiplimab, measured by the changes in peripheral blood biomarkers of T-cell activation, including ICOS⁺ CD4 T-cells.

Study Design

[0314] This study is an open-label, phase I, first-in-human (FIH) study evaluating REGN4659 alone, high-dose cemiplimab alone (cohort C), and the combination of REGN4659 with cemiplimab in the treatment of advanced or metastatic NSCLC. There are 2 phases of this study: a dose escalation phase in treatment-experienced patients (prior chemotherapy and/or anti-PD-1/PD-L1 immunotherapy) with NSCLC, and a dose expansion phase in anti-PD-1/PD-L1 immunotherapy experienced patients with NSCLC.

[0315] The study comprises a screening period of up to 28 days (day -28 to day -1), followed by up to seventeen 42-day treatment cycles (for up to 102 weeks of treatment), and a 24-week follow-up period. A patient will receive treatment until the 102-week treatment period is complete, or until unequivocal disease progression, unacceptable toxicity, withdrawal of consent, or until another study withdrawal criterion is met. After a minimum of 24 weeks of treatment, patients with confirmed complete response (CR) may elect to discontinue treatment and continue with all relevant study assessments. In dose escalation, tumor biopsies are expected to be performed unless medically contraindicated. Tumor biopsies are mandatory as part of the dose expansion cohorts. For patients who experience a response and subsequently progress, a tumor biopsy at the time of progression will be requested but is not required.

[0316] Patients who progress within 6 months after completing the treatment period for CR, partial response (PR), or stable disease (SD) after meeting study-defined criteria and

continuing with defined visits are allowed to resume study treatment following reconfirmation of relevant study eligibility criteria. Patients can receive up to 102 weeks of additional therapy. The resumed dose and drug(s) should generally be the same as the patient originally received or a dose level chosen for the expansion cohort(s) following discussion between the sponsor and investigator.

[0317] Patients in cohort C who tolerate 2 doses of cemiplimab (1050 mg Q3W), but who subsequently demonstrate PD, will have the option of adding the highest combination dose of cemiplimab and REGN4659 safely administered up to that point in an attempt to seek a response using combined CTLA-4 and PD-1 blockade.

[0318] Dose Escalation: Eight dose escalation cohorts are planned. Three dose levels of REGN4659 (25, 75, and 250 mg intravenous [IV] fixed dose) will be investigated at various schedules every 3, 6, and 12 weeks (Q3W, Q6W, Q12W) in combination with cemiplimab at 2 dose levels (350 and 1050 mg IV fixed dose) administered Q3W. Prior to beginning combination cohorts with 1050 mg of cemiplimab, a cohort of 1050 mg of cemiplimab Q3W monotherapy will be investigated (cohort C). For dose escalation cohorts designated with an asterisk (cohorts 1*, 2*, and 4*), a single lead-in dose of REGN4659 monotherapy will precede combination therapy by 3 weeks to assess safety of REGN4649 prior to combination with cemiplimab. Six of the 8 cohorts (1*, C, 2*, 2, 3, and 4*) will be used for dose-limiting toxicity (DLT) evaluation. In addition to the DLT-evaluable cohorts, 2 additional dose cohorts (5 and 6) will each enroll 6 patients for safety and PK/pharmacodynamics evaluation. Cohorts 5 and 6 will be enrolled after tolerability of cohorts 2 and 3 are established, respectively. The dose combinations in cohorts 5 and 6 are potentially of interest even if higher dose intensities of REGN4659 (cohorts 2 and 3) are tolerable. However, these cohorts will not require DLT evaluation if cohorts 2 and 3 are tolerable due to the lower exposures of REGN4659 in cohorts 5 and 6. Except for cohort C where 6 patients will be enrolled, a minimum of 3 patients in each dose cohort will be required to be evaluable for DLT. To maximize the efficiency of the phase 1 dose escalation while maintaining patient safety, 4 patients will be enrolled in each dose cohort (except cohort C), in case a patient discontinues prior to being evaluable for DLT. Cohorts 3 and 6 (combination cohorts with high dose cemiplimab) will not be initiated until all 6 patients in cohort C have completed the DLT period. Dose escalation will proceed through dose cohorts until a maximum tolerated dose (MTD) of the combination is attained or all dose cohorts have been tested. However, even prior to completion of dose escalation, dose cohort(s) may be selected for expansion once tolerability and pharmacodynamic activity are evaluated for any cohort.

[0319] Dose-Limiting Toxicities: In addition to the inability to administer (due to study drug toxicity) dose #2 within the window, a DLT will be considered upon occurrence of the

following study toxicities with the exception of events that are deemed clearly related to disease progression or intercurrent illness:

Non-Hematologic Toxicity:

- (i) Grade ≥ 2 uveitis (considered as a potential irAE);
- (ii) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5 times upper limit of normal (ULN) and/or total bilirubin >3 times ULN. For patients with liver metastases, AST, ALT and/or total bilirubin $>2\times$ baseline value if grade 2 at baseline; and
- (iii) Any grade ≥ 3 nonhematologic toxicity, including irAEs (as defined by experience with other immunomodulatory drugs, with the exception of the following:
 - (a) Grade 3 nausea, vomiting, or diarrhea unless persistent (>72 hours duration) despite maximal supportive care measures, as prescribed by the treating physician; and
 - (b) Grade ≥ 3 laboratory abnormalities that are considered clinically insignificant and do not meet criteria for an adverse event (AE).

Hematologic Toxicity:

- (i) Grade 4 neutropenia lasting more than 7 days;
- (ii) Grade 4 thrombocytopenia;
- (iii) Grade 3 thrombocytopenia with bleeding;
- (iv) Grade ≥ 3 febrile neutropenia (fever $\geq 38.5^{\circ}\text{C}$ with absolute neutrophil count $<1.0 \times 10^9/\text{L}$) or grade ≥ 3 neutropenia with documented infection;
- (v) Grade 4 anemia; and
- (vi) Grade 3 anemia lasting longer than 7 days or requiring transfusion.

[0320] If safety issues develop in an individual cohort subsequent to the DLT evaluation, enrollment may be paused after a discussion between the investigators and the sponsor has occurred. Safety issues triggering a pause could include early or late safety events.

[0321] Dose Expansion: Dose cohort(s) may be selected for expansion once tolerability and pharmacodynamics activity (including but not limited to an increase in peripheral ICOS+ T-cells) are evaluated for any cohort except for cohort C, which will not be expanded. Dose expansion cohort(s) will enroll anti-PD-1/PD-L1 immunotherapy-experienced patients with NSCLC who have progressed while receiving anti-PD-1/PD-L1 therapy to determine the tolerability and activity of combination therapy in this population. Up to 3 separate dose

regimens will be selected for dose expansion to identify the optimal combination regimen in patients with NSCLC. The expansion cohort(s) will enroll a maximum of 27 patients each based upon a Simon 2-stage design. If safety issues develop in an individual expansion cohort, enrollment may be paused after a discussion between the investigators and the sponsor has occurred. Safety issues triggering a pause could include early or late safety events.

Study Duration

[0322] The duration of the study is approximately 102 weeks, not including the screening or follow-up periods.

Population

[0323] Sample Size: Up to approximately 53 adult patients are expected to be enrolled during dose escalation and up to 3 expansion cohorts to a maximum of 27 patients in each cohort are expected to be enrolled during dose expansion at up to approximately 15 sites in the United States. The total number of patients enrolled will depend upon observed DLTs during dose escalation, PK/pharmacodynamics analyses, the number of expansion cohorts opened, and the efficacy in stage 1 of the Simon 2-stage expansion cohorts.

[0324] Target Population: The target population for this study is men and women ≥ 18 years of age diagnosed with unresectable stage IIIB or stage IV squamous or non-squamous NSCLC.

[0325] Inclusion Criteria: A patient must meet the following criteria to be eligible for inclusion in the study:

1. Men and women ≥ 18 years of age;
2. Patients with histologically or cytologically documented squamous or non-squamous NSCLC with unresectable stage IIIB or stage IV disease;
3. Dose escalation (except cohort C): Treatment-experienced patients who have received no more than 3 lines of systemic therapy including no more than 2 lines of cytotoxic chemotherapy, and for whom no available therapy is expected to convey clinical benefit. Patients who have received prior PD-1/PD-L1 immunotherapy must not have permanently discontinued due to a treatment-related AE. Patients with targetable mutations (including epidermal growth factor receptor [EGFR], ALK, and ROS1) are permitted during dose escalation but must have additionally received at least 1 line of targeted therapy.
 - a. NOTE: 1) Adjuvant or neoadjuvant chemotherapy or immunotherapy (after surgery and/or radiation therapy) OR 2) definitive chemoradiation therapy with or without subsequent immunotherapy for stage III disease is permissible and not included when evaluating line of therapy in patients who developed recurrent or metastatic disease more than 6 months after completing therapy;
4. Dose escalation cohort C: Anti-PD-1/PD-L1 naïve patients who have received 1 to 2

prior lines of cytotoxic chemotherapy including a platinum doublet-containing regimen. Patients with targetable mutations (including EGFR, ALK, and ROS1) are permitted during dose escalation but must have additionally received at least 1 line of targeted therapy.

a. NOTE: 1) Adjuvant or neoadjuvant chemotherapy OR 2) definitive chemoradiation therapy for stage III disease is permissible and not included when evaluating line of therapy in patients who developed recurrent or metastatic disease more than 6 months after completing therapy;

5. **Expansion cohort(s):** Anti-PD-1/PD-L1 experienced patients who have progressed while receiving therapy or within 6 months of stopping therapy for stage III or IV disease. Patients must not have permanently discontinued anti-PD-1/PD-L1 therapy due to treatment related AE. Patients must have received one line of anti-PD-1/PD-L1 immunotherapy. Patients may also have received one line of chemotherapy. Prior combination chemotherapy and immunotherapy is permissible as long as no additional line/s of either therapy has been received except as described in the note below.

a. NOTE: 1) Adjuvant or neoadjuvant chemotherapy or immunotherapy (after surgery and/or radiation therapy) OR 2) definitive chemoradiation therapy with or without subsequent immunotherapy for stage III disease is permissible and not included when evaluating line of therapy in patients who developed recurrent or metastatic disease more than 6 months after completing therapy;

6. Archival or newly obtained formalin-fixed tumor tissue which has not previously been irradiated;

7. **Expansion cohort(s):** At least 1 radiographically measureable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression at that site;

8. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 ;

9. Anticipated life expectancy of at least 3 months;

10. Adequate organ and bone marrow function as defined below:

- Hemoglobin ≥ 9.0 g/dL (NOTE: patients who have received transfusions for hemoglobin < 9.0 g/dL within 14 days prior to screening laboratory evaluation are not eligible)
- Absolute neutrophil count $\geq 1.5 \times 10^9$ /L
- Platelet count $\geq 75,000/\text{mm}^3$
- Glomerular filtration rate (GFR) > 30 mL/min/1.73m²
- Total bilirubin $\leq 1.5 \times \text{ULN}$ (if liver metastases $\leq 3 \times \text{ULN}$), with the exception of patients diagnosed with clinically confirmed Gilbert's syndrome

- AST) and ALT $\leq 3 \times$ ULN or $\leq 5 \times$ ULN, if liver metastases
- Alkaline phosphatase $\leq 2.5 \times$ ULN (or $\leq 5.0 \times$ ULN, if liver or bone metastases)
- Not meeting criteria for Hy's law (ALT and/or AST $> 3 \times$ ULN and bilirubin $> 2 \times$ ULN);

11. Willing and able to comply with clinic visits and study-related procedures; and

12. Provide informed consent signed by study patient or legally acceptable representative.

[0326] Exclusion Criteria: A patient who meets any of the following criteria will be excluded from the study:

1. **Expansion cohort(s) only:** Patients who have never smoked, defined as smoking ≤ 100 cigarettes in a lifetime;
2. Active or untreated brain metastases or spinal cord compression. Patients are eligible if central nervous system (CNS) metastases are adequately treated and patients have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment. Patients must be off (immunosuppressive doses of) corticosteroid therapy;
3. **Expansion cohort(s) only:** Patients with tumors tested positive for EGFR and ALK gene mutations or ROS1 fusions. All patients should have tumor evaluated for EGFR mutations, ALK rearrangement, and ROS1 fusions;
4. Radiation therapy within 2 weeks prior to enrollment and not recovered to baseline from any AE due to radiation;
5. Patients who received prior treatment with an anti-CTLA-4 antibody;
6. Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent;
7. History of interstitial lung disease (e.g., idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥ 6 months prior to enrollment;
8. Ongoing or recent evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related treatment-emergent adverse events (irTEAEs). The following are not exclusionary: vitiligo, childhood asthma that has resolved, type I diabetes, residual hypothyroidism that required only hormone replacement or psoriasis that does not require systemic treatment;
9. Patients with a condition requiring corticosteroid therapy (> 10 mg prednisone/day or equivalent) within 14 days of randomization. Physiologic replacement doses are allowed even if they are > 10 mg of prednisone/day or equivalent, as long as they are not being administered for immunosuppressive intent. Inhaled or topical steroids are permitted, provided that they are not for treatment of an autoimmune disorder;
10. **Expansion cohort(s) only:** Another malignancy that is progressing or requires

treatment, with the exception of non-melanomatous skin cancer that has undergone potentially curative therapy, or in situ cervical carcinoma or any other tumor that has been treated, and the patient is deemed to be in complete remission for at least 2 years prior to study entry, and no additional therapy is required during the study period;

11. Uncontrolled infection with human immunodeficiency virus, hepatitis B or hepatitis C infection; or diagnosis of immunodeficiency;

NOTES:

- Patients will be tested for hepatitis C virus (HCV) and hepatitis B virus (HBV) at screening;
- Patients with known HIV infection who have controlled infection (undetectable viral load (HIV RNA PCR) and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are permitted. For patients with controlled HIV infection, monitoring will be performed per local standards;
- Patients with hepatitis B (HepBsAg+) who have controlled infection (serum hepatitis B virus DNA PCR that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) are permitted. Patients with controlled infections must undergo periodic monitoring of HBV DNA. Patients must remain on anti-viral therapy for at least 6 months beyond the last dose of investigational study drug;
- Patients who are hepatitis C virus antibody positive (HCV Ab+) who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are permitted.

12. Active infection requiring systemic therapy within 14 days prior to start of study drug;

13. Treatment-related immune-mediated AEs from immune-modulatory agents (including but not limited to anti-PD1/PD-L1 therapy, other checkpoint inhibitor therapies, and PI 3K- δ inhibitors) that have not resolved to baseline at least 3 months prior to initiation of treatment with study therapy. Patients are excluded from treatment with cemiplimab if they experienced immune-mediated AEs related to prior treatment with a blocker of the PD-1/PD-L1 pathway that required permanent discontinuation of the agent, regardless of time of occurrence. NOTE: patients who experienced hypothyroidism or type I diabetes mellitus of any grade who are controlled with hormone replacement are permitted;

14. Previous treatment with idelalisib (ZYDELIG[®]) at any time;

15. Currently receiving treatment in another study, or has participated in a study of an investigational agent and received treatment, or used an investigational device within 4 weeks of first dose of study therapy, or received treatment with an approved systemic therapy within 3 weeks of first dose of study therapy, or has received any previous systemic therapy within 5 half-lives of first dose of study therapy, whichever is longer (with

the exception of anti-PD-1/PD-L1 therapy). Patients previously treated with bevacizumab, cetuximab, rituximab or other non-immunomodulatory antibodies with half-lives longer than 7 days are permitted after a discussion with the sponsor if at least 28 days have elapsed since last treatment. For anti-PD-1/PD-L1 experienced patients, prior anti-PD-1/PD-L1 therapy cannot have been given within 3 weeks of first dose of study therapy, regardless of half-life or approval status of the drug;

16. Receipt of a live vaccine within 30 days of planned start of study medication;
17. Major surgery or significant traumatic injury within 4 weeks prior to first dose;
18. Known sensitivity to doxycycline or similar compounds (ie, tetracyclines);
19. Documented allergic or hypersensitivity response to any protein therapeutics (e.g., recombinant proteins, vaccines, intravenous immune globulins, monoclonal antibodies, receptor traps);
20. Known psychiatric or substance abuse disorder that would interfere with participation with the requirements of the study, including current use of illicit drugs;
21. Prior allogeneic stem cell transplant;
22. Any medical condition that in the opinion of the investigator would make participation in the study not in the best interest of the patient;
23. Pregnant or breastfeeding women;
24. Positive serum hCG pregnancy test at the baseline (cycle 1 day 1, prior to dosing) visit;
25. Sexually active men and women of childbearing potential* who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 6 months after the last dose. Highly effective contraceptive measures include:

- stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening;
- intrauterine device (IUD); intrauterine hormone-releasing system (IUS);
- bilateral tubal ligation;
- vasectomized partner;
- and or sexual abstinence†, ‡.

*Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of childbearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

†Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated

with the study treatments. ‡Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception. Female condom and male condom should not be used together;

26. Member of the clinical site study team and/or his/her immediate family.

Treatments

[0327] REGN4659: 3 dose levels (25, 75, and 250 mg IV fixed dose) will be investigated at various schedules (Q3W, Q6W, Q12W).

[0328] Cemiplimab: 2 dose levels (350 and 1050 mg IV fixed dose) administered Q3W.

Primary Endpoints

[0329] In the Dose Escalation Phase: Rate of DLTs, treatment emergent adverse events (TEAEs), irAEs, serious adverse events (SAEs), deaths, laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]).

[0330] In the Dose Expansion Phase: Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, and rate of TEAEs, irAEs, SAEs, deaths, laboratory abnormalities (grade 3 or higher per CTCAE).

Secondary Endpoints

[0331] Tumor measurement based on multiple response criteria including: (i) ORR based on RECIST 1.1 (dose escalation), (ii) ORR based on immune-based therapy Response Evaluation Criteria (iRECIST), (iii) best overall response (BOR), duration of response (DOR), disease control rate, and progression-free survival (PFS) based on RECIST 1.1, iRECIST, and (iv) Overall survival (OS).

[0332] Quantitation of % change in absolute ICOS+ CD4 T-cells and other markers of activation via flow cytometry within each dose cohort.

Procedures and Assessments

[0333] The safety and tolerability of REGN4659 and cemiplimab will be monitored by clinical assessment of AEs and by repeated measurements of clinical evaluation including vital signs (temperature, blood pressure, pulse, and respiration), physical examinations (complete and limited), 12-lead electrocardiograms (ECGs), and laboratory assessments including standard hematology, chemistry, and urinalysis.

[0334] Anti-tumor activity will be assessed by CT/MRI.

[0335] Blood samples for the determination of functional REGN4659 and functional cemiplimab in serum and anti-drug antibodies (anti-REGN4659 or anti-cemiplimab) samples will be collected.

[0336] Serum, plasma, peripheral blood mononuclear cells (PBMCs), and tumor biopsies will be collected for analysis of biomarkers. A genomic DNA sample will be collected. Speculated pharmacodynamic, predictive and prognostic biomarkers related to REGN4659

and cemiplimab treatment exposure, clinical activity, or underlying disease will be investigated in serum, plasma, PBMCs, and tumor tissue.

Statistical Plan

[0337] Dose Escalation Phase: There is no formal statistical hypothesis for the dose escalation phase of the study; the analyses of this phase will be descriptive and exploratory in nature. Approximately 35 DLT-evaluable patients are planned based on a modified 3+3 design (“4+3”) for each dose-escalation cohort (cohort 1*, 2*, 2, 3 and 4*). Twelve patients are planned for cohort 5 and 6 (6 patients per cohort). The actual sample size of these dose escalation cohorts will depend on DLTs documented, resultant cohort sizes, and the number of dose levels implemented.

[0338] Dose Expansion Phase: For each expansion cohort in patients with NSCLC who are anti-PD-1/PD-L1 immunotherapy experienced and have progressed while receiving anti-PD-1/PD-L1 therapy, as there is few efficacy data available in these patients, sponsor believes any measurable ORR better than 5% represents a clinical meaningful treatment effect. The sample size of 27 patients for each expansion cohort is determined using Simon 2-stage Minimax design with 1-sided significant level of 5% and power of 80%.

[0339] Primary Efficacy Analysis: Best overall response determined by RECIST 1.1 for expansion cohort will be summarized using descriptive statistics, along with 2-sided 95% confidence interval.

[0340] The ORR will be summarized by descriptive statistics, along with 95% confidence interval. Patients who are not evaluable for the BOR will be considered as nonresponders.

[0341] For the expansion cohort, if the number of responders is greater than or equal to the minimum number of responders specified in the Simon 2-stage design, the treatment is considered as effective and worthy of further investigation.

[0342] The secondary analyses of efficacy include ORR as measured by iRECIST, DOR, rate of disease control and PFS. Those secondary efficacy endpoints will be summarized descriptively by dose escalation and expansion cohorts.

[0343] Safety observations and measurements including drug exposure, AEs, laboratory data, and vital signs will be summarized and presented in tables and listings.

[0344] For the dose escalation phase: DLTs observed during the DLT evaluation period will be summarized by dose cohort.

Results

[0345] In the dose escalation phase, REGN4659 and cemiplimab will be well tolerated alone and in combination in treatment-experienced patients with NSCLC. In the dose expansion phase, REGN4659 will be well tolerated in combination with cemiplimab and will demonstrate measurable anti-tumor responses in anti-PD-1/PD-1 immunotherapy experienced patients with NSCLC.

Exemplary Embodiments

[0346] The present invention also relates to the following items:

[0347] Item 1. An antibody or antigen-binding fragment thereof that binds human cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and blocks the interaction between hCTLA-4 and ligand B7-1 and/or ligand B7-2.

[0348] Item 2. The antibody or antigen-binding fragment of item 1 that induces T-cell activation.

[0349] Item 3. The antibody or antigen-binding fragment of item 2, wherein the T-cell is a cytotoxic T-cell.

[0350] Item 4. The antibody or antigen-binding fragment of item 2 or 3, wherein the T-cell is a tumor infiltrating lymphocyte.

[0351] Item 5. The antibody or antigen-binding fragment of any one of items 1-4, wherein the antibody or antigen-binding fragment binds monkey CTLA-4.

[0352] Item 6. The antibody or antigen-binding fragment of any one of items 1-5, wherein the antibody or antigen-binding fragment binds CTLA-4-expressing cells with an EC50 of less than 5 nM.

[0353] Item 7. The antibody or antigen-binding fragment of any one of items 1-6, wherein the antibody or antigen-binding fragment binds CTLA-4 expressing cells with an EC50 of less than 1 nM.

[0354] Item 8. The antibody or antigen-binding fragment of any one of items 1-7, wherein the antibody or antigen-binding fragment binds human CTLA-4 expressing cells with an EC50 of less than 0.5 nM.

[0355] Item 9. The antibody or antigen-binding fragment of any one of item 1-8 that binds monkey CTLA-4 expressing cells with an EC50 of less than 0.5 nM.

[0356] Item 10. The antibody or antigen-binding fragment of any one of items 1-9 that is a fully human antibody.

[0357] Item 11. The antibody or antigen-binding fragment of any one of items 1-10, wherein the antibody or antigen-binding fragment thereof competes for binding to human CTLA-4 with a reference antibody comprising an HCVR/LCVR amino acid sequence pair selected from the group consisting of: (a) SEQ ID NOs: 2 and 10, (b) SEQ ID NOs: 18 and 26, (c) SEQ ID NOs: 34 and 42, (d) SEQ ID NOs: 50 and 58, (e) SEQ ID NOs: 66 and 74, (f) SEQ ID NOs: 82 and 90, (g) SEQ ID NOs: 98 and 106, (h) SEQ ID NOs: 114 and 122, (i) SEQ ID NOs: 130 and 138, (j) SEQ ID NOs: 146 and 154, (k) SEQ ID NOs: 162 and 170, (l) SEQ ID NOs: 178 and 186, (m) SEQ ID NOs: 194 and 202, (n) SEQ ID NOs: 210 and 218, (o) SEQ ID NOs: 226 and 234, (p) SEQ ID NOs: 242 and 250, (q) SEQ ID NOs: 258 and 266, (r) SEQ ID NOs: 274 and 282, (s) SEQ ID NOs: 290 and 298, (t) SEQ ID NOs: 306 and 298, (u) SEQ ID NOs: 314 and 322, (v) SEQ ID NOs: 330 and 338, (w) SEQ ID NOs: 346

and 354, (x) SEQ ID NOs: 362 and 370, (y) SEQ ID NOs: 378 and 386, (z) SEQ ID NOs: 394 and 402, (a') SEQ ID NOs: 410 and 418, (b') SEQ ID NOs: 426 and 434, (c') SEQ ID NOs: 442 and 450, (d') SEQ ID NOs: 458 and 466, (e') SEQ ID NOs: 474 and 482, and (f') SEQ ID NOs: 490 and 498.

[0358] Item 12. The antibody or antigen-binding fragment of any one of items 1-11, wherein the antibody or antigen-binding fragment thereof binds to the same epitope on human CTLA-4 as a reference antibody comprising an HCVR/LCVR amino acid sequence pair selected from the group consisting of: (a) SEQ ID NOs: 2 and 10, (b) SEQ ID NOs: 18 and 26, (c) SEQ ID NOs: 34 and 42, (d) SEQ ID NOs: 50 and 58, (e) SEQ ID NOs: 66 and 74, (f) SEQ ID NOs: 82 and 90, (g) SEQ ID NOs: 98 and 106, (h) SEQ ID NOs: 114 and 122, (i) SEQ ID NOs: 130 and 138, (j) SEQ ID NOs: 146 and 154, (k) SEQ ID NOs: 162 and 170, (l) SEQ ID NOs: 178 and 186, (m) SEQ ID NOs: 194 and 202, (n) SEQ ID NOs: 210 and 218, (o) SEQ ID NOs: 226 and 234, (p) SEQ ID NOs: 242 and 250, (q) SEQ ID NOs: 258 and 266, (r) SEQ ID NOs: 274 and 282, (s) SEQ ID NOs: 290 and 298, (t) SEQ ID NOs: 306 and 298, (u) SEQ ID NOs: 314 and 322, (v) SEQ ID NOs: 330 and 338, (w) SEQ ID NOs: 346 and 354, (x) SEQ ID NOs: 362 and 370, (y) SEQ ID NOs: 378 and 386, (z) SEQ ID NOs: 394 and 402, (a') SEQ ID NOs: 410 and 418, (b') SEQ ID NOs: 426 and 434, (c') SEQ ID NOs: 442 and 450, (d') SEQ ID NOs: 458 and 466, (e') SEQ ID NOs: 474 and 482, and (f') SEQ ID NOs: 490 and 498.

[0359] Item 13. The antibody or antigen-binding fragment of any one of items 1-12, wherein the antibody or antigen-binding fragment comprises: (a) the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 314, 330, 346, 362, 378, 394, 410, 426, 442, 458, 474, and 490; and (b) the CDRs of a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 322, 338, 354, 370, 386, 402, 418, 434, 450, 466, 482, and 498.

[0360] Item 14. The antibody or antigen-binding fragment of any one of items 1-13, wherein the antibody or antigen-binding fragment comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of: (a) SEQ ID NOs: 2 and 10, (b) SEQ ID NOs: 18 and 26, (c) SEQ ID NOs: 34 and 42, (d) SEQ ID NOs: 50 and 58, (e) SEQ ID NOs: 66 and 74, (f) SEQ ID NOs: 82 and 90, (g) SEQ ID NOs: 98 and 106, (h) SEQ ID NOs: 114 and 122, (i) SEQ ID NOs: 130 and 138, (j) SEQ ID NOs: 146 and 154, (k) SEQ ID NOs: 162 and 170, (l) SEQ ID NOs: 178 and 186, (m) SEQ ID NOs: 194 and 202, (n) SEQ ID NOs: 210 and 218, (o) SEQ ID NOs: 226 and 234, (p) SEQ ID NOs: 242 and 250, (q) SEQ ID NOs: 258 and 266, (r) SEQ ID NOs: 274 and 282, (s) SEQ

ID NOs: 290 and 298, (t) SEQ ID NOs: 306 and 298, (u) SEQ ID NOs: 314 and 322, (v) SEQ ID NOs: 330 and 338, (w) SEQ ID NOs: 346 and 354, (x) SEQ ID NOs: 362 and 370, (y) SEQ ID NOs: 378 and 386, (z) SEQ ID NOs: 394 and 402, (a') SEQ ID NOs: 410 and 418, (b') SEQ ID NOs: 426 and 434, (c') SEQ ID NOs: 442 and 450, (d') SEQ ID NOs: 458 and 466, (e') SEQ ID NOs: 474 and 482, and (f') SEQ ID NOs: 490 and 498.

[0361] Item 15. The antibody or antigen-binding fragment of any one of items 1-14, wherein the antibody or antigen-binding fragment comprises comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 domains selected from the group consisting of: (a) SEQ ID NOs: 4, 6, 8, 12, 14 and 16 respectively; (b) SEQ ID NOs: 20, 22, 24, 28, 30 and 32 respectively; (c) SEQ ID NOs: 36, 38, 40, 44, 46 and 48 respectively; (d) SEQ ID NOs: 52, 54, 56, 60, 62 and 64 respectively; (e) SEQ ID NOs: 68, 70, 72, 76, 78 and 80 respectively; (f) SEQ ID NOs: 84, 86, 88, 92, 94 and 96 respectively; (g) SEQ ID NOs: 100, 102, 104, 108, 110 and 112 respectively; (h) SEQ ID NOs: 116, 118, 120, 124, 126 and 128 respectively; (i) SEQ ID NOs: 132, 134, 136, 140, 142 and 144 respectively; (j) SEQ ID NOs: 148, 150, 152, 156, 158 and 160 respectively; (k) SEQ ID NOs: 164, 166, 168, 172, 174 and 176 respectively; (l) SEQ ID NOs: 180, 182, 184, 188, 190 and 192 respectively; (m) SEQ ID NOs: 196, 198, 200, 204, 206 and 208 respectively; (n) SEQ ID NOs: 212, 214, 216, 220, 222 and 224 respectively; (o) SEQ ID NOs: 228, 230, 232, 236, 238 and 240 respectively; (p) SEQ ID NOs: 244, 246, 248, 252, 254 and 256 respectively; (q) SEQ ID NOs: 260, 262, 264, 268, 270 and 272 respectively; (r) SEQ ID NOs: 276, 278, 280, 284, 286 and 288 respectively; (s) SEQ ID NOs: 292, 294, 296, 300, 302 and 304 respectively; (t) SEQ ID NOs: 308, 310, 312, 300, 302 and 304 respectively; (u) SEQ ID NOs: 316, 318, 320, 324, 326 and 328 respectively; (v) SEQ ID NOs: 332, 334, 336, 340, 342 and 344 respectively; (w) SEQ ID NOs: 348, 350, 352, 356, 358 and 360 respectively; (x) SEQ ID NOs: 364, 366, 368, 372, 374 and 376 respectively; (y) SEQ ID NOs: 380, 382, 384, 388, 390 and 392 respectively; (z) SEQ ID NOs: 396, 398, 400, 404, 406 and 408 respectively; (a') SEQ ID NOs: 412, 414, 416, 420, 422 and 424 respectively; (b') SEQ ID NOs: 428, 430, 432, 436, 438 and 440 respectively; (c') SEQ ID NOs: 444, 446, 448, 452, 454 and 456 respectively; (d') SEQ ID NOs: 460, 462, 464, 468, 470 and 472 respectively; (e') SEQ ID NOs: 476, 478, 480, 484, 486 and 488 respectively; and (f') SEQ ID NOs: 492, 494, 496, 500, 502 and 504 respectively.

[0362] Item 16. The antibody or antigen-binding fragment of any one of items 1-15, wherein the antibody or antigen-binding fragment comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of: (a) SEQ ID NOs: 2 and 10, (b) SEQ ID NOs: 18 and 26, (c) SEQ ID NOs: 34 and 42, (d) SEQ ID NOs: 50 and 58, (e) SEQ ID NOs: 66 and 74, (f) SEQ ID NOs: 82 and 90, (g) SEQ ID NOs: 98 and 106, (h) SEQ ID NOs: 114 and 122, (i) SEQ ID NOs: 130 and 138, (j) SEQ ID NOs: 146 and 154, (k) SEQ ID NOs: 162

and 170, (l) SEQ ID NOs: 178 and 186, (m) SEQ ID NOs: 194 and 202, (n) SEQ ID NOs: 210 and 218, (o) SEQ ID NOs: 226 and 234, (p) SEQ ID NOs: 242 and 250, (q) SEQ ID NOs: 258 and 266, (r) SEQ ID NOs: 274 and 282, (s) SEQ ID NOs: 290 and 298, (t) SEQ ID NOs: 306 and 298, (u) SEQ ID NOs: 314 and 322, (v) SEQ ID NOs: 330 and 338, (w) SEQ ID NOs: 346 and 354, (x) SEQ ID NOs: 362 and 370, (y) SEQ ID NOs: 378 and 386, (z) SEQ ID NOs: 394 and 402, (a') SEQ ID NOs: 410 and 418, (b') SEQ ID NOs: 426 and 434, (c') SEQ ID NOs: 442 and 450, (d') SEQ ID NOs: 458 and 466, (e') SEQ ID NOs: 474 and 482, and (f') SEQ ID NOs: 490 and 498.

[0363] Item 17. An anti-CTLA-4 antibody or antigen-binding fragment thereof comprising: (a) the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 306, 314, 330, 346, 362, 378, 394, 410, 426, 442, 458, 474, and 490; and (b) the CDRs of a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 322, 338, 354, 370, 386, 402, 418, 434, 450, 466, 482, and 498.

[0364] Item 18. The antibody or antigen-binding fragment of item 17, wherein the antibody comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of: (a) SEQ ID NOs: 2 and 10, (b) SEQ ID NOs: 18 and 26, (c) SEQ ID NOs: 34 and 42, (d) SEQ ID NOs: 50 and 58, (e) SEQ ID NOs: 66 and 74, (f) SEQ ID NOs: 82 and 90, (g) SEQ ID NOs: 98 and 106, (h) SEQ ID NOs: 114 and 122, (i) SEQ ID NOs: 130 and 138, (j) SEQ ID NOs: 146 and 154, (k) SEQ ID NOs: 162 and 170, (l) SEQ ID NOs: 178 and 186, (m) SEQ ID NOs: 194 and 202, (n) SEQ ID NOs: 210 and 218, (o) SEQ ID NOs: 226 and 234, (p) SEQ ID NOs: 242 and 250, (q) SEQ ID NOs: 258 and 266, (r) SEQ ID NOs: 274 and 282, (s) SEQ ID NOs: 290 and 298, (t) SEQ ID NOs: 306 and 298, (u) SEQ ID NOs: 314 and 322, (v) SEQ ID NOs: 330 and 338, (w) SEQ ID NOs: 346 and 354, (x) SEQ ID NOs: 362 and 370, (y) SEQ ID NOs: 378 and 386, (z) SEQ ID NOs: 394 and 402, (a') SEQ ID NOs: 410 and 418, (b') SEQ ID NOs: 426 and 434, (c') SEQ ID NOs: 442 and 450, (d') SEQ ID NOs: 458 and 466, (e') SEQ ID NOs: 474 and 482, and (f') SEQ ID NOs: 490 and 498.

[0365] Item 19. The antibody or antigen-binding fragment of item 17 or 18, wherein the antibody or antigen-binding fragment comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 domains selected from the group consisting of: (a) SEQ ID NOs: 4, 6, 8, 12, 14 and 16 respectively; (b) SEQ ID NOs: 20, 22, 24, 28, 30 and 32 respectively; (c) SEQ ID NOs: 36, 38, 40, 44, 46 and 48 respectively; (d) SEQ ID NOs: 52, 54, 56, 60, 62 and 64 respectively; (e) SEQ ID NOs: 68, 70, 72, 76, 78 and 80 respectively; (f) SEQ ID NOs: 84, 86, 88, 92, 94 and 96 respectively; (g) SEQ ID NOs: 100, 102, 104, 108, 110 and 112

respectively; (h) SEQ ID NOs: 116, 118, 120, 124, 126 and 128 respectively; (i) SEQ ID NOs: 132, 134, 136, 140, 142 and 144 respectively; (j) SEQ ID NOs: 148, 150, 152, 156, 158 and 160 respectively; (k) SEQ ID NOs: 164, 166, 168, 172, 174 and 176 respectively; (l) SEQ ID NOs: 180, 182, 184, 188, 190 and 192 respectively; (m) SEQ ID NOs: 196, 198, 200, 204, 206 and 208 respectively; (n) SEQ ID NOs: 212, 214, 216, 220, 222 and 224 respectively; (o) SEQ ID NOs: 228, 230, 232, 236, 238 and 240 respectively; (p) SEQ ID NOs: 244, 246, 248, 252, 254 and 256 respectively; (q) SEQ ID NOs: 260, 262, 264, 268, 270 and 272 respectively; (r) SEQ ID NOs: 276, 278, 280, 284, 286 and 288 respectively; (s) SEQ ID NOs: 292, 294, 296, 300, 302 and 304 respectively; (t) SEQ ID NOs: 308, 310, 312, 300, 302 and 304 respectively; (u) SEQ ID NOs: 316, 318, 320, 324, 326 and 328 respectively; (v) SEQ ID NOs: 332, 334, 336, 340, 342 and 344 respectively; (w) SEQ ID NOs: 348, 350, 352, 356, 358 and 360 respectively; (x) SEQ ID NOs: 364, 366, 368, 372, 374 and 376 respectively; (y) SEQ ID NOs: 380, 382, 384, 388, 390 and 392 respectively; (z) SEQ ID NOs: 396, 398, 400, 404, 406 and 408 respectively; (a') SEQ ID NOs: 412, 414, 416, 420, 422 and 424 respectively; (b') SEQ ID NOs: 428, 430, 432, 436, 438 and 440 respectively; (c') SEQ ID NOs: 444, 446, 448, 452, 454 and 456 respectively; (d') SEQ ID NOs: 460, 462, 464, 468, 470 and 472 respectively; (e') SEQ ID NOs: 476, 478, 480, 484, 486 and 488 respectively; and (f') SEQ ID NOs: 492, 494, 496, 500, 502 and 504 respectively.

[0366] Item 20. The antibody or antigen-binding fragment of any one of items 17-19, wherein the antibody or antigen-binding fragment comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of: (a) SEQ ID NOs: 2 and 10, (b) SEQ ID NOs: 18 and 26, (c) SEQ ID NOs: 34 and 42, (d) SEQ ID NOs: 50 and 58, (e) SEQ ID NOs: 66 and 74, (f) SEQ ID NOs: 82 and 90, (g) SEQ ID NOs: 98 and 106, (h) SEQ ID NOs: 114 and 122, (i) SEQ ID NOs: 130 and 138, (j) SEQ ID NOs: 146 and 154, (k) SEQ ID NOs: 162 and 170, (l) SEQ ID NOs: 178 and 186, (m) SEQ ID NOs: 194 and 202, (n) SEQ ID NOs: 210 and 218, (o) SEQ ID NOs: 226 and 234, (p) SEQ ID NOs: 242 and 250, (q) SEQ ID NOs: 258 and 266, (r) SEQ ID NOs: 274 and 282, (s) SEQ ID NOs: 290 and 298, (t) SEQ ID NOs: 306 and 298, (u) SEQ ID NOs: 314 and 322, (v) SEQ ID NOs: 330 and 338, (w) SEQ ID NOs: 346 and 354, (x) SEQ ID NOs: 362 and 370, (y) SEQ ID NOs: 378 and 386, (z) SEQ ID NOs: 394 and 402, (a') SEQ ID NOs: 410 and 418, (b') SEQ ID NOs: 426 and 434, (c') SEQ ID NOs: 442 and 450, (d') SEQ ID NOs: 458 and 466, (e') SEQ ID NOs: 474 and 482, and (f') SEQ ID NOs: 490 and 498.

[0367] Item 21. The antibody or antigen-binding fragment of any one of items 17-20, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 509 and a light chain comprising the amino acid sequence of SEQ ID NO: 510.

- [0368]** Item 22. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof of any one of items 1-21 and a pharmaceutically acceptable carrier or diluent.
- [0369]** Item 23. An isolated polynucleotide molecule comprising a polynucleotide sequence that encodes a HCVR of an antibody as set forth in any one of items 1-21.
- [0370]** Item 24. An isolated polynucleotide molecule comprising a polynucleotide sequence that encodes a LCVR of an antibody as set forth in any one of items 1-21.
- [0371]** Item 25. A vector comprising the polynucleotide of item 23 and/or the polynucleotide of item 24.
- [0372]** Item 26. A host cell expressing the vector of item 25.
- [0373]** Item 27. The antibody or antigen-binding fragment thereof of any one of items 1-21, or the pharmaceutical composition of item 22, for use for inhibiting growth of a tumor or a tumor cell in a subject in need thereof.
- [0374]** Item 28. The antibody or antigen-binding fragment thereof, or the pharmaceutical composition, for the use according to item 27, wherein the tumor is a primary or a recurrent tumor.
- [0375]** Item 29. The antibody or antigen-binding fragment thereof, or the pharmaceutical composition, for the use according to item 27, wherein the tumor is an established tumor.
- [0376]** Item 30. The antibody or antigen-binding fragment thereof, or the pharmaceutical composition, for the use according to any one of items 27-29, wherein the tumor is present in a subject with a disease or disorder selected from the group consisting of blood cancer, brain cancer, renal cell cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, kidney cancer, cervical cancer, stomach cancer, pancreatic cancer, breast cancer, hepatic cell carcinoma, bone cancer, colon cancer, non-small-cell lung cancer, squamous cell carcinoma of head and neck, colorectal cancer, mesothelioma, B cell lymphoma, myeloma, and melanoma.
- [0377]** Item 31. The antibody or antigen-binding fragment thereof, or the pharmaceutical composition, for the use according to any one of items 27-30, wherein the antibody or antigen-binding fragment thereof or the pharmaceutical composition is administered to the subject as an initial dose followed by one or more secondary doses, wherein each secondary dose is administered 1 to 12 weeks after the immediately preceding dose.
- [0378]** Item 32. The antibody or antigen-binding fragment thereof, or the pharmaceutical composition, for the use according to item 31, wherein the antibody or antigen-binding fragment thereof or the pharmaceutical composition is administered to the subject at a dose of about 25-600 mg.
- [0379]** Item 33. The antibody or antigen-binding fragment thereof, or the pharmaceutical composition, for the use according to any one of items 27-32, wherein the antibody or

antigen-binding fragment thereof is administered to the subject in combination with a second therapeutic agent.

[0380] Item 34. The antibody or antigen-binding fragment thereof, or the pharmaceutical composition, for the use according to item 33, wherein the second therapeutic agent is selected from the group consisting of a LAG3 inhibitor, an antibody to a tumor specific antigen, an antibody to a virally-infected-cell antigen, a PD-1 inhibitor, a PD-L1 inhibitor, a CD20 inhibitor, a bispecific antibody against CD20 and CD3, a dietary supplement such as an antioxidant, a VEGF antagonist, a cancer vaccine, a chemotherapeutic agent, a cytotoxic agent, radiation, surgery, and any other therapy useful for ameliorating at least one symptom associated with the disease or disorder.

[0381] Item 35. The antibody or antigen-binding fragment thereof, or the pharmaceutical composition, for the use according to item 33 or 34, wherein the second therapeutic agent is a PD-1 inhibitor.

[0382] Item 36. The antibody or antigen-binding fragment thereof, or the pharmaceutical composition, for the use according to any one of items 33-35, wherein the PD-1 inhibitor is cemiplimab, nivolumab or pembrolizumab.

[0383] Item 37. The antibody or antigen-binding fragment thereof, or the pharmaceutical composition, for the use according to item 36, wherein the PD-1 inhibitor is administered at a dose of 1, 3 or 10 mg/kg of the subject's body weight.

[0384] Item 38. The antibody or antigen-binding fragment thereof, or the pharmaceutical composition, for the use according to any one of items 33-35, wherein the PD-1 inhibitor is administered at a dose of 50-1200 mg.

[0385] Item 39. The antibody or antigen-binding fragment thereof, or the pharmaceutical composition, for the use according to any one of items 27-38, wherein the antibody or antigen-binding fragment thereof or the pharmaceutical composition is administered subcutaneously, intravenously, intratumorally, peritumorally, intradermally, intraperitoneally, orally, intramuscularly or intracranially.

[0386] Item 40. The antibody or antigen-binding fragment thereof of any one of items 1-21, or the pharmaceutical composition of item 22, for use in the treatment of a disease or disorder that is treatable by antagonizing CTLA-4 in a subject in need thereof.

[0387] Item 41. The antibody or antigen-binding fragment thereof, or the pharmaceutical composition, for the use according to item 40, wherein the disease or disorder is a chronic viral infection caused by a virus selected from the group consisting of human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human papilloma virus (HPV), lymphocytic choriomeningitis virus (LCMV) and simian immunodeficiency virus (SIV).

[0388] Item 42. The antibody or antigen-binding fragment thereof, or the pharmaceutical composition, for the use according to item 40, wherein the disease or disorder is selected from the group consisting of blood cancer, brain cancer, renal cell cancer, ovarian cancer, bladder cancer, skin cancer, cervical cancer, stomach cancer, kidney cancer, prostate cancer, breast cancer, hepatic cell carcinoma, bone cancer, colon cancer, non-small-cell lung cancer, squamous cell carcinoma of head and neck, colorectal cancer, mesothelioma, B cell lymphoma, and melanoma.

[0389] Item 43. A method of producing an anti-CTLA-4 antibody or antigen-binding fragment thereof, comprising growing the host cell of item 26 under conditions permitting production of the antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof so produced.

[0390] Item 44. The method of item 43, further comprising formulating the antibody or antigen-binding fragment thereof as a pharmaceutical composition comprising an acceptable carrier.

[0391] Item 45. An anti-CTLA-4 antibody or antigen-binding fragment thereof for use in combination with an anti-PD-1 antibody in the treatment of non-small cell lung cancer in a subject in need thereof.

[0392] Item 46. The anti-CTLA-4 antibody or antigen-binding fragment thereof for the use according to item 45, wherein the anti-CTLA-4 antibody or antigen-binding fragment thereof is an antibody or an antigen-binding fragment thereof as claimed in any one of items 1-21.

[0393] Item 47. The antibody or antigen-binding fragment thereof for the use according to item 45 or 46, wherein the anti-CTLA-4 antibody comprises the CDRs of a HCVR comprising the amino acid sequence of SEQ ID NO: 194 and the CDRs of a LCVR comprising the amino acid sequence of SEQ ID NO: 202.

[0394] Item 48. The antibody or antigen-binding fragment thereof for the use according to any one of items 45-47, wherein the anti-CTLA-4 antibody comprises a HCDR1 of sequence SEQ ID NO: 196, a HCDR2 of sequence SEQ ID NO: 198, a HCDR3 of sequence SEQ ID NO: 200, a LCDR1 of sequence SEQ ID NO: 204, a LCDR2 of sequence SEQ ID NO: 206, and a LCDR3 of sequence SEQ ID NO: 208.

[0395] Item 49. The antibody or antigen-binding fragment thereof for the use according to any one of items 45-48, wherein the anti-CTLA-4 antibody comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 194, and a LCVR comprising the amino acid sequence of SEQ ID NO: 202.

[0396] Item 50. The antibody or antigen-binding fragment thereof for the use according to any one of items 45-49, wherein the anti-CTLA-4 antibody comprises a human IgG1 heavy chain constant region.

[0397] Item 51. The antibody or antigen-binding fragment thereof for the use according to any one of items 45-50, wherein the anti-CTLA-4 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 509 and a light chain of amino acid sequence of SEQ ID NO: 510.

[0398] Item 52. The antibody or antigen-binding fragment thereof for the use according to any one of items 45-51, wherein the anti-PD-1 antibody is cemiplimab.

[0399] Item 53. The antibody or antigen-binding fragment thereof for the use according to any one of items 45-52, wherein the anti-CTLA-4 antibody or antigen-binding fragment thereof is administered at a dose of 25-600 mg.

[0400] Item 54. The antibody or antigen-binding fragment thereof for the use according to any one of items 45-53, wherein the anti-PD-1 antibody is administered at a dose of 50-1200 mg.

[0401] Item 55. The antibody or antigen-binding fragment thereof for the use according to any one of items 45-54, wherein the anti-CTLA-4 antibody or antigen-binding fragment thereof is administered as an initial dose, followed by one or more secondary doses, wherein each secondary dose is administered 1 to 12 weeks after the immediately preceding dose.

[0402] Item 56. The antibody or antigen-binding fragment thereof for the use according to any one of items 45-55, wherein the non-small cell lung cancer (NSCLC) is advanced or metastatic NSCLC.

[0403] Item 57. The pharmaceutical composition of Item 22 for use in combination with an anti-PD-1 antibody in the treatment of non-small cell lung cancer in a subject in need thereof

[0404] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

What is claimed is:

1. An antibody or antigen-binding fragment thereof that binds specifically to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) contained within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 194; and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 202.
2. The antibody or antigen-binding fragment of claim 1, wherein the antibody or antigen-binding fragment comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 consisting of amino acid sequences of SEQ ID NOs: 196, 198, 200, 204, 206 and 208 respectively.
3. The antibody or antigen-binding fragment of claim 2, wherein the antibody or antigen-binding fragment thereof comprises a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 194/202.
4. The antibody or antigen-binding fragment thereof of any one of claims 1 – 3, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody.
5. The antibody or antigen-binding fragment thereof of any one of claims 1 – 4, wherein the antibody or antigen-binding fragment thereof is a fully human antibody.
6. The antibody or antigen-binding fragment thereof of any one of claims 1 – 5, wherein the antibody or antigen-binding fragment thereof comprises a human IgG1 heavy chain constant region.
7. The antibody of any one of claims 1 – 6 comprising a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence of SEQ ID NO: 509.
8. The antibody of any one of claims 1 – 6 comprising a heavy chain and a light chain, wherein the light chain comprises an amino acid sequence of SEQ ID NO: 510.

9. The antibody of any one of claims 1 – 6 comprising a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence of SEQ ID NO: 509 and the light chain comprises an amino acid sequence of SEQ ID NO: 510.

10. A pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof of any one of claims 1 – 9 and a pharmaceutically acceptable carrier or diluent.

11. An isolated polynucleotide molecule comprising a polynucleotide sequence that encodes a HCVR of an antibody as set forth in any one of claims 1 – 9, and an isolated polynucleotide molecule comprising a polynucleotide sequence that encodes a LCVR of an antibody as set forth in any one of claims 1 – 9.

12. A vector comprising the polynucleotide molecules of claim 11.

13. A host cell expressing the vector of claim 12.

14. A host cell comprising the polynucleotide molecules of claim 11.

15. A method of producing an anti-CTLA-4 antibody or antigen-binding fragment thereof, comprising growing the host cell of claim 13 or 14 under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.

16. The method of claim 15, further comprising formulating the antibody or antigen-binding fragment thereof as a pharmaceutical composition comprising an acceptable carrier.

17. Use of an antibody or antigen-binding fragment thereof of any one of claims 1-9 in the manufacture of a medicament for inhibiting growth of a tumor or a tumor cell in a subject.

18. The use of claim 17, wherein the tumor is a primary or a recurrent tumor.

19. The use of claim 17, wherein the tumor is an established tumor.

20. The use of any one of claims 17-19, wherein the tumor is present in a subject with a disease or disorder selected from the group consisting of blood cancer, brain cancer, renal cell cancer, ovarian cancer, bladder cancer, prostate cancer, breast cancer, hepatic cell carcinoma, bone cancer, colon cancer, non-small-cell lung cancer, squamous cell carcinoma of head and neck, colorectal cancer, mesothelioma, B cell lymphoma, and melanoma.

21. The use of any one of claims 17-20, wherein the medicament is to be administered as an initial dose followed by one or more secondary doses, wherein each secondary dose is to be administered 1 to 12 weeks after the immediately preceding dose.

22. The use of any one of claims 17-21, wherein the medicament is to be administered at a dose of 25 – 600mg.

23. The use of any one of claims 17-22, wherein the medicament is to be administered to the subject in combination with a second therapeutic agent or radiation.

24. The use of claim 23, wherein the second therapeutic agent is selected from the group consisting of a PD-1 inhibitor, an antibody to a tumor specific antigen, an antibody to a virally-infected-cell antigen, a PD-L1 inhibitor, a CD20 inhibitor, a bispecific antibody against CD20 and CD3, a VEGF antagonist, a chemotherapeutic agent, a cytotoxic agent, a NSAID, or a corticosteroid.

25. The use of claim 24, wherein the second therapeutic agent is a PD-1 inhibitor.

26. The use of claim 25, wherein the PD-1 inhibitor is cemiplimab, nivolumab or pembrolizumab.

27. The use of claim 26, wherein the PD-1 inhibitor is to be administered at a dose of 1, 3 or 10 mg/kg of the subject's body weight.

28. The use of claim 26, wherein the PD-1 inhibitor is to be administered at a dose of 50 – 1200mg.

29. The use of any one of claims 17-28, wherein the medicament is to be administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly or intracranially.

30. The use of any one of claims 25-29, wherein the tumor is non-small cell lung cancer (NSCLC).

31. The use of claim 30, wherein the PD-1 inhibitor is cemiplimab.

32. The use of claim 30 or 31, wherein the NSCLC is advanced or metastatic NSCLC.